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PREFACE
Over the past four years, spent in the Department of 
Materia Medica (Department of Medicine & Therapeutics) 
University of Glasgow, it has been a good opportunity to be 
involved in a series of clinical studies looking at the 
effects of calcium antagonist drugs in cardiovascular disor­
ders. This afforded me an opportunity to use computer models 
such as statistical, pharmacodynamic and pharmacokinetic 
analyses to explain and present my results.
I was primarily responsible for conducting and analy­
sing the studies described and the preparation of this 
thesis was entirely my own work.
Jawad H . Ahmed 
November, 1989.
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SUMMARY
SUMMARY
This thesis has investigated several aspects of the 
clinical pharmacology of calcium antagonist drugs.
The first study, in patients with mild to moderate 
essential hypertension, investigated the pharmacokinetics of 
verapamil, the concentration-effeet relationship of the 
antihypertensive response and some of the possible determi­
nants of response using concentration-effeet modelling. Thus 
the antihypertensive effect was characterised as "respon­
siveness" in mmHg/ng/ml, which is the magnitude of blood 
pressure reduction per unit change in plasma drug concentra­
tion, and is derived from the slope ("m") of the concentra­
tion-ef feet relationship. Responsiveness was closely corre­
lated with the height of pretreatment blood pressure but not 
independently with plasma renin activity or age. The results 
of this study suggest that the reported increased respon­
siveness in elderly hypertensives, which was correlated with 
increasing age and decreasing plasma renin activity, may 
have failed to take account of the height of pretreatment 
blood pressure. Since there is an age-related increase in 
blood pressure there is no substantive evidence for an 
independent role for age or plasma renin activity in the 
antihypertensive responses to calcium antagonist drugs. This 
study confirmed also the accumulation of verapamil with 
multiple doses, with an increase in the area under the 
concentration time curve and a prolongation of the terminal 
elimination half life.
In addition to the reports that the elderly are more
15
responsive to the effect of calcium antagonists, there is 
some evidence that the pharmacokinetics of calcium 
antagonist drugs are altered in the elderly, with increases 
in plasma drug levels. Increased plasma levels themselves 
obviously might lead to an increase in therapeutic effect 
but also might increase the risk of toxicity. Potentially 
increased toxicity was a particular component of the study 
in patients with stable angina pectoris receiving single and 
chronic doses of verapamil (oral and intravenous). There 
were no significant effect of verapamil on left ventricular 
ejection fraction (EF%) or atrio-ventricular conduction (PR 
interval). Verapamil had no significant effects on ERPF, GFR 
or apparent liver blood flow. The results of this study 
indicate that there was no increased susceptibility to the 
negative inotropic or dromotropic effects of verapamil in 
middle aged and elderly patients.
The effect of age on the pharmacokinetics of verapamil 
was investigated for the pooled data on 74 subjects (age 
range 19-79) by the application of linear regression 
analysis across the age range. The results of this study 
suggest that increasing age is associated with small but 
significant alterations in the pharmacokinetics of verapa­
mil. However, the variability in the pharmacokinetic parame­
ters of verapamil also increased with age which makes it 
inappropriate to make global dosage recommendations for 
elderly patients by virtue of age alone.
Since calcium ions are involved in many biological 
processes, it is appreciated that calcium antagonist drugs
16
are likely to have more than one target tissue where they 
can exert a pharmacological effect. However, not all effects 
of calcium antagonists can be explained solely on their 
calcium channel blocking activity. For example, their 
potential role as adjuvant agents in the treatment of cancer 
with chemotherapeutic drugs. In vitro verapamil has proved a 
very effective agent but, unfortunately, the concentrations 
of racemic verapamil required to overcome drug resistance in 
vitro are relatively high and ranged between 2-6 JJM (1000- 
3000 ng/ml). Such high concentrations are unlikely to be 
achieved in man without serious cardiovascular side effects 
particularly on atrioventricular conduction. Therefore, 
aiming to reach the required concentrations, we have under­
taken a clinical safety and tolerability study using the 
less potent single isomer d-verapamil which has adjuvant 
activity similar to the racemic formulation but has less 
cardiotoxicity. The results of this single dose study showed 
that the required high concentrations of verapamil could be 
achieved with a side effect profile of prolongation of PR 
interval and reduction in blood pressure which was no worse 
than that after the racemic mixture. It has been speculated 
that sustained high drug levels might be achieved if d- 
verapamil is administered in multiple dose. Prior to con­
ducting a steady state clinical study the concentrations 
likely to be achieved at steady state were predicted from 
the single dose data to provide us with a guide to the 
dosage regimen required. The 1000 mg dose was avoided be­
cause of its single dose toxicity but the predictions showed
17
that 500 mg d-verapamil three or four times daily might be 
appropriate to reach the required levels and maintain them 
for most of the period of dosage intervals.
Chapter 7 explores another aspect which would not 
readily have been expected from basic pharmacological 
principles. In renal impairment, many investigators have 
concentrated upon the effects of calcium antagonists on 
renal function and have largely ignored the elimination of 
these drugs on the basis that they are extensively 
metabolised in the liver. Although, nicardipine is 
extensively metabolised in the liver with less than 3% of 
the parent drug excreted unchanged in urine, in this study 
it was found that the plasma clearance was significantly 
reduced in patients with renal impairment but restored 
towards normal in patients undergoing regular haemodialysis. 
The reduction in plasma clearance was significantly 
correlated with renal function. The underlying mechanism is 
unknown. However, there were no changes in protein binding 
or volume of distribution; accumulation of renally- 
eliminated metabolites is also unlikely since the generation 
of metabolite is very limited after intravenous dosing. 
Restoration of the plasma clearance of nicardipine by 
haemodialysis has therefore been attributed to the removal, 
by haemodialysis, of some "inhibitory substances". This 
study emphasises the importance of fully investigating the 
pharmacokinetics of drugs in patients with renal failure 
even if the kidney is not the major site of elimination.
The final study (chapter 8) was undertaken to evaluate
18
the metabolic and hormonal responses to food and exercise 
after 4 weeks treatment with nicardipine. This "provocative" 
approach is seen as complementary to the conventional 
approach which depends only on baseline levels in 
investigating drug induced effects on serum lipids and 
hormones. The results of this study confirm that short-term 
treatment with nicardipine had no effect on the profile of 
lipids and hormones.
In conclusion, calcium antagonist drugs are likely to 
make an increasingly important contribution to the effective 
treatment of cardiovascular disorders. They have no adverse 
impact (perhaps even a beneficial effect) on end-organ blood 
flow, such as kidney or liver blood flow; they have a 
neutral effect on serum lipid and hormone profiles; they 
have no serious age-related toxicity; and, potentially, 
their use may be extended to the field of cancer research as 
adjuvant agents to overcome drug resistance.
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CHAPTER ONE 
INTRODUCTION
1.1 HISTORICAL REVIEW
Calcium antagonists do occur naturally. One such 
example is "tanshinone", which is derived from the root of a 
plant called "Salvia Miltiorrhiza Bunge", and which has been 
used in Chinese traditional medicine for centuries for the 
treatment of coronary disorders. In addition to plant 
sources, animal sources also have been identified such as in 
bee stings or from a tiapan snake venom. In traditional 
medicine, the therapeutic benefit of drugs is more important 
than a knowledge of the mechanism of action which, for 
calcium antagonist drugs, remained unexplored until about 
twenty years ago. While investigating the properties of two 
synthetic coronary vasodilator drugs, prenylamine and 
verapamil, Albert Fleckenstein and his colleagues observed 
that vasodilatation was accompanied by a negative inotropic 
effect which could then be reversed by the addition of 
calcium (Fleckenstein, 1971). From these experiments they 
concluded that these drugs inhibited the excitation-induced 
influx of calcium from outside to inside the cell.
Since the discovery of calcium antagonists came shortly 
after the introduction of beta blockers for the treatment of 
hypertension and angina, their comparably negative inotropic 
effect gave rise to the misconception that calcium 
antagonist drugs possessed beta blocking activity. Although, 
it then took only a very little time to establish that these 
drugs lacked beta adrenoceptor blocking activity their 
peripheral vasodilator action was largely ignored until the 
mid 1970's, when Lewis et al. (1978) first described a
21
sustained reduction in mean arterial pressure in a group of 
hypertensive patients receiving verapamil. However, by this 
time the potential use of calcium antagonists in the 
management of other cardiovascular disorders, including 
supraventricular tachycardia (Schamroth et al., 1972;
Krikler and Spurrell, 1974) and angina pectoris (Livesley et 
al., 1973; Parodi et al., 1979), had attracted widespread 
attention.
1.2. THE ROLE OF CALCIUM IN EXCITATION-CONTRACTION COUPLING
Two contractile proteins are fundamental to the 
contractile process in both myocardium and vascular smooth 
muscle. The thin filament, actin, is a globular protein 
which polymerises to form a double helical structure and the 
second filament, myosin, is a hexamer with one pair of heavy 
chains and two pairs of light chains arranged in parallel to 
form a thick filament. At regular intervals, a portion of 
the myosin molecule projects from the thick filament and 
muscle contraction occurs when this globular portion of the 
myosin molecule attaches to, and detaches from, the actin 
filaments.
During relaxation, the concentration of calcium ions in 
the extracellular space is several order of magnitude higher 
than the concentration inside the myocardial or vascular 
smooth muscle cells.
During activation, the intra cellular calcium 
concentration increases markedly and calcium ions bind to a 
specific subunit of a regulatory protein (troponin in the
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case of the myocardium; calmodulin in the case of vascular 
smooth muscle). This process initiates the interaction 
between the myosin bridge and the thin actin filaments so 
that the filaments are drawn toward the centre of the 
sarcomere resulting in the development of tension of the 
muscle and/or shortening (Figure l'.l.) • The process of 
relaxation which follows the contraction results from 
reduction in the intracellular concentration of calcium 
leading to dissociation of calcium ions from troponin, or 
calmodulin, and subsequent breakage of the actin and myosin 
cross-link.
THE ACTION POTENTIAL-ROLE OF CALCIUM
Influx of calcium ions (Ca^+) also plays an important 
role in the generation of the action potential of the heart. 
During phase 1 of the action potential, when depolarisation 
of the cardiac cell occurs, the membrane permeability to Na+ 
increases rapidly. The influx of Na+ through this so called 
"fast channel" in the cell membrane will result in a fast 
inward current. When the cell has been depolarised from 
approximately -90 to -40 mV a second inward current begins. 
This second current, which is due to the influx of Ca^ is 
relatively slow compared to the fast Na+ current (Figure
1.2.). Although, the amount of Ca^+ ions which enter the 
myocardium during each depolarisation is small and may be 
not sufficient to initiate contraction, it probably triggers
O  I ,
the release of Ca^ from the intracellular sequestered 
stores (Braunwald et al., 1982).
23
H zone 
M -line
z T Z
A band
I band
One Sarcomere
Figure 1.1. The relationship between the actin and myosin 
filaments in cardiac muscle. The A bands refer 
to the myosin filaments and the I bands to the 
actin filaments. The H zone refers to the 
myosin filaments when not overlapped with 
actin.
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Phase 1
Phase 2
Phase 33 §
Phase 4
-90
+Na I n t r a c e l l u l a r
E x t r a c e l lu  lar
++Na Oa1
Figure 1.2. Schematic representation of the movement of 
ions during action potential of the heart; 
phase 0 represents the influx of Na+ through 
the fast Na+ channel and the plateau (phase 2)
9 4-reflects the entry of Ca^ ions through the
9 +Ca^ channels; phase 3: repolanzation; phase 
4: diastole.
25
CONTRACTION OF MYOCARDIUM AND VASCULAR SMOOTH MUSCLE-ROLE OF
CALCIUM
Although the contraction of myocardium and of vascular 
smooth muscle is similar in terms of the involvement of 
actin and myosin there are fundamental differences in the 
biochemical processes which regulate the process of 
contraction (Figure 1.3.)• Contraction of vascular smooth 
muscle results from a series of reactions involving a small 
(15/000-Dalton) binding protein, calmodulin (Braunwald et 
al., 1982) to which Ca^+ ions bind when the intracellular 
Ca^+ concentration is approximately 10”  ^M to form Ca^+- 
calmodulin complex which activates the enzyme myosin kinase; 
this in turn phosphorylates a light chain of myosin leading 
to the interactions with actin resulting in smooth muscle 
contraction and arterial constriction. In the myocardium the 
calcium binds to a specific subunit of regulatory protein 
called troponin.
EXCITATION-SECRETION COUPLING-ROLE OF CALCIUM
Calcium is essential not only for muscle contraction 
but also for hormone release . This was first described by 
Douglas and co-workers (Douglas and Rubin, 1963; Douglas and 
Poisner, 1964) and confirmed by recent studies using calcium 
"activator drugs", such as Bay K8644, to increase the influx 
of calcium into the cell and produce an increase in the 
release of catecholamines (Montiel et al., 1984), or insulin 
(Panten et al., 1985). However, there is no good evidence
26
Internal  
♦ 2
Ca-ytores
Exci tat ion
Ca
Ca
Ca -  Ca lmodul in
Myosin-P + Actin
Con t rac t ion
a
Internal
*1
Ca- stores
Exc i tat ion
I
C m 2
Ca
Ca -Tropon in
Act in -myos in  inte rac t ion
Co n t ra c t io n
b
Figure 1.3. Schematic representation of the involvement of 
Ca^+ ions in the excitation-contraction 
coupling in (a) smooth muscle and (b) cardiac 
muscle.
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that calcium antagonists in clinical doses have an 
inhibitory effect on the release of hormones (Rojdmark et 
al., 1979; Anderson et al., 1980).
Unlike the excitation-contraction coupling process, the 
detailed role of calcium in the biochemical processes of 
excitation-secretion coupling is not well defined.
CALCIUM CHANNELS
Until recently the molecular properties and 
classification of calcium channels were not defined but 
technical advances have facilitated the conduct of detailed 
studies to isolate the calcium channels and it is now 
possible to record the electrical activity associated with 
opening and closing of a single channel (Reuter et al.,
1983).
The calcium channel is described as a macromolecular 
protein that traverses the lipid bilayer of the cell
94-membrane and selectively permits the movement of Ca^ ions 
from one side of the membrane to the other. Calcium channels 
have been classified into 3 major groups- L, T and N (Figure
1.4.). L, stands for long-lasting large-capacitance; T, 
stands for transient and N, for neuronal (Spedding et al.,
1987). These three types of calcium channel differ from each 
other in terms of:
1. Voltage: The T-type is activated at relatively low 
potential (from -110 to -70 mV), L- and N-type are less 
sensitive to depolarisation and high potential is required 
for their activation (-110 to -10 mV) (Hagiwara et al.,
28
1983).
2. a) Sensitivity to organic and inorganic calcium 
antagonists, such as Co^+ and Mn^+ : the L-type is strongly 
blocked by inorganic calcium antagonists, such as cadmium, 
and by organic calcium antagonists, such as verapamil, 
diltiazem and nifedipine (Nowycky et al., 1985).
b) Responsiveness to Bay K8644: the L-type can be 
stimulated by a calcium agonist, such as Bay k8644 (Nowycky 
et al., 1985a,b; Hess et al., 1985b) and by a beta- 
adrenoceptor agonist such as isoprenaline (Hagiwara et al.,
1988).
3. Acceptance of barium ions as a charge carrier in­
stead of calcium: N- & L-types but not the T-type can use 
Ba^+ (Nowycky et al., 1985a).
4. Responses to toxins: for example the T-type is not 
sensitive to neurotoxin (TaiCatoxin) whereas the Lm-type 
(m for muscle) is blocked by this toxin (Brown et al.,
1987) .
As these channels are highly specific for calcium ions 
it can be assumed that they have a filter mechanism to 
define and select appropriate ions. In addition, these 
channels require a site which is sensitive to the 
propagation of electrical stimuli so that depolarisation 
will decrease the electronegativity of the cell with 
subsequent activation (opening) of the calcium channels and 
entry of calcium. The channel will then close when the 
interior of the cell returns to its pre-activation level of 
electronegativity.
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Figure 1.4. Types of calcium channels.
L, N, T : types of calcium channels.
Ps (Pico Siemens): channel conductance. 
Lm : cardiac and smooth muscle L-channel 
Ln : neuronal L-channel. 
wCgTX : omega-conotoxin.
(modified from Nayler, 1988)
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Since the movement of calcium ions through these 
channels is controlled by electrical potential they have 
been termed "Voltage-dependent channel". In addition to 
their voltage dependency, however, calcium channels are also 
operated by membrane receptors, including betal and alpha2- 
adrenoceptors, and accordingly are named "Receptor-operated 
channels".
The distribution of these channels differs from one 
tissue to another. While some tissues have the three types 
of channel, other tissues including the myocardium, and 
particularly the cells of the pacemaker, contain only the 
"L" and "T" types (Hagiwara et al., 1988).
CELLULAR RECEPTORS FOR CALCIUM ANTAGONIST DRUGS
To produce its pharmacological effect a drug requires 
to bind to a receptor site. The specific binding sites for 
the different types of calcium antagonist drug have been 
studied by means of radio-labelling technique and saturable 
binding sites have been identified for the dihydropyridine, 
phenylalkylamines (verapamil), and the benzothiazepine 
(diltiazem) calcium antagonists (Triggle and Janis, 1984; 
Glossmann et al., 1987).
As with many other drugs, including the alpha and beta 
adrenergic blocking drugs, the binding sites of calcium 
antagonists may be affected by a number of different 
factors:
1. Age - Although there have been claims that elderly 
patients are more sensitive to the effect of calcium
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antagonist drugs (Buhler et al./ 1982) there is no 
conclusive evidence that the number of binding sites of 
calcium antagonists change with age. However, it has been 
shown recently that the density of binding sites (Bmax) for 
dihydropyridine calcium antagonists in rat heart membrane 
preparation is increased (Dillon et al., 1989) with no 
change in affinity. The significance of this remains 
unclear.
2. Hypertension - A relatively small increase in the 
number of binding sites (using ^H-nitrendipine) has been 
reported in hypertensive rats (Chatelain et al., 1984). No 
such evidence is available in man.
3. Ischemia - The number of binding sites has been 
reported to be reduced in ischemia (Dillon and Nayler,
1987) .
4. Chronic therapy with calcium antagonists - It is 
well known that, for example, chronic administration of the 
beta adrenoceptor antagonist propranolol results in "up- 
regulation" (i.e. increase in the number of binding sites of 
beta adrenoceptors) (Glaubiger & Lefkowitz, 1977). The same 
effect has been investigated for calcium antagonists but no 
such change has been detected in the number of binding sites 
(Nishiyama et al., 1986). This could have clinical 
importance since withdrawal symptoms are rare after calcium 
antagonists.
TISSUE SELECTIVITY
One of the interesting features of calcium antagonist 
drugs is their relative selectivities for particular
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tissues. For example, verapamil is effective not only on the 
peripheral vasculature but also on the myocardium and the 
conductive tissue of the heart, forming the basis of its use 
in controlling supraventricular tachyarrhythmias (Rowland et 
al., 1979). In addition, there is experimental evidence to 
suggest differential effects on different vascular beds. For 
example, in animal studies nitrendipine is highly selective 
for peripheral blood vessels, whereas nimodipine and 
nisoldipine are selective for cerebral and coronary blood 
vessels respectively (Kazda and Towart, 1981; Godfraind et 
al., 1987). It is not yet clear whether or not these 
differences in selectivity are due to differences in the 
distribution and type of calcium channels and their 
therapeutic relevance in man remains to be established. The 
relative tissue selectivities of the different calcium 
antagonists are summarised in table 1.1.
1.3. CLASSIFICATION OF THE CALCIUM ANTAGONISTS
Calcium antagonist drugs constitute a group of 
heterogeneous chemical compounds with the common property of
. • 9  +  . . •an ability to inhibit the Ca^ current. In addition to their 
chemical diversity, the differences in their tissue 
selectivity create difficulties for the construction of a 
useful clinical classification. Thus, the most commonly used 
classification, and the simplest, is related to the chemical 
classification. Accordingly calcium antagonists can be 
classified into 4 main groups (table 1.2.). The chemical 
structures of some calcium antagonist drugs are presented in 
figures 1.5., 1.6., 1.7.
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TABLE 1.1.
TISSUE SELECTIVITY OF THE CALCIUM ANTAGONISTS
Drugs Heart blood vessels A-V node
(-ve inotropy) (Vasodilatation)
Verapamil + + +
Gallopamil + + +
Diltiazem + + +
Nifedipine + ++ -
Nitrendipine + +++ -
Nisoldipine + ++++ -
Nimodipine + ++++ -
Felodipine + ++++ -
Amlodipine + ++++ -
Cinnarzine + ++++ —
+ refers to the presence of effect; and - to the absence of 
effect.
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Figure 1.5. Chemical structure of calcium antagonists 
which exert effects on AV conduction.
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1.4. THE PHARMACOKINETICS OF CALCIUM ANTAGONISTS
1.4.1. VERAPAMIL
Verapamil [2,8-bis (3,4-dimethoxyphenyl)-6-methyl-2- 
isopropyle-6-azaoctanitrile] was the first calcium 
antagonist introduced to the field of medicine in the early 
1960's by Fleckenstein. Because of the lack of sensitive and 
specific methods for the determination of plasma 
concentrations, it was not until the late 1970's that the 
pharmacokinetic characteristics of verapamil were fully 
described. A spectrophotofluorescence method was described 
by Koike et al. (1979) but this method cannot differentiate 
verapamil from its major metabolite and has restricted 
usefulness for single intravenous dosing. An HPLC method was 
developed by Cole et al (1981) and not only is it capable of 
differentiating between parent drug and metabolite but it 
also needs only a small sample size and short extraction 
procedures. This assay is sensitive to the level of 2 ng/ml.
PHARMACOKINETIC CHARACTERISTICS OF VERAPAMIL
Following oral administration, absorption from the 
gastrointestinal tract is almost complete (Schomerous et 
al., 1979) and the time to peak plasma concentration is 
about one hour after dosing. In normal subjects, verapamil 
is widely distributed throughout the body with an apparent 
volume of distribution in the range 2.5-4.8 1/kg after 
intravenous administration (Koike et al., 1979; Eichelbaum 
et al., 1981; McAllister et al., 1982).
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Verapamil is extensively metabolised by the liver 
resulting in a low oral bioavailability of 10-20%
(Eichelbaum et al., 1981; McAllister et al., 1982). 
Confirmatory evidence for the extensive first pass hepatic 
metabolism has been obtained from patients after mesocaval 
shunt operation in whom a bioavailability of 81% was 
observed (Eichelbaum et al., 1980 a).
Verapamil is metabolised in the liver by microsomal 
monooxygenase reactions catalysed by cytochrome P-450. 
Primary metabolic pathways of verapamil include N- 
dealkylation and 0,N-demethylation (Eichelbaum et al., 1979) 
with the N-demethylated metabolite, norverapamil, as the 
principal identifiable metabolite following oral 
administration. In common with other drugs which undergo 
extensive first pass hepatic extraction there is a wide 
inter and intra individual variability in the extent of 
verapamil metabolism (Woodcock et al., 1980). In general, 
this variability is due to a variety of factors including 
nutrition, environment, concomitant drugs, exposure to 
chemicals, cigarette smoking, alcohol, disease state (Meyer 
et al., 1984) or genetic factors such as those described for
nifedipine (Kleinbloesem et al., 1984).
One of the interesting features of verapamil 
pharmacokinetics is its accumulation with chronic dosing 
(Freedman et al., 1981; Shand et al., 1981). This is 
manifested as a reduction in clearance and a prolongation of
the elimination half life (table 1.3.).
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TABLE 1.3.
COMPARISON BETWEEN PHARMACOKINETICS FOLLOWING 
SINGLE AND MULTIPLE DOSES OF VERAPAMIL 
(MODIFIED FROM FREEDMAN et al., 1981)
Single dose Multiple doses P-value
mean ;t sd mean + sd
Verapamil t^/2 (h) 5 .7 9. 6 <0.05
Verapamil tmax (h) 1.1 + 0.3 1.0 + 0.3 ns
Verapamil AUC 378.0 + 149.0 895.0 + 309.0 <0.01
(ng/ml*h)
Verapamil Cl (ml/min) 4160.0 + 1900 1750.0 + 890 <0.01
Norverapamil t-^ /2 (h) 8.0 12.0 <0.01
Norverapamil tmax (h) 1.4 + 0.6 1.5 + 0.5 ns
Norverapamil AUC 590.0 + 140.0 1084.0 + 244.0 <0.01
(ng/ml*h)
Ratio Verapamil AUC/ 0.6 + 0.2 0.8 + 0.2 <0.01
Norverapamil AUC
ns represents not significant; t^/2 is the elimination half 
life; tmax is the time to reach peak plasma level; AUC is 
the area under the concentration time curve; Cl is the 
clearance.
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PHARMACOKINETICS FOLLOWING SINGLE DOSE:
The reported mean terminal elimination half life ranges 
from 1.85 to 5.2 hours; the mean systemic clearance ranges 
from 875 to 1257 ml/min; the mean apparent clearance 
following oral administration ranges from 3746 to 6383 
ml/min; and the mean apparent volume of distribution (Vd) 
ranges from 113 to 418 L. Norverapamil disposition has also 
been examined after single oral dose. Mean elimination half 
life ranges from 8 to 10.5 hours ( Freedman et al., 1981; 
Kate et al., 1981; Schwartz et al., 1985).
PHARMACOKINETICS AFTER REPEATED DOSES:
Compared to single oral administration, there are 
significant differences in the disposition of verapamil 
during repeated doses. Typically these manifest as an 
increased bioavailability and decreased oral clearance, with 
a prolongation of the elimination half life ( Freedman et 
al., 1981; Shand et al., 1981; Meredith et al., 1985; 
Schwartz et al., 1985). Apparent oral clearance (CL) during 
repeated doses was approximately half of that after a single 
oral dose. Eichelbaum (1984) has reported reduced apparent 
oral clearance but without significant prolongation of the 
elimination half life. To explain the differences in 
clearance and bioavailability after single and repeated 
administration a number of suggestions have been made:
1) Changes in hepatic blood flow
Because verapamil is highly extracted by the liver, its 
elimination is highly dependent upon changes in hepatic
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blood flow.
It has been reported that liver blood flow (using 
indocyanine green clearance) increases after the first dose 
of verapamil and then declines towards placebo value with 
continued administration (Meredith et al., 1985). In 
association with these changes in apparent liver blood flow 
the clearance of verapamil may be initially relatively rapid 
with a subsequent decline during continued dosing. Changes 
in liver blood flow have also been reported with other 
calcium antagonist including nifedipine ( Feely et al.,
1984) and nisoldipine ( Meredith et al., 1985; Van Harten et 
al., 1989). If the verapamil-induced change in hepatic blood 
flow is simply and directly related to verapamil plasma 
concentration, the maximum change in hepatic blood flow will 
be coincident with the peak plasma concentration but it will 
decline as plasma verapamil concentration declines. However, 
the extent of the increase in hepatic blood flow was 
attenuated with multiple doses in spite of the increases in 
cmax anci (Meredith et al., 1985). It seems likely that
the contribution of verapamil induced changes in hepatic 
blood flow to the changes in verapamil pharmacokinetics is 
acute and transient.
2) Non linear ( Saturation) pharmacokinetics ( Wagner 
et al.. 1984)
Wagner et al. (1984) studied the accumulation of 
verapamil at steady state by using published data (Freedman 
et al., 1981; Shand et al., 1981). Following oral 
administration, a relatively high concentration of verapamil
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reaches the liver and saturates the enzyme system to produce 
a subsequent reduction in the plasma clearance of verapamil. 
If enzyme saturation does account for decrease in clearance 
then, as the plasma concentration falls again there should 
be a corresponding increase in clearance: this has not been 
reported to date. Similarly, there should be no accumulation 
of metabolite: however, although the principal metabolite 
norverapamil accumulates at steady state, this only provides 
evidence that the N-demethylation pathway does not undergo 
saturation and saturation of other pathways cannot be ruled 
out.
The concentration of verapamil in the portal 
circulation will be less after intravenous administration 
compared to that after oral administration and may not be so 
readily able to saturate the metabolic sites. However, this 
aspect will be dealt with in chapter 4.
3) Enzvme inhibition
There is increasing evidence to suggest that calcium 
antagonist drugs interfere with hepatic metabolic capacity. 
For example, the clearance of antipyrine was reduced by the 
concomitant administration of verapamil ( Bauer et al.,
1986; Rumiatsev et al., 1986; Batch et al., 1986) and, since 
antipyrine is entirely metabolised by the oxidative pathway, 
it has been suggested that verapamil inhibits hepatic enzyme 
activity. This has been substantiated by in vitro studies 
(Renton et al., 1985). Similarly, verapamil has been report­
ed to inhibit the metabolism of carbamazepine (Macphee et 
al., 1986), digoxin ( Johnson et al., 1987) and quinidine
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(Edwards et al., 1987). Similar drug interactions have also 
been reported with other calcium antagonist drugs: nitrendi­
pine and digoxin (Kirch et al., 1984), nisoldipine and 
digoxin (Kirch et al., 1986), diltiazem and antipyrine 
(Bauer et al., 1986), diltiazem and cyclosporin ( Pochet et 
al., 1986; Carrum et al., 1986); nifedipine and digoxin 
(Kleinbloesem et al., 1985). Apart from the verapamil carba- 
mazepine interaction (Macphee et al., 1986), most of the 
other reports investigated the interaction after 2 or 3 days 
of dosing with verapamil and consequently the onset of the 
interaction was not defined. In the verapamil-carbamazepine 
interaction, the onset of carbamazepine neurotoxicity and 
high plasma carbamazepine concentrations were detected 36-96 
hours after the addition of verapamil and returned to normal 
7 days after the withdrawal of verapamil. This evidence 
suggests that the metabolic sites need to be exposed to 
verapamil for a period of time before being inhibited and 
corresponding period of time is required for metabolism to 
be restored to normal. Since verapamil has the ability to 
inhibit the metabolism of other drugs which share the same 
.metabolic pathway, it is highly possible that it may inhibit 
its own metabolism ( autoenzyme inhibition ) (Rumiatsev et 
al., 1986). Since the principal metabolite norverapamil 
accumulates at steady state it seems that the N-demethyla­
tion pathway does not undergo such autoinhibition.
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1.4.2. NICARDIPINE
Nicardipine is a dihydropyridine derivative recently 
licensed in the U.K. for the treatment of angina pectoris 
and hypertension. The plasma concentrations of nicardipine 
have been measured using several quantitative techniques 
such as Gas-Liquid Chromatography with a sensitivity of 0.5- 
3 ng/ml (Clair et al., 1985), Gas Chromatography Mass 
Spectrometry with a sensitivity of 5 ng/ml (Higuchi and
Kawamura, 1981) and HPLC which has a detection limit of 5
ng/ml and is capable of determining simultaneously 
nicardipine and its pyridine II metabolites (Wu et al.,
1984) .
Nicardipine is rapidly and completely absorbed after
oral administration (Higuchi et al., 1977) and peak plasma
concentrations are reached between 20 minutes and 2 hours 
after dosing.
In spite of the rapid and complete absorption of 
nicardipine from the gastrointestinal tract it has a low 
bioavailability (about 20%). Nicardipine is widely 
distributed throughout body tissues with an apparent volume 
of distribution of 63+19 1 in normal volunteers after 
intravenous administration (Campbell et al., 1985). In this 
study plasma concentrations declined in a bi-exponential 
manner with a terminal elimination half life of 59+34 
minutes and a plasma clearance of 1.2 1/min. This rate of 
plasma drug clearance corresponds approximately to the rate 
of liver blood flow.
There is also some evidence to suggest that the
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metabolic processes for nicardipine may be saturable (Seki 
and Takenaka, 1977; Silke et al., 1984a). The maximum plasma 
concentrations (Cmax) in 6 healthy volunteers given single 
oral doses of nicardipine 10, 20, 30 and 40 mg were 13, 32, 
91 and 253 ng/ml respectively. However, no accumulation of 
nicardipine has been reported in 57 elderly hypertensive 
patient receiving 10-30 mg three times daily for 8 weeks 
(Higuchi and Shiobara, 1980a).
1.5. THE PHARMACODYNAMICS OF CALCIUM ANTAGONISTS
Calcium ions are involved in many biological processes, 
including myocardial and vascular smooth muscle contraction, 
and the smooth muscle contractions of the bronchial tree and 
of the gastrointestinal and urinary tracts. In addition to 
its effects on smooth muscle it also has a role in the 
secretion of hormones.
1.5.1. BLOOD PRESSURE AND HEART RATE
THE MECHANISM OF ACTION OF CALCIUM ANTAGONIST
DRUGS IN HYPERTENSION
A characteristic feature of established hypertension is 
a raised peripheral vascular resistance (Lund-Johansen,
1980). Although the underlying mechanism is not clearly 
established, it has been proposed that, since cytosolic 
free calcium concentration is the final common trigger for 
phosphorylation of contractile proteins, there are close 
parallels between the contraction of myofibrils in smooth
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muscle and the respective contractile proteins in other 
cells such as platelets. As it has been shown in patients 
with essential hypertension that platelet free calcium 
concentrations were elevated and directly correlated with 
the height of systolic and diastolic blood pressure (Erne et 
al., 1984; Asheley et al., 1986 ) the concept has arisen 
that defective "handling” of calcium may be involved in the 
genesis of hypertension (Aoki et al., 197 6; Lederballe 
Pedersen, 1981; MacGregor et al., 1985; Buhler and Kiowski, 
1987) .
The antihypertensive action of calcium antagonist drugs 
mainly results from the vasodilatory effect which stems from 
the inhibition of entry of calcium ions into vascular smooth 
muscle cells, with subsequent reduction in the interaction 
between the contractile proteins. However, the "vasodilator" 
action is accompanied by several other factors which are 
relevant to cardiovascular regulation and may contribute to 
the net antihypertensive effect of calcium antagonists:
1. Increased cardiac output due to the reduction in 
after load which results from vasodilatation.
2. Reflex sympathetic activation (Millar et al., 1982; 
Littler et al., 1983) and activation of the renin-angio- 
tensin system (Asplund et al., 1985; Baba et al., 1987).
3. Direct diuretic and natriuretic action (Young et 
al., 1985), although it seems unlikely that these have 
clinical significance since generally these effects are 
small and not sustained.
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TREATMENT OF HYPERTENSION WITH CALCIUM ANTAGONIST
Calcium antagonist drugs have been shown to be very 
effective in the treatment of hypertension (Lewis et al., 
1978; Midtbo and Hals, 1980; Gould et al., 1984) but their 
definitive position still remains to be established. Both 
verapamil and nifedipine reduce blood pressure significantly 
(Midtbo et al., 1982) but reflex sympathetic activation and 
increased heart rate are more common with nifedipine (Aoki 
et al., 1978; Lederballe Pedersen et al., 1980a) whereas the 
fall in blood pressure after verapamil is not usually 
accompanied by significant changes in heart rate or plasma 
renin activity (Leonetti et al., 1980; Corea et al., 1981).
Rapid falls in blood pressure have been reported after 
oral or sublingual doses of nifedipine (Guazzi et al., 1977; 
Jaker et al., 1989) providing a basis for its use in 
emergencies such as in the treatment of hypertensive crises.
Numerous reports have confirmed the antihypertensive 
efficacy of chronic monotherapy with calcium antagonist 
drugs (Midtbo & Hals, 1980; Anavekar et al., 1982) the 
magnitude of which is comparable to that of beta-blocking 
drugs (Doyle et al., 1983).
Calcium antagonist drugs can also be combined with 
other antihypertensive drugs. Although the combination of 
beta blockers with verapamil is not widely used the same 
combination with nifedipine offers potential advantages not 
only in efficacy but also in reducing side effects. 
Nevertheless, although nifedipine in vivo has less 
cardiodepressant activity than verapamil, some caution
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concerning its potential cardiodepressant activity may be 
necessary in combination with beta-blockers particularly in 
those patients with impaired cardiac function (Singh et al.,
1982) .
Several other studies have reported clinically useful 
additive antihypertensive effects from the combinations with 
a thiazide diuretic (Labriola et al., 1978; Wicker et al.,
1983) and with an alphal-antagonist (Jee and Opie, 1983; 
Pasanisi et al., 1984). Similarly, the combination of calci­
um antagonist drugs and angiotensin converting enzyme inhib­
itors has been shown to be effective, initially in treatment 
of severe and resistant hypertension (Guazzi et al., 1984; 
White et al., 1986) but more recently in a wider range of 
patients with mild to moderate hypertension (Donnelly et 
al., 1986; Lees et al., 1987).
TREATMENT OF HYPERTENSION IN THE ELDERLY
The need for effective, safe and well tolerated 
antihypertensive treatment for elderly patients with 
hypertension has become more apparent since the results of 
the European Working Party on Hypertension in the Elderly 
(EWPHE) trial showed the benefit of blood pressure reduction 
in this population (Amery et al., 1985).
The principal aim of the treatment of hypertension is 
to reduce the morbidity and mortality of cardiovascular 
disease. Since there is a correlation between increasing age 
and increasing blood pressure (Editorial (Lancet), 1981; 
Sower, 1987) the therapeutic approach to hypertension in the
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elderly has naturally generated considerable interest.
Until recently, the benefit of antihypertensive 
treatment of this age group was uncertain. The selection of 
the most appropriate antihypertensive agent for elderly 
patients presented some problems since it was generally 
thought that the therapeutic window of most drugs was 
relatively narrow in this age group and that serious side 
effects might compromise the benefits of treatment. In 
addition, the age-related decreases in renal and hepatic 
function might result in higher drug concentrations with a 
potential further risk of increased toxicity. A further 
complicating factor might also be the presence of a 
concomitant disease state, such as congestive heart failure, 
obstructive airways disease, peripheral vascular disease, 
diabetes or renal failure.
Since calcium antagonist drugs are generally free of 
serious adverse or toxic effects, such as depression of 
central nervous system responses, they appear to be a useful 
possible treatment for the elderly. Furthermore, some early 
studies with calcium antagonist drugs suggested that they 
were particularly effective antihypertensive agents in the 
elderly, in patients with low plasma renin activity and in 
black patients (Buhler, 1988). However, more recent studies 
have shown that these drugs are equally effective in both 
young and elderly hypertensives (Ram, 1987; Montamat and 
Abernethy, 1989) and the apparently greater antihypertensive 
response in the older age group may well be related to their 
higher pretreatment blood pressures (Lederballe Pedersen et
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al., 1980a; Meredith et al., 1987). However, there may be 
age-related qualitative differences in the antihypertensive 
response such as are related to diminished counter-regulato­
ry responses (Gribbin et al., 1971).
1.5.2. A-V CONDUCTION
The conductive tissue in the heart is preferentially 
sensitive to the effect of verapamil and diltiazem resulting 
in prolongation of the P-R interval (Smith et al., 1983). It 
is not specifically clear, however, why the dihydropyridine 
derivatives lack this effect. The effect on the P-R interval 
is also influenced by several other factors:
1. Route of administration- Studies with verapamil have 
shown that the effect on P-R interval varies with the route 
of administration whereby the concentration needed to 
produce a 10% prolongation of P-R interval was 2-3 times 
higher after oral than after intravenous administration. A 
possible explanation for this difference is that the most 
pharmacologically active isomer, L-verapamil, is 
preferentially metabolised by the liver after oral 
administration (Eichelbaum et al., 1980 ; Johnson et al., 
1981; Reiter et al., 1982) whereas, after intravenous 
administration, the two isomers D- and L-verapamil are 
metabolised equally. The overall effect, therefore, is that 
more L-verapamil is available after intravenous 
administration.
2. Age- Since it is possible that there might be 
increased drug levels in the elderly and since there is
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evidence to show that prolongation of P-R interval is 
correlated with verapamil plasma concentrations (Eichelbaum 
et al., 1980) it might have been expected that more 
pronounced prolongations of P-R interval would occur in the 
elderly. However, Abernethy et al. (1986) have shown that 
the P-R prolongation was less pronounced in elderly 
hypertensive patients compared to young hypertensives 
treated with verapamil. This implies that the sensitivity of 
the conductive tissue is decreased in the elderly. In a 
comparative study in a group of young and elderly subjects, 
diltiazem has been shown to be less effective on PR interval 
in the elderly although there was no age-related differences 
in the pharmacokinetics between the two groups (Montamat and 
Abernethy, 1989).
3. Other factors- Heart rate, sympathetic, 
parasympathetic and intrinsic baroreflex activity can 
influence the atrioventricular conduction responses to 
calcium antagonists. For example, the P-R interval shortens 
in relation to an increase in heart rate or sympathetic 
activity.
1.5.3. INOTROPIC EFFECT
All calcium antagonist drugs have negative inotropic 
effects on isolated cardiac muscle due to their inhibition 
of the transmembrane influx of calcium necessary for 
activation of the cross-bridges between actin and myosin. In 
humans, this effect depends on the route of administration 
of the calcium antagonists. For example, nifedipine has the
53
most potent negative inotropic effect when administered 
directly into the coronary arteries; diltiazem and verapamil 
are approximately equipotent when they are given by the same 
route (Nayler et al., 1983). However, if these drugs are 
given by the intravenous, oral or sublingual route, 
verapamil shows the most potent negative inotropic effect; 
and nifedipine is the least depressant; diltiazem is 
intermediate in action. Thus, in intact man, the overall 
effect on cardiac performance reflects the direct negative 
inotropic effects, vasodilatation with reduction in 
afterload as a result of improvement in myocardial perfusion 
and the resultant baroreceptor-mediated sympathetic stimula­
tion of the myocardium. Nevertheless it is possible that the 
therapeutic benefits of these drugs, in the treatment of 
angina and hypertension, might be compromised in those 
patients who additionally have preexisting impairment of 
cardiac function.
The mechanisms by which calcium antagonists produce 
their different inotropic effects have been widely studied. 
In a study in guinea pigs, for example, the positive 
inotropic response to A 23187 (an agent which is known to 
transfer calcium into the cell without involving the calcium 
channels) was not influenced by nifedipine and was only 
slightly antagonised by verapamil and diltiazem (Boddeke et 
al., 1988). In contrast the positive inotropic effect of BAY 
K8644 (a calcium promoter through the dihydropyridine 
channel) was blocked by nifedipine, verapamil and 
diltiazem. These findings suggest that the negative
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inotropic effect of calcium antagonists is not simply due to 
blockade of calcium entry but also involves other mechanisms 
at the cellular level, perhaps inhibition of calmodulin or 
inhibition of the release of sequestered calcium.
1.5.4. LIVER BLOOD FLOW
The liver is the central metabolic organ in the body 
and therefore liver blood flow and the integrity of hepatic 
enzyme systems are the major determinants of hepatic 
metabolic function. In recent years clinicians and 
pharmacologists have paid close attention to the problem and 
limitation of the techniques for assessing liver blood flow 
as it has been found that drug metabolism can be influenced 
by changes in liver blood flow.
Different methods have been described for the 
measurement of liver blood flow (Ohnhaus et al., 1979). Some 
of these methods are highly invasive and involve 
catheterisation of the hepatic vein (Woodcock et al., 1981) 
and thus are not suitable for research purposes. The 
indirect methods which depend on the clearance of a highly 
extracted marker such as indocyanine green, have the 
advantages of being non-invasive. Indocyanine green (ICG) is 
a sterile, water soluble, tricarbocyanine which is widely 
used and preferred because it does not undergo 
biotransformation in the liver and there is no evidence of 
enterohepatic recirculation. In addition reliable methods 
have been developed for its measurement using 
spectrophotometry or HPLC (Rappaport et al., 1982).
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Studies with calcium antagonists have shown that 
verapamil, nisoldipine and nifedipine significantly increase 
liver blood flow (Feely et al., 1984; Meredith et al.,
1985a,b). However, this increase in liver blood flow is 
particularly pronounced after acute dosing and declines 
towards baseline values with continued administration 
(Meredith et al., 1985a,b). The underlying mechanism 
responsible for this pattern of change is not clear but may 
reflect either increased cardiac output, consequent upon 
afterload reduction, or direct portal and splanchnic 
vasodilatation or both.
1.5.5. RENAL FUNCTION
Maintaining (ideally improving renal perfusion) is an 
important aim in the treatment of hypertension.
Reduction of blood pressure and cardiac contractility 
by calcium antagonists potentially might compromise renal 
function. However, because calcium antagonists are potent 
vasodilators renal blood flow is preserved, despite the 
reduction in blood pressure. This is a potential therapeutic 
advantage of calcium antagonists in patients with renal 
impairment since there is some evidence that betablockers 
(particularly propranolol) reduce renal blood flow and 
glomerular filtration rate (Warren et al., 1974; Webber and 
Drayer, 1980; Bauer et al., 1983). Thiazide diuretics are 
less effective when there is a moderate to severe renal 
impairment and angiotensin converting enzyme inhibitor may 
have adverse effects on renal function especially where
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there is renovascular disease and the maintenance of 
adequate renal plasma flow is dependent on the renin 
angiotensin system (Hricik, et al., 1983; Curtis, et al.,
1983). Not only do calcium antagonist drugs avoid reducing 
ERPF but there is evidence that renal plasma flow and 
glomerular filtration rate may in fact be increased, at 
least in the short term, in normotensive and hypertensive 
patients after the administration of nisoldipine, verapamil, 
nifedipine and nicardipine (Yokoyama et al., 1983; Van Shaik 
et al., 1984; Meredith et al., 1985a,b; Baba et al., 1986; 
Chaignon et al., 1986).
1.6. EFFECT OF AGE ON THE PHARMACOLOGY OF CALCIUM
ANTAGONISTS
The increasing proportion of middle-aged and elderly 
patients in the general population has stimulated a specific 
interest in the factors which influence the responses of the 
elderly to various drugs, including the calcium antagonists. 
There are two basic factors which can modify the response to 
a drug: firstly, as already discussed (1.4), age-related 
changes in drug clearance, disposition and plasma 
concentration. Secondly, alteration to the response mediated 
via an "effector" site, either directly with respect, for 
example, to the number and affinity of the responsible 
receptors, or indirectly in terms of the extent of the 
compensatory cardiovascular responses.
Age related structural and physiological changes have 
been recognised which are associated with altered hepatic
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drug metabolism in the elderly. Such changes include 
reduction in liver size and liver blood flow, in the 
synthesis of binding protein and in the capacity of the 
metabolising enzymes. Other factors such as nutrition, 
disease state, concomitant drug administration, genetics, 
smoking habit and environmental factors can additionally 
affect the metabolism of drugs in the elderly.
While there is a good evidence in man that liver blood 
flow declines with age (Bender et al., 1965/ Wynne et al., 
1988), there is only indirect evidence from pharmacokinetic 
studies to suggest a reduction of hepatic enzyme capacity. 
However, in animal studies an age-related reduction in 
hepatic metabolic capacity has been demonstrated (Kato and 
Takanaka, 1968). These age-related changes in liver function 
can affect drugs such as the calcium antagonists since the 
liver is the major site for their metabolism.
1.7. THE METABOLIC AND HORMONAL EFFECTS OF CALCIUM
ANTAGONISTS
Several epidemiological studies have established that 
the prevalence and incidence of clinical ischemic heart 
disease in western countries are correlated positively with 
plasma total cholesterol and low density lipoprotein 
cholesterol (LDL) and negatively with the plasma high 
density lipoprotein cholesterol (HDL) (Miller et al., 1977; 
Hulley et al., 1980; Castelli et al., 1986). These findings 
have produced an increased awareness of the need to 
investigate the metabolic effects of antihypertensive drug,
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on plasma lipids, especially for those drugs which have 
recently been licensed. The effects of different 
antihypertensive drugs on plasma lipid are summarised in 
table 1.4.
Beta blockers, including propranolol, and thiazide 
diuretics have been used for many years for the treatment of 
hypertension and have been proved effective in controlling 
high blood pressure. However, several large clinical trial 
have shown that treatment regimens based upon propranolol or 
thiazide diuretics have made no significant difference to 
the overall rate of coronary events, although the total 
cardiovascular events (which include stroke and coronary 
heart disease) are significantly reduced (MRC, 1985). This 
relative lack of therapeutic success raised the possibility 
that drug-induced adverse metabolic changes, particularly on 
serum lipids and lipoproteins, might be compromising the 
benefits of blood pressure reduction.
As described earlier in this chapter, since calcium 
ions have an established role in the processes which are 
responsible for the secretion of hormones, it is important 
to investigate the effect of calcium antagonist drugs on 
hormonal secretion and metabolic responses. A number of 
published studies have investigated the effect of calcium 
antagonist drugs on insulin secretion. No significant 
interference was found with verapamil (Rojdmark, 1979; 
Anderson and Rojdmark, 1980) or with nifedipine (Joffe et 
al., 1983) or nicardipine (Dow et al., 1985). Similarly, 
there was no significant effect on the secretion of
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TABLE 1.4.
THE EFFECT OF ANTIHYPERTENSIVE TREATMENT 
ON PLASMA LIPIDS AND LIPOPROTEINS (MODIFIED 
FROM WEINBERGER, 1985)
D ru g t o t a l
c h o l e s t e r o l
HDL T r i g l y c e r i d e
Diuretics
Chlorthalidone t ns t
Hydrochlorthiazide t ns t
Beta blockers
Propranolol I t
Atenolol ns I t
Pindolol ns ns ns
Calcium antacronists
Nicardipine ns ns
Nifedipine ns ns
Verapamil ns ns ns
Others
Methyldopa ns —  1 ns
Prazosin I —  t t l
Captopril ns ns ns
Row represent direction of effect; ns: not significant.
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leutinizing hormone (LH), follicular stimulating hormone 
(FSH) or thyroid stimulating hormone (TSH) (Struthers et 
al./ 1983/ Isles et al., 1985).
1.8. THE SIDE EFFECTS OF CALCIUM ANTAGONISTS
Generally, calcium antagonist drugs are well tolerated. 
The most common side effects, which are an extension of the 
vasodilatory effects, are usually transient although 
occasionally they result in withdrawal of the drug. Thus, 
ankle oedema and headache are more common with nifedipine 
whereas verapamil is commonly associated with constipation 
and atrio-ventricular block (table 1.5.) .
1.9. SCOPE OF THE THESIS
This thesis aimed to clarify some aspects of the 
clinical pharmacology of calcium antagonist drugs.
Detailed studies have been undertaken with verapamil 
and nicardipine. These studies have addressed several 
themes. For example the antihypertensive responses to 
verapamil and some of the possible determinants of the 
responses such as age, plasma renin activity, pretreatment 
blood pressure have been investigated in hypertensive 
patients using concentration effect modelling. The safety 
and the effect of verapamil on left ventricular function in 
middle age and elderly patients with stable angina has been 
investigated.
Using pooled data from 74 subjects receiving verapamil, 
age related changes in pharmacokinetics of verapamil have
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TABLE 1.5.
THE REPORTED SIDE EFFECTS AFTER 
TREATMENT WITH CALCIUM ANTAGONISTS
Calcium antagonist Side effect
Verapamil Constipation (30%)
Facial flushing (8%) 
Dizziness (6%)
Headache (8%)
AV block (1%)
Worsening of heart failure
Nifedipine Ankle oedema (15%)
Facial flushing (12%) 
Headache (6%)
Nausea (3%)
Tachycardia (15%)
Dizziness (3%)
Diltiazem Headache (2%)
Facial flushing (1%)
Nausea (3%)
Ankle oedema (2%)
Constipation (22%)
The figures in parentheses are included to give an 
idea of the frequency with which these side effects 
are encountered (modified from Nayler, 1988).
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been investigated.
The pharmacokinetics and pharmacodynamic of the single- 
isomer d-verapamil have been studied in healthy volunteers 
aiming to reach high plasma levels suitable for adjuvant 
activity to enhance the activity of anticancer drugs.
On nicardipine, two studies have been completed. One to 
evaluate its effect on serum lipids and hormones and the 
other on the effect of renal impairment and haemodialysis on 
the pharmacokinetics of nicardipine.
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CHAPTER TWO 
METHODS
2.1. GENERAL PROCEDURES
All protocols for the studies described in this thesis 
received prior approval by the Research and Ethical 
Committee of the Northern District of Greater Glasgow Health 
Board. All subjects gave written informed consent. For those 
studies which used radionuclides for the assessment of 
cardiac function or renal function subjects were 
particularly informed about their use. An ARSAC 
(Administrative of Radioactive Substances Advisory 
Committee) certificate is licensed to the supervisor, Dr. 
Elliott.
All subjects had routine clinical, biochemical, 
haematological and electrocardiographic examinations before 
starting each study and at the end of each study. Subjects 
reported to the clinical pharmacology research unit 
(C.P.R.U.) at approximately 08.30 in the morning having 
abstained from food, alcohol, nicotine and caffeine from 
2200 on the night before the study day. An intravenous 
cannula was introduced into an antecubital vein for blood 
sampling. A fresh solution of heparin in normal saline was 
prepared for each subject and used to keep the cannula 
patent after blood collection. Thereafter, the subjects 
rested for at least 20 minutes before any recordings were 
taken.
2.2. ASSAY FOR DRUGS
2.2.1. DETERMINATION OF VERAPAMIL AND NORVERAPAMIL
Verapamil and norverapamil plasma concentrations were
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determined by an HPLC method (Cole et al., 1981). This 
method has the advantages of being sensitive for detection 
of low plasma levels, employs simple extraction procedures 
and permits the simultaneous determination of verapamil and 
its major metabolite, norverapamil.
The mobile phase was a solution of potassium bromide (3 
mM) and perchloric acid (0.37 mM) and was helium-degassed 
before use. A constant flow rate of 2.0 ml/min was 
maintained by a pressure of approximately 60 bar.
Sample preparation
Plasma or serum (100 pi) was pipetted into a small 
(Dreyer) test-tube (Poulton, Selfe and Lee, Wickford, Great 
Britain). Internal standard solution (50 /al), sodium 
hydroxide solution (50 pi) and methyl tert.-butyl ether (200 
pi) were added using Hamilton repeating mechanism fitted 
with Hamilton gas-tight Luer-fitting glass syringes and 
stainless steel needles. The contents of the tube were 
vortex-mixed for 30 seconds and centrifuged at 9950 g for 2 
minutes in an Eppadrof centrifuge. Subsequently, a portion 
(approximately 110 pi) of the extract was taken and used to 
fill the sample loop of the injection valve.
Samples were analysed in duplicate and the mean result 
was taken.
The intra-assay and the inter-assay coefficients of 
variation were less than 5% for both verapamil and 
norverapamil. The limit of detection of the assay was 2 
ng/ml using a 100 pi sample.
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2.2.2. DETERMINATION OF NICARDIPINE
The plasma concentrations of nicardipine were 
determined by an HPLC method developed by Wu et al. (1984).
This method permits the simultaneous measurement of 
nicardipine and its pyridine metabolite. These assays were 
carried out in Syntex Research Laboratories, Riccarton 
Scotland.
2.3. PHARMACOKINETIC ANALYSIS
The pharmacokinetics of verapamil and its principal 
metabolite norverapamil were analysed both by model- 
dependent and model-independent means. The area under the 
concentration time curve to infinity (AUC) was calculated by 
application of the trapezoidal rule over the period of 
plasma sampling, plus the residual area. The area of the 
trapezoid is 1/2 (Cl +■ C2) * At. If At is too large 
(greater than 4 hours) the area of the trapezoid can be 
accurately measured by logarithmic trapezoidal rule so that:
(Cl - C2)*At
The area of the trapezoid=------   —
InCl - lnC2
Where Cl and C2 are two consecutive plasma concentrations,
At is the time between these points and (In) is the natural 
logarithm. From this, apparent oral clearance was determined 
by dividing dose by the AUCq_0o for acute dosing and dose by 
the AUCq_t for chronic dosing, where T is the dosage 
interval. Terminal elimination half-life was estimated from 
the log linear regression of the final concentration data
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points. The verapamil and norverapamil concentrations were 
then analysed by model-dependent methods by fitting to a 
hierarchy of different models, the most appropriate model 
being selected by application of the General Linear Test 
(Boxenbaum et al., 1974). In all individuals the most 
appropriate model was an integrated model in which parent 
drug concentrations were fitted by a two-compartment model 
whilst the metabolite norverapamil was simultaneously fitted 
by a third compartment arising from the drug central 
compartment (figure 2.1.). The concentrations after the 
intravenous administration of verapamil were appropriately 
fitted by a two compartment model with a first order input 
to the central compartment (figure 2.2.). The concentrations 
after intravenous infusion were best fitted to a two 
compartment model of the form described by Gibaldi & Perrier 
(1975) :
R0(K21- a.) (e~OT -1) R0< j6-K21).(ei3T -i)
_c= ------------------- e"0* +   e"|3t
v c a (a - (3 ) v c (a  -  | 8 )
Where,
C = Plasma concentration (ng/ml)
Rq = Infusion rate (/ag/h)
K 2 1 = Apparent first order mass rate constant associated
with movement of-the drug from the peripheral to the central
compartment (h-^).
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Vc = Volume of distribution of the central compartment (1) 
aj3 = Hybrid rate constant (h~^) . 
t = Time following start of infusion (h).
T = Time of infusion (h).
The derivations of the pharmacokinetic model are shown 
in appendix I.
The bioavailability (F) was calculated according to the 
following equation:
AUCoral x Dosei .v.
F = -------------------
AUCi.v. x Doseoral
2.4. CONCENTRATION-EFFECT RELATIONSHIP ANALYSIS
The establishment of a relationship between plasma 
drug concentrations and effect is an important tool in the 
assessment of dose requirements in individual patients.
Most previous studies on calcium antagonist drugs have 
shown a wide interindividual variability in pharmacokinetics 
and such variability clearly contributes to the large 
differences in response between patients.
Although, a simple direct relationship between plasma 
concentration and effect can be est-ablished for some drugs, 
for many drugs such a relationship cannot be simply 
established, primarily because the concentration-time 
profile is out of phase with effect-time profile (Whiting 
and Kelman, 1980) (figure 2.3.). This phase discrepancy 
might reflect the formation of an intermediate active
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K12
K21
K1M
K10
P a r a m e te r s  of th e  model 
A, Alpha, B, B eta ,  Ka, 
KIM.Vc/VM, KMO
KMO
Figure 2.1. Schematic representation of two compartment 
. model following oral administration 
C=central compartment.
P=peripheral compartment.
K^2=first order rate constant of drug transfer 
between the central and peripheral compartment 
K2^=first order rate constant of drug transfer 
between the peripheral and central compartment 
K^o=slimination rate constant from the central 
compartment.
KiM^first order rate constant of drug transfer 
between the central and metabolite compartment 
KMQ=elimination rate constant from the metabo­
lite compartment.
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I.V. DOSE
K12 •c P
K21
/
K10 P a r a m e te r s  of th e  model
A, Alpha, B, B e ta
Figure 2.2. Schematic representation-of two compartment 
model following intravenous administration 
C=central compartment.
P=periphe.ral compartment.
K^2=first order rate constant of drug transfer, 
between the central and peripheral compartment 
K2i=first order rate constant of drug transfer 
between the peripheral and central compartment 
K]i Q=elimination rate constant from the central 
compartment.
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substance or metabolite or simply reflect the time required 
for drug to be made available at the receptor site and 
produce an effect. To take account of this delay in effect 
Sheiner et al./ (1979) has developed a model which inte­
grates kinetics and dynamics. This model augments the cen­
tral and peripheral pharmacokinetic compartments with an 
effect compartment which is small enough that it feeds in 
only one direction from the predetermined kinetic 
compartments (figure 2.4.). The mathematical derivation of 
this compartment is:
dXe/dt=KleXl - KeqXe .
Where XI is the amount of drug in the central compartment,
Xe is the amount of drug in the effect compartment, K^e and 
Keq are first order rate constants which describe the entry 
and removal of the drug to and from the effect compartment. 
To characterise the concentration-effect relationship, 
effect (E) which is, for example, reduction in blood pres­
sure is related to the concentration of drug in the effect 
compartment (Ce) by means of a Langmuir (Emax) model or a 
simple linear model of the form E=mCe + i. In many inst­
ances, for the range of the concentrations and the magnitude 
of the effects obtained in clinical studies, a linear model 
is often appropriate (figure 2.5.). Thus, a concentration- 
effect relationship can be established for each individual 
patient and, from the linear model, parameters such as 
"sensitivity" ("m") can be obtained: this is defined as the 
magnitude of blood pressure reduction in mmHg per unit 
change in drug concentration.
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I C o n c e n t r a t i o n  
I p ro f i l e E f f e c t  !
T i m e
Figure 2.3. A schematic representation of the discrepancy 
between the concentration time profile and 
effect profile.
K12
K21
K10
linear model
E • mCe ♦ i
Keq m * responsiveness
Figure 2.4. Extended kinetic model which incorporates the 
pharmacokinetic and pharmacodynamic model, C= 
central compartment, P= peripheral compart­
ment, E= effect compartment which is small 
enough to effect the pharmacokinetic compart­
ments .
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E = f(Ce)
Sigmoid model
Emax
inear  model
Ce m = r e s p o n s i v e n e s s
Figure 2.5. Effect (E) which is blood pressure reduction
■ as a function of drug concentration in the
effect compartment (C0). A sigmoid relation­
ship could well describe the data but in 
clinical practise the linear part of the 
sigmoid curve (marked by box) is often more 
relevant.
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2.5. HORMONES AND METABOLIC ANALYSIS
2.5.1. PLASMA RENIN ACTIVITY
Plasma renin activity was measured by an indirect 
method which involves incubating plasma with the substrate, 
angiotensinogen (Derkx et al., 1972).
Renin + angiotensinogen ..  ■- » angiotensin I
(in plasma)
The enzymatic reaction which leads to the generation of 
angiotensin I is stopped after a fixed period and 
angiotensin I levels are determined by radio-immunoassay.
The normal range for plasma renin activity is 0-12 ng 
Al/ml/h with intra- and inter-assay coefficient of variation 
of 7% and 5.5% respectively.
2.5.2. PLASMA ALDOSTERONE
Plasma aldosterone concentration was measured by 
radio-immunoassay using commercially available kit methods 
(SB-ALDO-M, SB-ALDO, SB-ALDO-D). Venous blood was collected 
into lithium heparin tubes. The principle of the assay 
depends on competition between - ^ ^ I - l a b e l l e d  aldosterone and 
the aldosterone contained in standards or in specimens with 
a fixed and limited number of antibody binding sites. After 
incubation, the amount of labelled aldosterone bound to the 
antibody is inversely related to the amount of unlabelled 
aldosterone present in the sample. The method adopted for
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bound/free separation is based on the use of antibody-coated 
tubes in which the antibody is fixed on to the tube walls by 
the method of Catts. Plasma samples, or standards, were 
added to the antibody treated tubes, mixed by vortex and 
incubated at 2-8 °C for 18-24 hours. The contents of the 
tubes were carefully aspirated and rinsed and the 
radioactivity (^^I) 0f ^he tubes was counted by a gamma 
counter. For each group of tubes, the mean count (corrected 
for background activity) was calculated as a percentage of 
the zero "standard" group:
std or sample
B/Bo% = -------------  x 100
std "0"
Where B is the counted radioactivity, Bo is the background. 
Std "0" is the counted radioactivity of the radioactive free 
standard sample.
The standard curve was constructed by plotting B/Bo 
versus the concentrations (pg/ml) on linear-linear 
coordinates.
The assay is sensitive for concentrations greater than 
10.5 + 2.2 pg/ml. Within-assay coefficient of variation is 
7.8% and between assay is 12.4%. Normal range is 12-125 
pg/ml supine and 70-295 pg/ml erect.
2.5.3 SERUM LIPIDS
The serum was separated by centrifugation for 10
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minutes at 1000 x g and stored at 4°C for not more than 5 
days prior to the analysis. Serum triglyceride was measured 
enzymatically (Bucolo & David, 1973) using a Techncon RA 
1000. Cholesterol concentrations were estimated manually 
using an enzymatic technique (Allain et al., 1974). Very low 
density lipoprotein (VLDL) was separated by ultracentri­
fugation (Airfuge. Beckman Instruments Ltd.) (Farish et al., 
1983); High density lipoprotein (HDL) and subfractions were 
quantified using the method of Eyre et al., (1981) and Low 
density lipoprotein (LDL) cholesterol levels were calculated 
by subtraction.
Free fatty acid was analysed using a commercial kit 
(Wako Chemical GmbH, GDR).
2.5.4. SERUM INSULIN
Blood samples were collected in plain tubes. Serum was 
separated by centrifugating for 10 minutes at 1000 x g and 
stored at -20 °C until analysis.
The serum was diluted with assay diluent (0.05 m 
phosphate buffer, PH 7.4 containing bovine plasma albumin) 
and incubated overnight at 4 °C. 100 pi of -^^I-labelled 
insulin is added and the mixture is incubated for 3 hours at 
room temperature. 200 pi of sheep anti-guinea pig serum 
linked to sepharose CL-4B beads (solid-phase 2nd antibody) 
is added and the mixture then shaken for 30 minutes, sepa­
rated by washing and centrifugated between washes with 2 ml 
of 0.9% normal saline using the Watson Marlow semiautomatic 
washing apparatus. Gamma counter NE 1600 linked to apple II
77
linked to apple II microprocessor was used to calculate the 
level of insulin.
2.5.5. PLASMA LACTATE
The lactate level was analysed by enzymatic UV-method 
(Boehringer Mannheim GmBH). The principle of the test is 
based on the conversion of L-lactate to pyruvate by the 
enzyme lactate dihydrogenase (LDH).
L-Lactate + NAD 1 -■ — ^ pyruvate + NADH + H+
Pyruvate + L-alutamate~    ^ L-alanine + alpha-oxoglutarate
2 mis of blood were collected in fluoride/EDTA-tubes and 
centrifuged for 5 minutes at 3000 rpm. Plasma was separated 
and stored at -20°C until analysis. Normal range is 5.7 - 22 
mg/100 ml (0.63 - 2.44 mmol/1).
2.5.6. PLASMA ADRENALINE AND NORADRENALINE
Plasma adrenaline and noradrenaline concentrations were 
estimated by radio-enzymatic assay of Peuler and Johnson 
(1977). Venous blood samples were collected into lithium 
heparin tubes. Plasma was separated by centrifugation at 4°C 
and 300 rpm for 10 minutes and stored at -70 °C until 
analysis. The principle of the method is based on the 
utilisation of the enzyme catechol-O-methyl transferase 
(COMT) to transfer a radioactive methyl group from 
S-adenosyl-L-methionine (SAM) to an endogenous catecholamine
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levels of picomoles. The intra-assay coefficient of 
variation for adrenaline and noradrenaline was 13% and 10% 
respectively.
2.5.7. THYROID FUNCTION TEST (TSH & T4)
Thyroxine (T4) was analysed using Amerlex-MT4 
radioimmunoassay kit. The sensitivity of the methods is 
better than 4.0 nmol/1. The method is specific for thyroxine 
(T4). However cross-reactivity occurs with L-tri- 
iodothyronine (12%). The normal range of T4 = 62-165 nmol/1.
TSH was analysed using radio-immunoassay method using 
RIA-Gnost hTSH kit. In normal thyroid function TSH = 0 . 1 - 4  
jilU/ml.
2.6. PHARMACODYNAMICS MEASUREMENTS
2.6.1. BLOOD PRESSURE AND HEART RATE
After at least 20 minutes in the recumbent position, 
blood pressure and heart rate were recorded in duplicate by 
semiautomatic recorder (Sentron, Bard Medical) both supine 
and after 2 and 5 minutes in erect position. The "Sentron" 
monitor is an accurate, noninvasive arterial blood pressure 
monitor which uses the oscillometric method of pressure 
determination. The oscillometric method makes use of the 
pressure pulsations which are induced into the cuff by the 
pulsatile motion of the artery wall while partially occluded 
by a compressive cuff. Systolic and diastolic pressure are 
determined by a microprocessor analysis of the pulsation
amplitudes which are measured and recorded at a succession 
of cuff pressure. Accuracy of cuff pressure measurement 
correlates with a pressure standard +1% (Johnson et al., 
1985).
2.6.2. DETERMINATION OF GLOMERULAR FILTRATION RATE AND 
EFFECTIVE RENAL PLASMA FLOW.
Effective renal plasma flow and glomerular filtration 
rate were estimated from the clearance of [-^^I] -hippuran 
and [^Crj-EDTA respectively. The radioactive compounds were 
administered simultaneously by intravenous bolus injection 
(5mls total volume). Blood samples were collected from the 
contralateral side before the injection and at 2, 5, 10, 20, 
30, 60, 90, 120, 180, 240 minutes after the injection. 
Patients were asked to empty the urinary bladder before the 
injection and then urine was collected over the following 4 
hours. Fluid intake was encouraged during the test.
Blood samples were centrifuged and plasma removed . 
Equal aliquots (usually 1 ml) were taken from each of the 
plasma samples, the urine and a standard solution consisting 
of the dose made up to one litre with water. The activity of 
the samples was measured by a Packard Counter Auto-Gamma, 
model 5650). The results obtained for one subject are 
presented in table (2 .1 .) and figure (2 .6.).
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TABLE 2.1.
THE RADIOACTIVITY COUNT OF 51Cr-EDTA FOR A REPRESENTATIVE
PATIENT (J.M.) OBTAINED FROM GAMMA COUNTER
Time
(min)
Count Background corrected plasma activity * 
activity (% dose/1)
Bkg 48
0 51
2 986 935 14.62
5 586 535 8.36
10 456 405 6.33
20 384 333 5.20
30 344 293 4.58
60 272 221 3.45
90 233 182 2.84
120 214 163 2.55
180 173 122 1.90
240 141 90 1.40
* Plasma activity =(plasma count-BKgd)/ (std.count-BKgd)xl00
Standard count =6442
Urine count =16114
Total urine volume/4 hours=245 mis
The calculated area under the curve (by trapezoidal rule) of
the plasma activity expressed as % dose/l=715
(16114-48)x 245 x 100
% dose excreted in urine = ------------------------
(6442-48)x 1000
= 61.56%
Clearance (GFR) = dose/AUC = 61.56/715 =86 ml/min.
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Figure 2.6. A graph of the plasma activity of Cr-EDTA 
(for GFR measurement) vs time for a repre­
sentative subject. The area under the con­
centration time curve (AUC) was calculated 
by trapezoidal role. Elimination rate 
constant was calculated by fitting the 
terminal part of the curve to one 
exponential.
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If urine collection is not complete or there is no 
urine data then it is assumed that 100% of the radioactive 
material injected is excreted in the urine after an infinite 
time. Hence GFR=100/AUCq_q^ . The area under the curve to 
infinity is calculated by adding the AUCq_4 to the AUC of 
the terminal part which can be obtained by fitting the 
terminal part of the elimination phase of the plasma 
activity to an exponential function and then by dividing the 
last concentration by the elimination rate constant. Hence 
GFR (extrapolated) = 100 x 1000/1016 = 98 ml/min.
The determination of renal plasma flow is similar to 
the GFR except that 5% of ^Cr-EDTA count subtracted from 
the radioactivity count of -hippuran to allow for the
interference caused by ^Cr-EDTA.
The individual data for glomerular filtration rate or 
renal plasma flow are adjusted for body surface area. The 
average normal body surface area for an adult is 1.73 square 
meters. Body surface areas for individuals were calculated 
from an equation described in Martindale (Reynolds, 1982) .
s = w0.45 x R0.725 x 71.84 (a constant)
Where S = surface area in square centimetres, W = weight in 
kilograms, and H = height in centimetres.
2.6.3. DETERMINATION OF LIVER BLOOD FLOW
Indocyanine green (ICG) was administered intravenously 
as a bolus dose of 0.5 mg/kg and blood samples were
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collected every 3 minutes over 24 minutes. The 
concentrations of ICG in plasma were analysed by HPLC method 
(Rappaport et al., 1982). The concentration time profile for 
each individual and after each treatment was fitted to a one 
compartment model. Volume of distribution and plasma 
clearance of ICG were calculated directly from curve fitting 
(figure 2.7.). The plasma clearance of ICG which 
approximates to liver plasma flow is corrected for 
haematocrit to calculate apparent liver blood flow (Caesar 
et al., 1961).
Clp x 100
Liver blood flow = ----------
1 - HCT%
2.6.4. LEFT VENTRICULAR EJECTION FRACTION
Radionuclide angiography has been increasingly utilised 
in the evaluation of left ventricular function in a variety 
of disease states. It is relatively safe and non-invasive 
and can be repeated on the same individual after a short 
period of time (for example 30 minutes).
The study was performed in the Nuclear Medicine 
Department, Stobhill general hospital.
The patients were injected with intravenous "Amerscan" 
(a stannous red blood cell agent containing stannous 
fluoride and sodium medronate) to facilitate the binding of 
the radioactive material to red blood cells. ECG electrodes 
were placed on the left and right shoulder and at the apex
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Figure 2.7. The concentration time profile of indocyanine 
green (ICG) injected as a bolus intravenous 
dose (0.5 mg/kg). One compartment model was 
appropriate for describing the concentration 
time profile.
85
of the heart. The electrodes were connected to a Rigel 
monitor and gating circuit which provides a suitable signal 
for input to a Nodecrest V77-600 computer (figure 2.8.) •
The patients then rested in the supine position. Twenty 
to thirty minutes after the injection of the Amerscan/ 800 
MBq (22 mCi) ^ mTc-pertechnetate was injected intravenously. 
This labels the circulating red blood cells with ^^mTc.
After a few minutes the face of the gamma camera was set at 
45 to the horizontal and placed as close to the left side of 
the chest as possible.
A total of 4 X 106 counts were acquired by the gamma 
camera and computer. The computer divides the cardiac cycle 
(between two R waves) into 20 frames which show the 
radioactivity at different stages of the cardiac cycle.
To ensure that a given frame represents the same stage of 
the cardiac cycle/ beats which differ in length by more than 
10% from the value specified at the start of the acquisition . 
were rejected.
At the end of the acquisition/ a region of interest 
(ROI) is drawn around the left ventricle on the end of 
diastole frame (usually frame 1). In addition a crescent 
shaped area is drawn around the outer wall of the left 
ventricle/ to represent background activity. The left 
ventricle ROI is then corrected for background and the left 
ventricle activity-time curve is generated (fig 2.9.).
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Rigel monitor 
Computer terminal \ Gamma camera
\ Bicycle ergometer
Figure 2.8. A photographic representation of the
equipments used for the measurement of left 
ventricular ejection fraction at rest and 
during exercise:the face of the gamma 
camera placed close to the left side of the 
chest and linked to Nodecrest V77-600 com­
puter. ECG electrodes were placed on the 
left side of chest and connected to Rigel 
monitor.
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Figure 2.9. Left ventricle activity-time curve
(expressed as fraction of end diastolic 
activity).
The minimum of this curve represents the point of end 
systole (ES) and the ejection fraction is calculated as:
ED - ES
Ejection fraction % = --------
ED
where ED = end diastolic radioactivity count
ES = end systolic radioactivity count
The cardiac cycle is divided into 20 frames; each frame 
takes 1/20 of a second (for a heart rate of 60 bpm). The
mean difference in ejection fraction between observers is
about 1% and the mean within subject difference is about 5%.
2.6.5. P-R INTERVAL
P-R interval is an electrocardiographic (ECG) term 
which refers to the distance on the ECG trace between the 
beginning of P-wave and beginning of Q-wave (figure 2.10.).
Lead II ECG was recorded at a speed of 50 mm/s and ten 
consequent cardiac beats were used for the calculation of 
P-R interval.
A digitiser linked to Nodecrest V77-600 computer was 
used for the calculation of P-R interval. This method is 
faster and relatively more accurate than using the ruler for 
the measurements.
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RST
Interval
PR 
Interval»
QRS
Complex
QT Interval
Figure 2.10. Schematic presentation of Electrocardiogram
(ECG). PR interval measured from the 
beginning of P wave to the beginning of 
Q wave.
Standard times (ms):
PR = 120 - 200
ST = 270 - 330
QT = 350 - 420
QRS = 80 - 110
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2.7. DATA ACQUISITION AND STATISTICAL ANALYSIS
Data were transcribed and stored on an electronic 
spread sheet (Lotus 123) which offered the following 
advantages:
1. Data can be manipulated with reasonable flexibility 
so that full exploration is relatively straightforward and 
an output file, to suit the format needed by a particular 
statistical package, can easily be prepared.
2. The output data file can be exported to powerful 
statistical packages such as Statgraphics or Minitab which 
run on microcomputers.
3. The output file can be also transferred to the 
University main frame computer using a transfer programme 
(Kermit, Ver 2.31) which is available in the Department on 
Apricot personal computer. Transferred data can be analysed 
directly by "Rummage" or "BMDP" statistical packages.
STATISTICAL ANALYSIS
The data were first plotted on appropriate graph 
paper and normality of distribution was tested using 
method. If the data did not follow the normal distribution 
pattern, various transformation were attempted, such as 
Logarithmic or natural Logarithmic transformation.
Parametric tests, which are potentially more powerful 
and more informative than non parametric tests, were 
preferred if possible, after appropriate data 
transformation, rather than application of non-parametric 
test.
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Repeated measures analysis of variance (ANOVA) was used 
(using Rummage statistical package) for the evaluation of 
time and treatment effects for the repeated measurements of 
blood pressures and heart rate. This package has the advan­
tage on "BMDP" of performing the test of time/treatment 
interactions.
For the analysis of the metabolic and hormonal 
responses to nicardipine (chapter 8), because some of the 
repeated observations were interdependent and therefore 
potentially "correlated" (a critical violation of the 
assumption for regular ANOVA) (O'Brien et al., 1985), an 
alternative statistical test, multivariate analysis of 
variance (MANOVA), was considered. MANOVA is a 
generalisation of ANOVA that allows the researcher to 
analyse more than one dependent variable (Bray et al., 1985) 
but, if the sample size is small, it is less powerful and 
has no advantage over ANOVA.
Ninety five percentage (95%) confidence intervals were 
calculated based on the equation published by Altman and 
Gardner (1988). Power of the test to detect a given 
difference was calculated according to formulae described by 
Jacob Cohen (1979) and Machin & Campbell, (1987).
A P-value of less than 0.05 is considered statistically 
significant.
Bonferroni correction has been applied, as appropriate, 
to allow for multiple comparisons.
Various additional statistical tests, including paired 
and unpaired t-tests and linear regression analysis were
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carried out for specific circumstances and are described in 
the appropriate chapters.
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CHAPTER THREE
AGE AND ANTIHYPERTENSIVE EFFICACY OF VERAPAMIL: APPLICATION 
OF CONCENTRATION EFFECT ANALYSIS
94
INTRODUCTION
Buhler and colleagues (1982) have described a 
relatively greater antihypertensive efficacy to calcium 
antagonist drugs in elderly hypertensive patients and in 
patients with low plasma renin activity (Muller et al.,
1984; Kiowski et al., 1985). Although the underlying 
mechanism was not clearly defined there are two fundamental 
possibilities; an age related increase in plasma drug 
levels, presumably reflecting a reduction in plasma drug 
clearance; or an increase in tissue responsiveness; or 
possibly both.
Recent studies have demonstrated that it is possible to 
define a relationship between the plasma concentrations of 
different antihypertensive drugs and the blood pressure 
reductions in individual patients (Meredith et al., 1983; 
Elliott et al., 1984; Donnelly et al., 1988) by means of 
concentration-effeet analysis or "effect modelling" , as 
first proposed by Sheiner et al. (1979). This approach,
which integrates the kinetic and dynamic data, has provided 
a useful tool for investigating antihypertensive responses. 
The aim of this study, therefore, was to investigate the 
effect of age on the pharmacokinetics and pharmacodynamics 
following single and multiple doses of verapamil by 
application of an integrated concentration-effeet modelling 
technique.
SUBJECTS AND METHODS
Fourteen patients with mild to moderate essential
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hypertension (Four male, 10 females, age 41-7 9 years, weight 
50-92 kgs) (table 3.1.) were studied. All previous 
antihypertensive medication had been withdrawn at least one 
month prior to the study. The protocol was approved by the 
hospital ethical committee and all patients gave informed 
consent. The study design was single blind (patient-blind), 
randomised and crossover. The patients received placebo for 
2 weeks followed by verapamil 120 mg twice daily for 4 weeks 
and attended for three 8-hour study days to evaluate the 
effect of placebo, first dose (120 mg) verapamil and steady 
state verapamil (120 mg). On each study day, blood pressure 
and heart rate (supine and erect) were measured by 
semiautomatic recorder (Sentron; Bard Medical). Blood 
samples were withdrawn at frequent intervals for 8 h after 
dosing for the determination of plasma concentrations of 
verapamil and norverapamil according to the method of Cole 
et al. (1981). In 8 "elderly" patients (patients no. 
1,2,5,6,9,10, 13,14) (age range 63-79 years) apparent liver 
blood flow,^ glomerular filtration rate (GFR) and effective 
renal plasma flow (ERPF) were measured. Apparent liver blood 
flow was calculated from the clearance of intravenously 
administered indocyanine green (0.5 mg/kg) and GFR/ERPF were 
measured by standard radioisotope methods. These test 
substances were simultaneously administered one hour after 
drug administration.
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TABLE 3.1.
THE CLINICAL CHARACTERISTICS OF PATIENTS
Subject Age
(years)
Weight
(kg)
Pretreatment 
B.P. (mmHg)
PRA 
(ng Al/ml/h)
1 69 74 184 0.86
2 72 76 174 1.32
3 64 77 182 1.68
4 41 76 185 1.93
5 70 50 177 1.76
6 77 60 216 1.43
7 50 52 172 1.46
8 51 79 197 1.19
9 78 63 231 1.68
10 79 58 171 2.13
11 58 63 192 1.28
12 56 92 159 1.89
13 77 58 200 2.13
14 63 57 203 2.24
Mean
Sd
64.6
12.0
66.8
12.2
189
19
1.64
0.40
PRA : Plasma Renin Activity
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The pharmacokinetics of verapamil and norverapamil were 
most appropriately described using an integrated model with 
two compartments for drug disposition and a third 
compartment for the metabolite. Concentration-effeet 
analysis was applied to integrate the pharmacokinetic and 
pharmacodynamic profiles. The effect profile (erect systolic 
or erect diastolic blood pressure corrected for placebo 
response) was fitted to a hierarchy of models to account for 
effects from drug alone and from metabolite. In all 
patients, following both acute and chronic treatment, the 
model accounting for effect from drug alone was most 
appropriate (see methods chapter) and there was a linear 
relationship between drug concentration (in the effect 
compartment) and the measured effect. Two parameters were 
derived from this approach; "m", which is an index of 
"responsiveness" i.e. the change in blood pressure per unit 
change in drug concentration in the effect compartment and 
"keq" a first-order rate constant characterising the 
temporal discrepancy between the concentration and effect 
profiles.
The results throughout are presented as mean +, sd and 
comparison of the pharmacokinetic results was by Student's 
t-test (paired data).
RESULTS
Pharmacokinetics
The apparent oral clearance was significantly reduced
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at steady state to 1.4 ± 1.0 compared with 2.8 ± 1.4 1/min 
with acute dosing. This was associated with a significant 
prolongation of terminal elimination half life from 3.8 +
1.2 to 11.2 +. 5.8 h with chronic dosing.
Peak plasma concentration of verapamil was increased 
with chronic dosing from 202 + 104 to 263 + 104 ng/ml but 
this was not statistically significant. The ratio of the AUC 
norverapamil to the AUC of verapamil was increased with 
chronic dosing from 0.8 + 0.2 to 1.0 + 0.2 but this was not 
significant; P = 0.0502, 95% C.I.= -0.3,0.0002 (table 3.2.).
Liver and renal function
Apparent liver blood flow was higher both with the 
first dose and with chronic dosing of verapamil, to 1.670 + 
0.700 and 1.640 + 0.630 1/min respectively, but these were 
not statistically different from 1.200 ± 0.380 1/min with 
placebo (table 3.3.). Acute and chronic dosing of verapamil 
had no effect on glomerular filtration rate or effective 
renal plasma flow (table 3.4.).
Pharmacodynamics
There were significant falls in supine blood pressure 
and erect blood pressure following acute and chronic 
administration of verapamil. For example, the erect blood 
pressure (after 5 minutes standing), expressed as an average 
of all recordings obtained over the 8-hours, was reduced 
from 184/102 mmHg with placebo to 165/92 mmHg with acute 
therapy and to 154/85 mmHg with chronic treatment.
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TABLE 3.2.
THE PHARMACOKINETIC OF VERAPAMIL
Cl/F Apparent Cmax AUC Ratio *
(1/min) elimination (ng/ml)
Subject half life (h)
Acute Chronic Acute Chronic Acute Chronic Acute Chronic
1 5.7 2.3 3.5 7.6 98 142 1.1 1.3
2 5.8 3.0 3.0 4.0 104 133 0.8 0.7
3 2.6 0.7 6.0 8.7 131 398 0.5 0.9
4 2.3 0.8 3.4 22.3 234 289 0.8 0.9
5 1.3 0.6 4.1 11.8 443 323 0.9 1.1
6 3.2 4.1 2.3 4.3 181 125 0.7 1.1
7 2.0 1.4 5.5 15.8 228 323 0.6 0.7
8 2.9 0.7 4.5 10.9 134 402 1.3 1.0
9 2.3 0.9 3.9 13.7 183 217 0.7 1.1
10 2.4 0.9 4.7 8.2 225 392 0.9 1.1
11 3.3 1.3 1.9 6.6 99 118 1.0 1.0
12 1.1 0.9 3.9 19.3 264 287 0.8 1.1
13 3.3 0.9 2.0 6.0 131 217 0.8 0.7
14 1.3 0.9 4.4 18.3 376 313 0.5 0.9
Mean 2.8 1.4 3.8 11.2 202 263 0.8 1.0
Sd 1.4 1.0 1.2 5.8 104 104 0.2 0.2
P value 0 .01 0 . 0001 0 .1 0 . 0502
95% C.I. 0.46,2.4 -10 .8,-4 -141,20 -0.3 , 0.0002
* AUC Ratio refers to AUC of norverapamil/AUC verapamil.
P value refers to the results of paired t-test between 
acute and chronic.
95% C.I. is the 95% confidence interval for the mean 
difference between acute and chronic data.
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TABLE 3.3.
APPARENT LIVER BLOOD FLOW (1/min)
PATIENTS
Chronic
MEASURED IN 8 ELDERLY HYPERTENSIVE
Patients no. Placebo Acute
1 1.648 2.406 2.605
2 0.923 1.269 0.749
5 0.914 1.959 1.994
6 1.630 2.978 1.956
9 0.728 0. 979 1.830
10 1.616 1.484 1.844
13 1.248 1.338 0.859
14 0.913 0.876 1.267
Mean 1.200 1.661 1.640
Sd 0.380 0.731 0.630
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TABLE 3.4.
RENAL FUNCTION MEASURED IN 8 ELDERLY 
HYPERTENSIVE PATIENTS
a . Glomerular filtration rate (ml/min)
Patients no. Placebo Acute Chronic
1 77 77 74
2 75 79 75
5 53 66 61
6 87 89 80
9 64 73 67
10 32 30 32
13 64 59 52
14 58 41 43
Mean 63.8 64.3 60.5
Sd 16.9 20.0 16.9
b. Effective Renal Plasma Flow (ml/min)
Patients no. Placebo Acute Chronic
1 268 284 274
2 285 383 324
5 254 288 286
6 360 416 408
9 268 315 276
10 164 162 160
13 231 235 214
14 264 167 187.
Mean 261.8 281.3 266.1
Sd 54.6 91.9 79.5
The data are corrected for 1.73 m^ body surface area.
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Concentration-effeet analysis
Responsiveness to acute and chronic verapamil 
administration is presented in table 3.5. On average, there 
was a reduction of 0.13 mmHg/ng/ml in systolic and of 0.063 
mmHg/ng/ml in diastolic blood pressure following the first 
dose. There were highly significant correlations between 
responsiveness to acute dosing of verapamil and initial 
blood pressure (r = 0.7 9; P<0.001) and between chronic 
dosing and initial blood pressure (r = 0.7; P<0.005; figure 
3.1.) .
Similar results were obtained for erect diastolic blood 
pressure and again there were highly significant 
correlations between responsiveness to acute or chronic 
dosing of verapamil and initial blood pressure (r = 0.77; 
PCO.001; figure 3.2.).
When the responsiveness to the first dose of verapamil 
was correlated with the responsiveness after 4 weeks of 
treatment with verapamil, there were close correlations for 
both erect systolic (r = 0.89; p = 0.0001) and erect 
diastolic blood pressure (r = 0.96; p = 0.0001) with a slope 
approaching 1 and an intercept not significantly different 
from zero (Figure 3.3.). There was no significant 
correlation between responsiveness, for the fall in either 
erect systolic or in erect diastolic blood pressure, and age 
(r = 0.17; p = 0.57) or plasma renin activity PRA (r = 0.22; 
p = 0.45) (figure 3.4.).
103
TABLE 3.5.
RESPONSIVENESS (mmHa/na/ml) TO ACUTE AND CHRONIC VERAPAMIL
CALCULATED IN TERMS OF THE PLACEBO--SUBTRACTED CHANGES IN
ERECT SYSTOLIC AND DIASTOLIC BLOOD PRESSURE
Subject Systolic B.P. Diastolic B.P.
Acute Chronic Acute Chronic
1 -0.177 -0.137 -0.083 -0.072
2 -0.149 -0.147 -0.064 -0.061
3 -0.080 -0.053 -0.031 -0.029
4 -0.164 -0.151 -0.084 -0.078
5 -0.107 -0.068 -0.054 -0.036
6 -0.214 -0.262 -0.103 -0.119
7 -0.112 -0.124 -0.048 -0.055
8 -0.129 -0.119 -0.078 -0.064
9 -0.267 -0.205 -0.129 -0.133
10 -0.055 -0.052 -0.038 -0.029
11 -0.090 -0.081 -0.042 -0.040
12 -0.053 -0.073 -0.026 -0.032
13 -0.116 -0.102 -0.04 9 -0.042
14 -0.156 -0.152 -0.061 -0.058
Mean -0.133 -0.123 -0.063 -0.060
Sd 0.059 0.059 0.029 0.032
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Erect Systolic Blood Pressure
First dose 1
0 . 3  -
n = 14 
r = 0.79
n = 0.001
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Erect Systolic Blood Pressure 
Chronic dosing
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Figure 3.1. The correlation of responsiveness to verapamil 
(fall in erect systolic blood pressure, place­
bo corrected per unit concentration of drug) 
with pretreatment blood pressure after the 
first dose (a) and chronic administration (b) 
of verapamil. Power of correlation coeff.=98%
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a
Erect Diastolic Blood Pressure
First dose
n = 14 
r = 0.77 
p = 0.0070.12 -
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b
Erect Diastolic Blood Pressure 
Chronic dosing
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.2. The correlation of responsiveness to verapamil 
(fall in erect diastolic blood pressure, 
placebo corrected per unit concentration of 
drug) with pretreatment blood pressure after 
acute (a) and chronic administration (b) of 
verapamil.
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Figure 3.3. The correlation between the responsiveness to 
the first dose of verapamil and the respon­
siveness after 4 weeks of treatment for erect 
systolic blood pressure (a) and erect 
diastolic blood pressure (b).
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Figure 3.4. The correlation of responsiveness to verapamil 
(fall in erect systolic blood pressure at 
steady state, placebo corrected per unit 
concentration of drug) with age (a) or plasma 
renin activity (b).
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DISCUSSION
In their evaluations of the antihypertensive efficacy 
of calcium antagonist drugs, some previous authors have 
correlated the maximum reduction in blood pressure with the 
height of the pretreatment blood pressure, or with age, or 
with plasma renin activity (Buhler et a1., 1982; Erne et 
al., 1983). This approach not only has some statistical 
problems especially for comparing changes in blood pressure 
vs starting blood pressure since essentially the same 
variable appears on both axes (Gill et al., 1985) but it 
also ignores the inter-individual variability in the 
pharmacokinetics of the drug and considers the blood 
pressure response only at a single time point. Concentration 
effect modelling, which takes account of the variability in 
pharmacokinetics and which assesses the pharmacodynamic 
response over time, characterises "responsiveness" as the 
fall in blood pressure per unit concentration of drug. The 
significant correlations between responsiveness and 
pretreatment blood pressure, but not independently with age 
or plasma renin activity, suggest that the height of 
pretreatment blood pressure is a more important determinant 
of the magnitude of the response to antihypertensive 
treatment than either age or plasma renin activity (Sumner 
et al., 1988). This result contradicts the observation by 
Buhler et al. (1982) who suggested that the antihypertensive 
responses to calcium antagonists were increased in relation 
to age per se.
The strong correlation between the responsiveness after
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the first dose and after chronic dosing might have some 
clinical application: for example, on the basis of the 
integrated data after the first dose the poor or 
nonresponder can be distinguished from the patient who needs 
a higher dose of drug.
A characteristic feature of verapamil pharmacokinetics 
is reduction of plasma clearance with chronic dosing. The 
present study has again shown that the apparent oral 
clearance of verapamil was reduced at steady state with a 
significant prolongation of elimination half life. To 
further investigate the underlying mechanisms liver blood 
flow, which is a major determinant of verapamil metabolism, 
has been measured in this study. There were slight and 
insignificant increase in apparent liver blood flow after 
acute and chronic verapamil administration. It is noteworthy 
that liver blood flow determination was made only on one 
occasion during the dosage interval (at the absorption 
phase, 1 hour after the dose) and it is not known if these 
changes in liver blood flow will maintain throughout the day 
when the plasma drug levels decline. Thus the contribution 
of liver blood flow to the pharmacokinetics of verapamil is 
not clear but it might be for short period and confined to 
the absorption phase. The contribution of changes in liver 
blood flow at the absorption phase has been studied after 
acute and short term dosing with nisoldipine which showed a 
significant correlation between changes in liver blood flow 
and the flow dependent part of the total AUC of nisoldipine 
(Van Harten et al., 1989) . The pattern of increase in liver
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blood flow after acute and chronic dosing of verapamil in 
the present study was different from that reported in young 
healthy volunteers (Meredith et al., 1985). Thus it would be 
expected that the pharmacokinetics of verapamil after acute 
and chronic administration must be the same if liver blood 
flow is the only factor responsible but since verapamil 
accumulates with chronic dosing in spite of the increase in 
liver blood flow this indicates that possibly other mecha­
nisms such as enzyme saturation or inhibition might be 
involved in the mechanisms of the accumulation of verapamil 
at steady state. Although the ratio AUC of 
norverapamil/verapamil did not change between acute and 
chronic treatment, this provides evidence only that the 
N-demethylation pathway did not undergo saturation or 
inhibition whereas an inhibitory effect on other pathways 
cannot be ruled out.
In conclusion, by applying concentration-effeet 
modelling, the antihypertensive response to verapamil has 
been characterised in hypertensive patients including some 
elderly hypertensive patients. The apparent age-related 
increase in responsiveness is mainly due to the higher 
pretreatment blood pressures of the elderly patients and 
there was no independent effect for age or for plasma renin 
activity.
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CHAPTER FOUR
THE EFFECTS OF ORAL AND INTRAVENOUS DOSES OF VERAPAMIL ON 
EJECTION FRACTION AND P-R INTERVAL IN PATIENTS WITH STABLE
ANGINA PECTORIS
1 1 2
INTRODUCTION:
As discussed in the previous chapter there have been 
reports of an age-related preferential response to calcium 
antagonist drugs. In addition, there are reports that age 
has effects on the pharmacokinetics of calcium antagonist 
drugs. For example Robertson et al., (1988) reported an age
related reduction in the plasma clearance of nifedipine, 
which has been explained on the basis of an age-related 
decline in hepatic metabolic capacity or due to a reduction 
in hepatic blood flow. Regardless of the underlying 
mechanisms, any increase in plasma drug concentration has 
the potential for increasing the pharmacological responses.
If responsiveness to calcium antagonist drugs increases 
with age, whether as a result of increased "tissue 
responsiveness" or as a result of increased plasma drug 
levels, then not only is there potential for enhanced 
therapeutic effects but there is also potential for 
increased susceptibility to adverse effects. One such 
established adverse effect of verapamil is its negative 
effect on atrioventricular conduction (dromotropic effect) 
and on left ventricular contraction (inotropic effect) and 
accordingly there might be particular concern about the use 
of this drug in the treatment of middle-aged and elderly 
patients with angina pectoris. The principal aim of this 
study, therefore, was to evaluate the effects of verapamil 
on cardiac conduction and left ventricular function in an 
older patient group.
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PATIENTS AND METHODS
The study was approved by the hospital Research and 
Ethics Committee and all patients gave written informed 
consent. A total of 14 patients with a clinical diagnosis of 
stable angina pectoris, 9 males, 5 females, body weight 74 + 
11 kg and age ranging from 42 to 76 years (60 ± 9 years) 
completed the study (table 4.1.). All patients were 
otherwise normal on clinical examination and had no 
clinically significant renal or hepatic insufficiency on 
routine blood biochemistry. Patients were allowed short 
acting nitrates as required but no other antianginal therapy 
was permitted for the duration of the study. The study 
design was placebo-controlled, single blind (patient blind), 
randomised and crossover with half the patients undergoing a 
placebo assessment prior to the active treatments and the 
other half undertaken placebo after the active treatments, 
following a washout period of 2 weeks. Patients attended the 
Clinical Pharmacology Research Unit for a total of five 8- 
hour study days to evaluate the effect of placebo and four 
active treatments. Single doses of verapamil, 5 mg 
intravenously and 80 mg orally, were administered on two 
separate occasion, one week apart, and oral treatments with 
80 mg three times daily was administered for 4 weeks. At the 
end of the 4 week active treatment period, patients returned 
for a further evaluation of superimposed doses of verapamil, 
5 mg intravenously and 80 mg orally, on two further separate 
occasions, one week apart (figure 4.1.).
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TABLE 4.1.
SUMMARY OF CLINICAL DETAILS
Clinical characteristic of 14 patients with chronic stable 
angina pectoris.
History
Pat. Sex Age Wt of angina Additional diagnosis 
(Yrs) (kg) (Yrs) and drug treatment
1 M 62 76 5
2 M 57 76 2
3 M 63 67 2
4 M 70 70 1
5 F 76 60 3
6 M 63 70 4
7 F 57 75 10
8 M 68 75 13
9 F 58 75 7
10 F 64 67 1
11 M 58 60 14
12 M 42 75 8
13 M 57 103 3
14 F 46 82 11
Mean 9M 60 73. 6
Sd 5F 9 10. 5
Frusemide/Spironolactone 
Old posterior Ml/bendrofluazide 
Atrial fibrillation/Warfarin 
Aspirin
Mild hypertension
Coronary artery bypass ,1984
Coronary artery bypass ,197-9 
Mild hypertension/bendrofluazide
Mild hypertension/bendrofluazide
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Group 1
STUDY
DAYS
PLACEBO
8 weeks
t t t© © ©
Placebo Acute Acute
intravenous oral 
(5mg) (80mg)
t t
© ©
"Chronic" "Chronic" 
intravenous oral
Group 2
STUDY
DAYS
WASHOUT
PLACEBOPLACEB
t t 
© ©
8 weeks
Acute Acute 
oral intravenous
"Chronic* "Chronic" 
oral intravenous
Placebo
Figure 4.1. A diagram of treatments and study design
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At each study day, measurement were made of the 
following:
a. Blood pressure and heart rate: Supine and erect 
blood pressure and heart rate were recorded by semiautomatic 
sphygmomanometer (Sentron, Bard Medical) before the dose 
(after 20 minutes recumbent rest) and then every hour for 8 
hours.
b. Cardiac conduction: PR intervals (calculated from 
the departure of P wave to the beginning of Q wave) were 
measured from ten consecutive cardiac beats using a standard 
lead II electrocardiogram at a speed of 50 mm/sec. PR 
intervals were measured before the dose and at 1, 4, 6, 7 
hours after the dose. Measurement of the PR interval at 2 
and 3 hours was omitted because it coincided with the time 
of the evaluation of left ventricular function.
c. Left ventricular function: Left ventricular function 
(ejection fraction) was assessed 1.5 hours after the dose by 
a standard radioisotope technique, at rest and during 
exercise (at a fixed load of 50 watts for approximately 3 
minutes). LV function was assessed on three of the five 
study days (placebo, after the single intravenous dose and 
after chronic oral dosing).
d. Apparent liver blood flow: Apparent liver blood flow 
was measured from the clearance of indocyanine green (ICG) 
following a bolus intravenous dose 0.5 mg/kg at 1 hour after 
the administration of placebo or active drug.
e. Renal function: Effective renal plasma flow (ERPF) 
and glomerular filtration rate (GFR) were measured 1 hour
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after the dose from the clearance of radioisotopes, 125j_ 
hippuran and ^1-edta respectively. As a result of various 
practical problems, full data are available for only 8 
patients.
PHARMACOKINETIC ANALYSIS
Venous blood was sampled for plasma drug measurement 
via an indwelling intravenous cannula at times corresponding 
with the blood pressure recordings. Plasma was separated and 
stored at -20 °C until analysis. Verapamil and its principal 
metabolite norverapamil were assayed by an HPLC method with 
fluorescence detection (Cole et al., 1981).
The pharmacokinetics of verapamil and norverapamil were 
analysed by both model-independent and model-dependent means 
as described in the method section.
STATISTICAL ANALYSIS
After plotting and visually examining the data, 
appropriate transformation was performed if the distribution 
was skewed.
Repeated measures analysis of variance was used to 
evaluate the time and treatment effects for blood pressure, 
heart rate, PR interval, LV ejection fraction and apparent 
liver blood flow. The pharmacokinetic parameters obtained 
from single and multiple doses were evaluated by paired 't' 
test. Analysis for age related effects was made by a linear 
regression analysis across the age range.
Results throughout are expressed as mean + sd.
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RESULTS
1. PHARMACODYNAMICS
i) Blood pressure and heart rate
There was a tendency for all verapamil treatments to 
reduce blood pressure but this reduction was small and 
statistical significance was achieved only for supine 
diastolic blood pressure during chronic treatment (figure 
4.2.) with an overall average reduction of 6 mmHg during the 
8-hour study day.
There were similar small reductions in supine heart 
rate which achieved statistical significance on both study 
days during chronic treatment with overall reductions of 6 
bpm (figure 4.2.) (69 bpm with placebo and 64 bpm with both
chronic treatments) during the 8-hour study day.
ii) Cardiac conduction:
None of the active treatments was associated with any 
significant changes in PR interval throughout the 8-h study 
period (table 4.2.). From the linear regression analysis, 
there was no evidence of any age related effects on PR 
interval.
iii) LV ejection fraction
Left ventricular ejection fractions are summarised in 
table 4.3. There was no significant effect of either first 
dose (intravenous) or chronic oral dosing of verapamil on 
ejection fraction at rest or during exercise.
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Figure 4.2. Average supine blood pressure and heart rate 
for all treatments . □ placebo, ■ acute
i.v., #acute oral, Ochronic i.v., A  
chronic oral. Results of statistical analysis 
showed that supine diastolic blood pressure 
and supine heart rate achieved statistical 
significance during chronic treatments.
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TABLE 4.2.
CARDIAC CONDUCTION 
Mean PR intervals (ms)
Treatment Time after dosing (ms)
Pretreat. lh 4h 6h 7h
Placebo 175+22 17 6+17 177+22 170+20 167+18
Acute I.V. (5mg) 173+15 17 6+23 178+15 177+12 177+16
Acute oral (80 mg) 180+12 178+20 181+17 178+22 177+15
Chronic+I.V. 179±14 180+21 181+16 178±16 177+15
Chronic+oral 178+14 183+21 183+26 174+18 173+16
1 2 1
TABLE 4.3.
THE EJECTION FRACTION (%) AT REST AND EXERCISE FOLLOWING 
PLACEBO. SINGLE I.V. AND CHRONIC ORAL ADMINISTRATION.
REST DURING EXERCISE
Pat. No. Pla. I.V. si Oralgg Pla. 0ralss
1 28 10 36 37 24 33
2 18 16 25 27 18 nr
3 29 nr 39 34 nr 41
4 59 48 42 47 41 39
6 33 40 59 38 48 64
7 43 48 39 54 52 38
8 34 47 38 39 37 44
9 43 37 32 43 41 38
10 33 28 24 36 32 36
11 26 18 27 50 nr 38
12 27 28 37 33 35 41
13 25 24 31 32 nr nr
14 49 50 32 75 51 61
MEAN 34.4 32. 8 35.4 42 38 43
SD 11.2 14. 0 9.0 12 11 10
nr: represents no results due to technical problem.
Pla: placebo; I.V.g^: single intravenous dose; 
Oralss: steady state oral dosing.
1 2 2
In addition, verapamil has no effect on the magnitude of 
change in ejection fraction during exercise. There was no 
independent effect of age on LV ejection fraction.
iv) Apparent liver blood flow
There was a tendency for apparent liver blood flow to 
increase with chronic treatment but this did not achieve 
statistical significance (table 4.4.). Overall there was no 
significant treatment effect and there was no correlation 
between apparent liver blood flow and age.
v) Renal function
The results of glomerular filtration rate (GFR) and 
effective renal plasma flow (ERPF) are presented in table 
4.5. There was no significant effect attributable to any of 
the verapamil treatments on GFR or ERPF. Age had no 
independent effect on renal function.
2. PHARMACOKINETICS
i) Intravenous dosing
The plasma clearance of verapamil was significantly 
reduced during chronic dosing from 1.3 to 0.8 1/min and 
there was an associated significant prolongation of the 
terminal elimination half life from 3.6 to 7.9 hours ( p <
0.01). These results are summarised in table 4.6.
The magnitude of the changes in plasma clearance 
(during the translation from acute to chronic dosing) tended 
to decline with age (r = -0.52, p = 0.08) but overall, by 
linear regression analysis, there was no significant age 
related effect on pharmacokinetics.
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TABLE 4.4.
THE EFFECT OF VERAPAMIL ON LIVER BLOOD FLOW (ML/MIN)
Pat. Placebo I -v -si °ralsi 1 *v * ss Oralgg
1 1600 1800 nr 1640 1000
2 770 760 710 980 810
3 550 560 550 490 660
4 780 700 1040 750 900
5 1250 nr 1310 nr 1657
6 520 650 nr 960 1280
7 880 730 980 600 710
8 540 1120 1610 1330 2700
9 1010 1120 830 700 760
10 1300 840 990 1590 1360
11 750 560 600 600 820
12 800 1020 950 820 960
13 780 782 870 860 960
14 770 1090 900 800 960
Mean 879 902 945 932 1110
Sd 312 336 292 369 534
I.V.si: single intravenous dose; Orals :^ single oral dose 
I.V.SS: chronic intravenous; Oralss: steady state oral 
dosing.
nr: represents no results due to technical problems.
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TABLE 4.5.
RENAL FUNCTION
Glomerular Filtration Rate (ml/min)
Patient Placebo I.V.si Orals^ 1 -v -as Oralgg
1 68 79 73 79 78
3 100 110 104 118 120
4 75 75 85 80 69
8 73 75 76 78 78
11 53 66 62 61 59
12 90 122 91 95 90
13 123 126 118 104 109
14 86 98 103 97 97
Mean 85.5 93.9 89.0 89.0 87.5
Sd 21.5 23.3 18.7 17.9 20.5
Effective
Patient
Renal
Placebo
Plasma Flow 
* *v * si
(ml/min)
0ralsi I V A •v * ss 0ralss
1 294 329 339 342 269
3 220 237 359 419 455
4 370 321 418 400 379
8 271 285 304 343 340
11 184 241 201 220 207
12 413 289 415 508 428
13 393 409 444 403 326
14 414 394 435 396 420
Mean 319.9 313.1 364.4 378.8 353.0
Sd 90.1 63.7 82.6 82.4 84.9
The data are corrected for 1.73 mz body surface area. 
I.V.si: single intravenous dose; Orals :^ single oral dose
I.V.SS: chronic intravenous; Oralss: steady state oral 
dosing.
There were no significant differences between different 
treatments on GFR or ERPF (using one way ANOVA)
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ii) Oral administration
The area under the concentration time curve (AUC) was 
significantly increased from 429 to 868 ng/ml*h (p < 0.01) 
.and this was associated with a prolongation of terminal 
elimination half life from 5 to 9.5 hours (p < 0.01) .
Correspondingly the AUC of norverapamil also increased, 
from 252 to 875 ng/ml*h (p <0.01). These results are 
summarised in table 4.6. Linear regression analysis for AUC 
during chronic dosing showed no significant correlation with 
patient age (r = 0.44) (figure 4.3.).
DISCUSSION
The putative increase in cardiovascular responsiveness 
to calcium antagonist drugs in the elderly might result from 
either altered pharmacokinetics, with increased plasma drug 
levels, or increased sensitivity to the pharmacological 
effects reflecting either a direct increase in tissue or 
cellular "responsiveness" or indirectly due to impaired 
cardiovascular reflex mechanisms (Gribbin et al., 1971).
The results of this study indicate that there was no 
increased susceptibility to the negative inotropic or 
dromotropic effects of verapamil in middle-aged and elderly 
patients. It might be argued that the lack of effect on 
cardiovascular indices could be due to low doses used in 
this study. However, the plasma concentrations achieved were 
similar to those observed in other studies which have 
reported significant prolongation of the PR interval 
(Eichelbaum et al., 1980; Dominic et al., 1981; McAllister
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TABLE 4.6.
THE PHARMACOKINETICS OF VERAPAMIL
S in g le  d o se  C h r o n ic  d o s in g  D i f f e r e n c e
Intravenous dosing
Clearance (Cl) 1.3 ± 0.3 0.8 + 0.5 -0.5 ± 0.5 b
(1/min)
Volume of distri- 346.0 + 98 410.0 ± 240 58.0 ± 23 ns
bution (Vdss) (1)
Elimination half- 3 . 6 + 1  7 . 9 +  3 4 . 4 + 3 . 2 d
life (t1/2) (h)
Oral dosing
AUC-verapamil 429.0 + 219 868.0 + 422 438.0 + 287 d
(ng/ml*h)
Clearance/F 4.1 + 2.5 1.9 ± 0.9 -2.1 + 1.7 c
(1/min)
Elimination half- 5 . 0 + 1 .6 9 . 5 + 5 . 4  4 . 5 + 5 . 5 a
life
Cmax 74.0 + 29 165.0 + 68 90.0 ± 5 2  d
(ng/ml)
Tmax 1 . 7 + 0 .8 1 . 4 + 0 . 5  -0.3 ± 0.9 ns
( h )
AUC-norverapamil 252.0 + 97 875.0 + 353 622.0 + 285 d
(ng/ml*h)
a: p < 0.05 b: p < 0.01 c: p < 0.001 d: p <0.0001 
ns: not significant.
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the concentration time curve (AUCQ_gh ) during 
chronic dosing.
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et al., 1982). In these studies, significant prolongations • 
in the PR interval were obtained in healthy young volunteers 
within the concentration range 30-50 and 50-150 ng/ml 
following intravenous and oral verapamil respectively. Thus 
with clinically recommended doses, the mean Cmax values (the 
peak plasma concentration) of 74 and 165 ng/ml in this study 
might have been expected to produce significant prolongation 
of PR interval particularly in those older patients if there 
was an increased sensitivity to the drug's actions.
Prolongation of PR interval may constitute a "rough1 
guide in the clinical use of verapamil and indicate that 
potentially therapeutic drug levels have been achieved; the 
presence of second or third degree AV block suggests drug 
toxicity and implies excessive plasma drug concentrations 
(Dominic et al., 1981). However, this would appear to have 
limited application in the elderly who, in the absence of a 
measurable effect on PR interval, were still able to 
demonstrate small but significant haemodynamic effects with 
reductions in supine blood pressure and in supine heart rate 
during chronic verapamil dosing.
The mechanism underlying the accumulation of 
verapamil with continued administration also has been 
investigated in this study. After oral administration, a 
high concentration of verapamil is delivered to the liver 
via the portal vein and there is the possibility of 
saturating the capacity of the hepatic enzymes (Wagner et 
al., 1984). After intravenous administration relatively low 
concentrations are delivered to the liver, mainly through
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the hepatic artery with each cardiac cycle. In this study 
oral dosing with verapamil was continued for 4 weeks and a 
supervised intravenous dose was then administered. The 
plasma clearance of verapamil after this intravenous dose 
was reduced compared to the clearance after the first 
intravenous dose. It is unlikely, even with steady state 
verapamil, that the pre-dose concentrations would be 
sufficiently high to have already saturated the enzymes. The 
more likely explanation is that verapamil inhibits the 
enzyme(s) responsible for its metabolism and that this will 
only be reversed when drug is cleared from the metabolising 
sites following cessation of treatment.
Although, these patients with ischemic heart disease 
generally had low LV ejection fractions, there was no, 
significant effect attributable to verapamil. Moreover 
verapamil prevented any reduction in ejection fraction 
during exercise. This result is in agreement with the 
results of other studies in which oral daily doses of 320 
and 480 mg verapamil (Tan et al., 1982; Josephson et al., 
1981) or an intravenous dose (0.06 mg/kg) (Klein et al.,
1983) were used . These studies have not only shown that 
verapamil prevented the exercise-induced reduction in 
ejection fraction but it also reduced the number of exercise 
induced abnormalities in regional wall motion.
From animal studies it appears that the concentration 
range for the negative inotropic effect is approximately 3- 
folds greater than the range for negative chronotropic 
effect (Hof et al., 1983). Such a range of concentration is
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unlikely to be achieved in routine clinical practice.
There is evidence from human studies that the 
pharmacokinetics of verapamil (Abernethy et al.,' 1986) and 
of dihydropyridine calcium antagonists (Robertson et al., 
1988; Donnelly et al'., .1988; Abernethy et al., 1988) change 
with increasing age leading to increased peak plasma levels 
and increased AUG. It has been assumed that this reflects an 
age-related decline in hepatic metabolic capacity and, 
although there is no direct evidence in man, there is 
experimental evidence in the rat that hepatic metabolic 
capacity declines with age (Kato & Takanaka, 1968). In this 
present study, although there was a tendency for the plasma 
clearance of verapamil to decline in relation to increasing 
age, none of the calculated pharmacokinetic parameters 
showed any significant age-related differences. This study, 
however was designed to examine the population likely to ; 
have ischemic heart disease and to require treatment with 
verapamil. Since such patients would generally fall into the 
40-75 years age group, as in this study, the lack of 
significant age-related differences may simply reflect the 
age range studied. A very broad age range (23-102 years) was 
studied by Abernethy et al., 1986 to demonstrate significant 
age-related differences in the disposition of verapamil but 
other studies, either with fewer subjects (Norris et al.,
1987) or with a narrower age range (19-79 years) (chapter 5) 
have failed to confirm a significant age-related decline in 
the clearance of verapamil. Thus, while the age range 
studied may explain the failure to detect a significant
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age-related effect on the disposition of verapamil, there 
appears to be no need for major adjustments in the patient 
population likely to receive verapamil in routine clinical 
practice. Clearly the full dose-concentration range was not 
explored in this study and no attempt was made to define an 
anti-anginal therapeutic range. The principal findings of 
this study are that middle-aged and elderly patients with 
ischemic heart disease do not show exaggerated response to 
the cardiac effects of verapamil.
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CHAPTER FIVE
THE INFLUENCE OF AGE ON THE PHARMACOKINETICS OF VERAPAMIL
133
INTRODUCTION
The ageing process is associated with a range of 
physiological changes which might be expected to affect drug 
disposition and pharmacokinetics.
The systemic clearance of verapamil, which undergoes 
high hepatic extraction, depends on two major factors: liver 
blood flow and the integrity of the hepatic metabolising 
enzymes. While there is a good evidence that liver blood 
flow declines with age (Bender et al., 1965; Wynne et al.,
1988), there is only indirect evidence from studies in rats 
that the activity of the metabolising enzymes is reduced 
with age (Kato & Takanaka, 1968). Thus there is a 
considerable background evidence to suggest that increasing 
age might affect the disposition of verapamil."The pharmaco­
kinetics of verapamil have been clearly defined in healthy 
volunteers (Freedman et al., 1981; Shand et al., 1981; 
Meredith et al., 1985) but there is only limited information 
about the steady state disposition of verapamil in the 
elderly.
SUBJECTS AND METHODS
The data for this analysis were collected from a series 
of studies conducted in the Clinical Pharmacology Research 
Unit (C.P.R.U) of Stobhill Hospital. All studies followed a 
similar protocol and, in particular, the sampling time 
schedules and drug assay methods were identical. Seventy 
four subjects were studied including patients with mild to 
moderate essential hypertension (n=51) or stable angina
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pectoris (n=l3) and healthy normotensive volunteers (n=10). 
No subject had clinically significant renal or hepatic 
insufficiency on routine blood biochemistry. The study 
population was arbitrarily sub-divided into 3 age groups and 
their demographic details are given in table 5.1. Group 1 
ranged in age from 19 to 44 years (n=26) and was designated 
the "young" age group; Group 2 ranged from 45 to 64 years 
(n=27) and was designated "middle-aged" group; and Group 3 
ranged from 65 to 79 years (n=21) and was designated the 
"elderly" group. All individuals were established on a twice 
daily regimen with verapamil, 240 or 360 mg total daily 
dose, for at least 1 week prior to study. On the study day 
subjects reported fasting to the C.P.R.U. to receive a 
supervised dose of 120 or 180 mg verapamil orally and 
thereafter to have withdrawal of venous blood samples. Blood 
samples were collected onto ice and immediately centrifuged 
to separate off the plasma which was then stored at -20 C 
for subsequent analysis.
Plasma drug analysis
Concentrations of verapamil and norverapamil were 
analysed by HPLC with fluorescence detection using the 
method of Cole et al. (1981)
Pharmacokinetic analysis
The pharmacokinetic parameters of verapamil such as the 
AUC, clearance/F, elimination half life, tmax and Cmax were 
calculated by standard techniques described in the methods 
chapter.
Statistical analysis
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Normality of distribution was tested by the test. 
Appropriate transformations of data were required for age, 
tf/2 and tmax. Age related effects were evaluated by apply­
ing linear regression analysis across the age range and by 
one way analysis of variance following the arbitrary divi­
sion into three groups.
RESULTS
The derived pharmacokinetic characteristics are 
summarised in table 5.1.
There was a significant increase in maximum plasma 
concentration (Cmax) with increasing age (r=0.24, t=2.16, 
p=0.03) (figure 5.1.). The Cmax was 400 ± 197 ng/ml in the 
elderly group compared to 270 ± 86 and 348 ± 189 ng/ml in 
the young and middle aged group respectively. The time to 
attain the maximal concentration (tmax) was not 
significantly changed with increasing age (figure 5.2a.) and 
although there was a trend for the ratio AUCnorverapam:Q /  
AUCyerapamil t0 increase with age this was not statistically 
significant (figure 5.2b.)
Although terminal elimination half life was apparently 
longer in the elderly group, 9.8 ± 6 hours, compared to 8.0 
+3.6 in the young group, there was no significant age 
related increase in terminal elimination half life across 
the whole age range (figure 5.3a.) (r=0.11, t=0.95, p=0.34).
There was no significant correlation between age and clear- 
ance/F (figure 5.3b) although clearance/F tended to decline 
with increasing age (r=-0.2, t=1.73, p=0.08) and the lowest 
value, 91 +. 46 1/h, was obtained in the elderly group.
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TABLE 5.1.
SUMMARY OF THE DEMOGRAPHIC DATA AND THE DERIVED 
PHARMACOKINETIC PARAMETERS (MEAN + SD)
Group 1 2 3 Total
Age range 19-44 45-64 65-79 19-79
Mean age 31 58 73 53
Number of 
subjects
26 27 21 74
Weight
(kg)
70 + 7 70 + 1 66 + 11 69 + 10
^max (n9f/ml) 270 + 86 348 + 189 400 + 197 335 + 169
-^max (k) 1.2 + 0.3 1.6 + 0.9 1.6 + 1 1.4 +_ 0.8
tl/2 <h> 8.0 + 3.6 9.3 + 4 9.8 + 6.1 9.0 + 4 . 6
CL/F (1/h) 109.7 + 25 117.5 + 52 90.5 + 46 106 + 43
(1/h/kg) 1.57 + 0.4 1.64 + 0.6 1.34 + 0.6 1.53 + 0.54
^ n o r v e r ^ 0.96 + 0.2 1.01 + 0.2 1.03 + 0.2 0.99 + 0.17
AUCyer
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DISCUSSION
Overall, the results of this analysis suggest that 
there are small age-related alterations in the disposition 
of verapamil. A statistically significant change was found 
for peak plasma concentrations and there were non­
significant trends for age related changes in apparent oral 
clearance and elimination half life.
These findings are consistent with the findings of 
other studies which have investigated the effect of 
increasing age on the pharmacokinetics of calcium antagonist 
drugs. For example, with dihydropyridine calcium 
antagonists, Robertson et al. (1988) have reported a
reduction with age in the plasma clearance of nifedipine, 
Donnelly et al., (1988) have reported an age-related 
increase in Cmax for nifedipine and Abernethy et al. (1988)
and Elliott et al. (1988) have reported age-related changes 
in the clearance and terminal elimination half life of 
amlodipine. Abernethy et al. (1986) have also described a 
reduction in the clearance of intravenous verapamil in 
elderly and very elderly hypertensive patients when compared 
to young patients. A similar nonsignificant trend for an 
age-related change in apparent oral clearance has been also 
described (Norris et al., 1987). While the most probable 
explanation for these pharmacokinetic differences lies with 
altered hepatic function, it remains unclear whether this
reflects age-related changes in liver blood flow or in
(•)
intrinsic metabolic capacity. Additionally, in the present 
study, it is not possible to exclude changes in volume of
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distribution.
An obvious problem with this type of evaluation is the 
difficulty in quantifying the contribution of age 
independently from a variety of other genetic, pathological 
and environmental factors. For example, in a large study 
reported by Vestal, 1975, the clearance of antipyrine which 
is entirely metabolised by the liver, was found to be 
significantly reduced with age. However, age per se 
accounted for only 3% of the variability which was otherwise 
attributable to smoking and other incidental factors (Vestal 
1975). In this present study there was a nonsignificant 
reduction in clearance/F of verapamil and associated with 
this there were significantly higher peak plasma levels in 
the elderly. This may be of clinical relevance insofar as 
some of the pharmacological effects of verapamil are 
directly related to plasma concentrations and there might be 
increased risk of side effects.
Increasing age is also associated with increasing 
inter-subject variability, as can readily be seen in all the 
figures. Such heterogeneity in the data may itself confound 
interpretation as illustrated by the absence of an overall 
correlation between Cl/F and age, whereas there was a 
significant correlation between age and clearance/F in the 
young subjects (age range 19-45 years) (r=-0.47, p=0.02, 
n=26) when the correlation was separately examined for each 
age group, but no significant correlation for middle-aged or 
elderly subjects. This age-related increase in variability 
will have two important consequences. Firstly, statistical
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confirmation of the age-related differences will be 
compromised unless relatively large numbers are studied. 
Secondly, it makes it inappropriate to make global dosage 
recommendations for the older age groups.
In summary, these results suggest that increasing age 
is associated with alterations in the pharmacokinetics of 
verapamil. This is consistent with the evidence from other 
studies and is consistent with an age-related decline in 
drug clearance. However, although this small but 
statistically significant age-related difference has been 
confirmed it seems unlikely that it will have major clinical 
significance.
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CHAPTER SIX
A STUDY OF THE PHARMACOKINETICS OF D-VERAPAMIL 
AND ITS EFFECTS ON PR INTERVAL, BLOOD PRESSURE
AND HEART RATE
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INTRODUCTION
The calcium antagonist drugs verapamil, diltiazem, 
nicardipine, nifedipine, niludipine, nimodipine and other 
unrelated compounds, such as amiodarone and quinidine, have 
been shown to enhance the cytotoxicity of natural product 
anticancer drugs such as vinca alkaloids and anthracyclines 
in Multiple Drug Resistance (MDR) cancer cells (Tsuruo et 
al., 1983b; Beck et al., 1985; Harker et al., 1986)
The mechanism underlying the development of 
resistance is not well defined although several 
investigators attribute it to decreased retention of the 
cytotoxic drug inside the cell as a result of an "active 
efflux pump" (Skovsgaard, 1978; Inaba et al., 1981). Since 
the hallmark of MDR cells is an increase in the amount of a 
high molecular-weight surface glycoprotein, p-glycoprotein 
(P-180), (Kartner et al., 1985) it is suggested that this 
leads to alterations in the cell membrane and increased 
transfer of drugs across the membrane (Riordan & Ling 1985) . 
The mechanism by which adjuvant drugs, such as verapamil, 
reduce the development of resistance is also unknown. 
However, with the conventional (i.e. racemic) form of 
verapamil the drug concentration required to overcome MDR 
cells in vitro is relatively high (in the range 2-6 pM: 1000 
- 3000 ng/ml, approximately) (Merry et al., 1989). Such 
concentrations are difficult to achieve in vivo in man 
without serious cardiovascular side effects, particularly 
depression of atrioventricular conduction (i.e. negative 
dromotropism).
145
Racemic verapamil, however, is a mixture of d- and 1- 
isomers and previous studies have shown that d-verapamil is 
8-10 times less potent than 1-verapamil in terms of its 
effect on cardiac conduction and prolongation of PR interval 
(Echizen et al., 1985, Echizen et al., 1988). D-verapamil 
has been shown to have activity similar to the racemic 
formulation of verapamil as a modulator in the treatment of 
cancer (Plumb et al., 1989). Therefore, it may be possible 
to achieve the required high plasma concentrations with less 
cardiovascular side effects, by administering the single d- 
isomer. The principal aim of the study, therefore, was to 
investigate the pharmacokinetics and pharmacodynamics of 
relatively high doses of d-verapamil in healthy volunteers.
SUBJECTS AND METHODS
Eight healthy normotensive male volunteers, aged 2 7 + 7  
years, range 19-40 years; body weight 74.5 +6 . 5  kg. (table
6.1 .) gave written informed consent to participate in the 
study which had received prior approval from the Hospital 
Research and Ethical Committee. All subjects were deemed 
normal on the basis of routine clinical and laboratory 
examinations with pre-study electrocardiogram (ECG) 
examinations which confirmed normal sinus rhythm and a PR 
interval not greater than 180 ms.
The 8 subjects were sub-divided into 2 groups of 4. 
Subjects in group 1 attended the Clinical Pharmacology 
Research Unit (CPRU) at weekly intervals for a series of 
four 24-h study days to receive single doses of placebo, 240
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mg racemic verapamil, 250 mg d-verapamil and 500 mg d- 
verapamil. The study design was double blind but the 
randomisation was incomplete such that the 500 mg dose of 
d-verapamil was, for safety reason, always administered as 
the fourth treatment, following screening (blinded) of the 
blood pressure, heart rate and PR interval data from the 
previous study days. Subjects in group 2 followed the same 
overall study design with placebo and 240 mg racemic 
verapamil but with doses of 500 mg and 1000 mg d-verapamil.
On each study day, subjects reported to the CPRU having 
abstained from food, alcohol, nicotine and caffeine since 10 
pm the previous evening. An intravenous cannula was 
introduced for blood sampling and after 20 minutes 
recumbency baseline measurements of blood pressure and heart 
rate were recorded by semiautomatic sphygmomanometer and a 
standard lead II ECG was recorded at a speed of 50 mm/sec 
for the measurement of PR interval. Following oral dosing 
with verapamil or placebo, along with 150 ml of water, 
measurements of blood pressure, heart rate and PR interval 
were repeated at times 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10,
12, and 24 hours.
Plasma drug analysis
For both racemic and d-verapamil, concentrations of 
verapamil and norverapamil were analysed by HPLC with 
fluorescence detection after the method of Cole et al 
(1981).
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TABLE 6.1.
CLINICAL CHARACTERISTIC OF VOLUNTEERS
Subjects wt
(kg)
age
(years)
PR
(ms)
BP.
(mmHg)
HR
(bpm)
Group 1
1 72 22 168 125/62 63
2 68 19 124 159/91 79
3 68 40 178 119/74 76
4 78 35 150 126/91 91
Group 2
1 67 25 128 128/69 65
2 80 26 175 136/74 62
3 83 27 143 117/59 61
4 80 22 167 137/85 67
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Pharmacokinetic analysis
The concentration time profiles of racemic verapamil 
and d-verapamil and their respective metabolites were best 
fitted to a two compartment model with a third compartment 
for metabolite.
The area under the concentration time curve (AUC), 
clearance/F and terminal elimination half life were obtained 
by standard techniques, as described in the methods chapter.
Prediction of steady state concentrations
Using the parameters obtained from the single dose 
fitting in each individual subjects, a model was derived to 
predict steady state concentrations. The model for steady 
state comprised two compartments for drug with first order 
input from the gut and one compartment for metabolite. 
Predictions were based upon dosage intervals of two, three 
and four times daily administration. Since it is known that 
the clearance of racemic verapamil decreases during 
continued administration, the predictive model has been 
modified to incorporate a "correction" factor of 2.4, as 
suggested by Wagner et al. (1984) . This model takes account
not only of the prolongation of elimination half life of 
verapamil but also of its major metabolite, norverapamil 
which also has been shown to accumulate with multiple 
doses.
Statistical analysis 
Analysis of variance (ANOVA) has been used to evaluate 
treatment and time effects for repeated measurements of
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blood pressure, heart rate and PR intervals. This test has 
been applied on the separate groups (n = 4) and also on the 
two groups combined (n = 8) for the common treatments - 
placebo, 240 mg racemic verapamil and 500 mg d-verapamil. A 
P value of less than 0.05 was considered significant.
RESULTS
1. PHARMACOKINETICS
Peak plasma concentrations (Cmax) and times to attain 
the peak (tmax) are presented for all doses in table 6 .2 .
There were dose-related increases in Cmax, 308 and 640 
ng/ml in group 1 and 1143 and 2103 ng/ml in group 2 and no 
significant changes in tmax which occurred between 1-2 hours 
after the dose.
The fitted parameters for verapamil and norverapamil 
are presented in tables 6.3. and 6.4. The AUC for d- 
verapamil increased as the dose increased (table 6.5.) but 
at the highest dose of 1000 mg there was a tendency to 
nonlinearity with a mean value of 11818 ng/ml*h which is 
about 22% more than would have been projected from the 4 835 
ng/ml*h obtained with 500 mg.
Apparent oral clearance (clearance/F) is presented in 
table 6 .6 . and, as indicated by the AUC itself, the lowest 
clearance value of 1.6 + 0.5 1/min occurred after a 1000 mg 
dose. Elimination half life did not differ between doses and 
ranged between 4 and 6 hours (table 6.7.).
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TABLE 6.2.
PEAK PLASMA CONCENTRATION (Cma„) AND TIME 
TO REACH PEAK OF VERAPAMIL
GROUP 1
2 40 mg 2 5 0 mg - V 5 00 mg - V
R a c e m ic d - is o m e r d - is o m e r
S u b je c t ^max ^max c^max ^max ^max ^max
1 321 1.5 233 1.0 621 1.5
2 236 1.0 450 1.5 526 3.0
3 432 1.0 309 2.0 807 1.0
4 294 1.0 241 1.0 607 1.5
Median 307 1.0 275 1.3 614 1.5
Mean 321 1.1 308 1.4 640 1.7
Sd 82 0.25 100 0.5 119 0.9
GROUP 2 
S u b je c t
2 4 0  mg 
R a c e m ic
*nnax ^max
5 0 0  mg - V  
d - is o m e r
C t nn ax  umax
1 0 0 0  mg - V  
d - is o m e r
c t umax umax
1 261 1.5 876 1.5 2029 2.0
2 353 1.0 621 1.5 1586 1.5
3 318 1.0 1042 1.5 1723 1.5
4 636 1.0 2033 1.0 3074 1.0
Median 336
Ot— 1 959 1.5 1876 1.5
Mean 392 1.1 1143 1.4 2103 1.5
Sd 167 0.2 618 0.2 673 0.4
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TABLE 6.3.
PHARMACOKINETICS OF VERAPAMIL
GROUP 1
240 mg Racemic verapamil
Sub. A Alpha B Beta Ka Tlag KmO R2
1 301 0.8 209 0.13 4.5 0.5 1.3 0.980
2 151 1.1 99 0.13 10.3 0.5 0.6 0.946
3 742 2.8 266 0.21 7.4 0.5 0.7 0.957
4 168 0.7 161 0.18 11.3 0.6 0.7 0.968
Median 234 0.9 185 0.16 8.8 0.5 0.7
Mean 340 1.3 184 0.16 8.4 0.5 0.8
Sd 239 0.9 62 0.03 2.7 0.02 0.3
250 mg d-verapamil
1 239 0.4 81 0.09 4.0 0.5 4.8 0 .969
2 254 0.2 287 0.15 2.6 0.4 1.4 0 .925
3 126 0.7 815 0.12 1.5 0.8 1.7 0 .982
4 127 1.2 144 0.16 10.9 0.5 2.2 0 .886
Median 183 0.6 216 0.14 3.3 0.5 1.9
Mean 187 0.6 332 0.13 4.7 0.5 2.5
Sd 60 0.4 289 0.03 3.7 0.2 1.4
500 mg d-verapamil
1 368 0.3 318 0.25 19.8 1.0 1 . 5 0 . 949
2 499 0.2 449 0.16 0.9 0.8 1 .3 0 .955
3 646 0.5 311 0.15 58.0 0.5 1 .,0 0 .977
4 394 0.6 433 0.15 3.1 0.5 0 . 9 0 .959
Median 446 0.4 376 0.16 11.4 0.7 1 .. 1
Mean 477 0.4 378 0.18 20.0 0.7 1 ,.2
Sd 109 0.2 64 0.04 23.0 0.2 0 ,.3
A & B are coefficients; Alpha, KmO & Beta are elimination rate 
constants; Ka is absorption rate constant; Tlag is the time befo: 
the drug is detected in plasma; R2 is coefficient of determinate
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TABLE 6.4.
PHARMACOKINETICS OF VERAPAMIL 
GROUP 2
240 mg Racemic verapamil
Sub. A Alpha B Beta Ka Tlag KmO R2
1 286 0.4 571 0.22 0.6 0.5 0.9 0.946
2 305 1.0 139 0.14 10.8 0.6 0.6 0. 935
3 195 0.8 201 0.15 17.0 0.5 1.4 0.966
4 2441 1.8 292 0.16 3.0 0.3 0.6 0.957
Med­ 296 1.0 301 0.16 6.9 0.5
COo
ian
Mean 807 1.0 301 0.17 7.8 0.5 0.9
Sd 944 0.5 165 0.03 6.5 0.1 0.3
500 mg d-verapamil
1 1981 5.9 1043 0.21 3.9 0.2 2.3 0.957
2 1144 0.7 387 0.16 1.8 0.3 1.0 0.966
3 1272 0.6 505 0.16 2.3 0.5 1.8 0.954
4 3138 1.0 922 0.17 3.4 0.4 0.7 0.965
Med­ 1627 0.9 714 0.17 2.8 0.3 1.4
ian
Mean 1884 2.0 714 0.17 2.8 0.3 1.5
Sd 711 2.2 275 0.02 0.8 0.1 0.6
1000 mg d-verapamil
1 1734 0.2 1145 0.19 2.2 0.5 0.8 0.954
2 1802 0.5 599 0 .13 2.2 0.4 1. 9 0.956
3 3288 0.6 647 0.09 1.5 0.4 1.0 0.954
4 1647 0.5 2896 0.14 3.3 0.4 0.7 0.975
Med­ 1768 0.5 896 0.14 2.2 0.4 0.9
ian
Mean 2118 0.4 1322 0.14 2.3 0.4 1 .1
Sd 678 0.1 934 0.03 0.6 0.04 0.4
A & B are coefficients; Alpha, KmO & Beta are elimination 
rate constants; Ka is absorption rate constant; Tlag is the 
time before the drug is detected in plasma; R^ is 
coefficient of determination.
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TABLE 6.5.
AREA UNDER THE CONCENTRATION TIME CURVE (AUCq 
NG/ML*H) (CALCULATED BY TRAPEZOIDAL RULE)
GROUP 1
240 mg 250 mg -V 500 mg -V
Racemic d-isomer d-isomer
Subject Ver Nor Ver Nor Ver Nor
1 1819 816 1376 808 2501 2160
2 1810 1098 2983 1853 3969 3942
3 1304 1021 1563 1196 2865 2902
4 1003 1138 907 957 3115 3689
Median 1557 1059 1470 1077 2990 3295
Mean 1484 1018 1707 1203 3113 3173
Sd 347 124 774 400 540 700
GROUP 2 
Subject Ver
240 mg 
Racemic
Nor
500 mg 
d-isomer
Ver Nor
1000 mg 
d-isomer
Ver Nor
1 2368 1940 4496 3722 13480 . 9368
2 1208 1185 3089 2459 7698 5953
3 1368 1174 4002 3757 8975 8032
4 2550 2083 7754 5780 17119 11154
Median 1868 1562 4249 3739 11227 8700
Mean 1873 1595 4835 3929' 11818 8627
Sd 592 419 1759 1189 3739 1900
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TABLE 6.6.
CLEARANCE/F OF VERAPAMIL (L/MIN) 
(CALCULATED BY DIVIDING DOSE BY AUCq 0q)
GROUP 1
Subject 240 mg 
Racemic
250 mg -V 
d-isomer
500 mg -V 
d-isomer
1 2.2 3.0 3.3
2 2.2 1.4 2.1
3 3.1 2.7 2.9
4 4.0 4.6 2.7
Median 2.7 2.9
COCM
Mean 2.9 2.9 2.7
Sd 0.7 1.1 0.4
GROUP 2
Subject 240 mg 500 mg -V 1000 mg -T
Racemic d-isomer d-isomer
1 1.7 1.8 1.2
2 3.3 2.7 2.2
3 2.9 2.1 1 . 9
4 1.6 1.1 1.0
Median 2.3 1.9 1.6
Mean 2.4 1.9 1 . 6
Sd 0.8 0.6 0.5
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TABLE 6.7.
TERMINAL ELIMINATION HALF LIFE OF 
VERAPAMIL AND NORVERAPAMIL T1 /o (HOURS)
GROUP 1
240 mg 250 mg -V 500 mg -V
Racemic d-isomer d-isomer
Subject Ver Nor Ver Nor Ver Nor
1 5.4 0.5 7.7 0.1 2.8 0.5
2 5.3 1.2 4.6 0.5 4.3 0.5
3 3.3 1.0 5.8 0.4 4.6 0.7
4 3.9 1.0 4.3 0.3 4.6 0.8
Median 4.6 1.0 5.2 0.3 4.4 0.6
Mean 4.5 0.9 5.6 0.3 4.1 0.6
Sd 0.9 0.2 1.3 0.1 0.8 0.1
GROUP 2
240 mg 500 mg -V 1000 mg -V
Racemic d-isomer d-isomer
Subject Ver Nor Ver Nor Ver Nor
1 3.2 0.8 3.2 0.3 3.6 0.9
2 5.0 1.0 4.4 0.7 5.5 0.4
3 4.5 0.5 4.2 0.4 7.7 0.7
4 4.4 1.1 4.1 1.0 5.0 1.0
Median 4.4 0.9 4.1 0.6 5.2 o 00
Mean 4.3 0.9 4.0 0.6 5.5 0.8
Sd 0.7 0.3 0.5 0.3 1.5 0.3
240 mg : racemic verapamil; 250, 500, 1000 mg : d-verapamil 
ver : verapamil, nor : norverapamil.
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2. PHARMACODYNAMICS
2.1) Blood pressure and heart rate:
There were no significant changes in either blood 
pressure or heart rate in the group receiving the lower 
doses of d-verapamil. Therefore, the data presented are 
based on the mean values found in group 2 which contained 
significant differences from placebo.
a) Supine blood pressure and heart rate:
Supine systolic blood pressure tended to fall after all 
active treatments but none achieved statistical 
significance. For example, after 1000 mg d-verapamil (figure
6.1. & 6.3.) supine systolic blood pressure fell from 114 ±
5 (pre-dose) to 104 + 10 mmHg at 1.5 hours after dosing, 
compared to the corresponding values of 115 ± 1 and 117 + 7 
mmHg after placebo. Less reduction in supine systolic blood 
pressure was found after 240 mg racemic or 500 mg d- 
verapamil.
Supine diastolic blood pressure was also reduced after 
active treatments and statistical significance was achieved 
after the 1000 mg d-verapamil and 240 mg racemic verapamil. 
The average differences between the active treatments and 
placebo, calculated as an average over the 12 hours, were 
-7.5 mmHg (95% C.I. -9.4, -5.6) after 1000 mg d-verapamil,
-2 mmHg (95% C.I.-0.24,3.6; NS) after 500 mg d-verapamil and 
-3 mmHg (95% C.I. -4.8, -0.9) after 240 mg racemic 
verapamil. When the effects on diastolic blood pressure
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between active treatments were compared the reduction after 
1000 mg d-verapamil was significantly greater than after 240 
mg racemic (the difference in average over 12 hours was -4.5 
mmHg (95% C.I. -6 .6, -2.7)) and also from that after 500 mg 
d-verapamil (-5.8 mmHg (95% C.I. -7.8, -3.9)).
Supine heart rate increased after verapamil 
administration and achieved statistical significance after 
240 mg racemic, 500 mg d-verapamil and 1000 mg d-verapamil 
between 1 & 2 hours (figure 6.2. & 6.4.). Between these 
times the maximum heart rate increases were by 16, 13, 22 
bpm after 240 mg racemic, 500 mg and 1000 mg d-verapamil 
respectively compared to placebo.
b) Erect blood pressure and heart rate:
Erect systolic blood pressure was significantly reduced 
by verapamil with the greatest reduction occurring after 
1000 mg d-verapamil. For erect systolic blood pressure, 
statistical significance was attained only at 1.5 and 4 
hours after the dosing. At 1.5 hour, blood pressure was 
reduced to 9 3 + 1 6  mmHg as compared to 1 1 5 + 7  mmHg with 
placebo (figure 6.5.). Overall no statistically significant 
effects were attributable to any of the active treatments 
although there was a rank order of treatment effect: 240 mg 
racemic, 500 mg d-verapamil, 1000 mg d-verapamil.
Erect diastolic blood pressure was significantly 
lowered by all verapamil treatments with the same rank order 
of treatments. The differences, expressed as the averages 
over the 12 hour study days, between the active treatments
158
and placebo, were as follows: -11 mmHg (95% C.I. -14, -8.3)
after 1000 mg d-verapamil, -4.5 mmHg (95% C.I. -7, -2) after 
240 mg racemic verapamil & -2.9 mmHg (95% C.I. -5.6, -0.35) 
after 500 mg of d-verapamil. When the effects on erect 
diastolic blood pressure between active treatments were 
compared the reduction after 1000 mg d-verapamil was 
significantly greater than after 240 mg racemic mixture 
(-6.6 mmHg; 95% C.I. -9.4, -3.7) and also significantly 
greater than that after 500 mg d-verapamil (-8.2 mmHg; 95% 
C.I. -11, -5.4).
Erect heart rate was significantly increased after 1 &
2 hours (figure 6 .6 .) by both the 500 mg and 1000 mg doses 
of d-verapamil. At one hour after dosing, erect heart rate 
was increased by 18 bpm after 500 mg and by 20 bpm after 
1000 mg d-verapamil, compared to placebo.
2.2) Atrioventricular conduction (PR interval)
PR intervals were significantly increased after all 
doses of verapamil. The maximum increases occurred between 1 
& 2 hours after dosing. Prolongations of about 38 ms in PR 
interval were achieved one hour after both racemic verapamil 
and 1000 mg d-verapamil. These were significantly different 
from placebo (95% Cl 12,65, for each treatment). Two hours 
after dosing the prolongation in PR interval after 240 mg 
racemic verapamil started to decline towards placebo but the 
effect of 1000 mg d-verapamil seemed to continue throughout 
the study day (figure 6.7).
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p < 0.05 (ANOVA).
2. Effect of verapamil on supine heart rate
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6.3. Effect of verapamil on supine systolic (a) and 
diastolic (b) blood pressure for the combined 
groups.
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* Significantly different from placebo 
p < 0.05 (ANOVA).
4. Effect of verapamil on supine heart rate.
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p < 0.05 (ANOVA).
Figure 6.5. Effect of verapamil on erect systolic (a) 
and diastolic (b) blood pressure.
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5.6. Effect of verapamil on erect heart rate
165
PR 
IN
TE
RV
AL
 
(m
s) 
PR 
IN
TE
RV
AL
 
(m
s)
PR INTERVAL
a
220
Group f
200
190
180
170
160
150]
140
130
120
100
0 122 4 6 8 10
TIME (HRS)
~©~ P lacebo  2 4 0  mg Racemic
2 5 0  mg d -verapam il  5 0 0  mg d -verapam ll
b
220
210
200
190
180
170
1601
150<
140
130
120
Group 2
100
0 2 4 6 8 10 12
TIME (HRS)
- e -  Placebo 2 4 0  mg Racemic
♦  500 mo d-verapamll -O - XXX) mo d-verapamll
* Significantly different from placebo 
p < 0.05 (ANOVA).
Figure 6.7. Effect of verapamil on PR interval in group 1 
(a) and group 2 (b).
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2.3) Adverse effects
Adverse events are presented in table 6 .8 . Flushing was 
most commonly reported and it occurred in 6/8 subjects who 
received 500 mg d-verapamil and in 4/4 subjects who received 
1000 mg d-verapamil. Gastrointestinal upset was the second 
most frequently reported adverse events with epigastric pain 
starting 30 minutes after dosing and lasting up to 2 hours 
reported by all 4 subjects who received 1000 mg d-verapamil. 
Nausea was reported by 1/8 subjects receiving 500 mg d- 
verapamil. Symptomatic, postural hypotension was reported by 
3 subjects; 1 after 500 mg and 2 after 1000 mg d-verapamil.
3) SIMULATIONS
Using the individual values of the parameters derived 
from the single dose studies, the predicted concentration 
time profiles for 500 mg twice daily, 500 mg thrice and four 
times daily d-verapamil are presented in figures 6 .8 . and 
6.9.
The predicted peak plasma concentrations at steady 
state fell into the range 1800 - 3000 ng/ml following 500 mg 
d-verapamil two to four times daily, with associated 
predicted norverapamil concentration ranges similar to the 
parent drug. It was also noted that the predicted verapamil 
and norverapamil concentrations were maintained above 1000 
ng/ml (i.e. 2 juM - the "minimal" required level) for about 4 
hours or more.
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TABLE 6 .8 . 
ADVERSE EFFECTS
Side effect Placebo 240 mg 500 mg 1000 mg
racemic d-verapamil d-verapamil
Flushing 0/8 0/8 6/8 4/4
Nausea/
epigastric pain
0/8 0/8 1/8 4/4
Dizziness/
hypotension
0/8 0/8 1/8 2/4
Headache 0/8 1/8 0/8 0/8
The numbers in the table refer to the proportion of subjects 
reported side effects to the number of subjects treated.
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Figure
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6 .8 . a: the plasma concentration of d-verapamil
after 500 mg single dose; b: predicted steady 
state concentration after 500 mg twice daily.
Error bars: SD,
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Figure 6.9. Predicted steady plasma concentration from 
single dose data after 500 mg three times 
daily (a) and four times daily (b).
Error bars: SD,
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DISCUSSION
With respect to the use of single isomer d-verapamil as 
an adjuvant cytotoxic drug treatment the principal aims of 
this study were to determine the disposition and 
cardiovascular effects of d-verapamil when administered in 
doses likely to produce the required (or thought to be 
required) plasma drug concentrations.
The target range of 1000-3000 ng/ml ( 2 - 6  pM) can be 
reached with the intravenous administration of racemic 
verapamil (9 micrograms/kg/min) but in association with a 
severe and unacceptable degree of cardiac toxicity (Ozols et 
al., 1987).
In this single dose study, 1000 mg d-verapamil produced 
peak concentrations around 2000 ng/ml (about 4 pM). However, 
this peak level was relatively short-lived and declined 0.5 
to 1 hour after dosing. It seems likely that the optimal 
cytotoxic adjuvant will require that the verapamil level 
should be sustained for a longer period. In addition, 
although the 1000 mg dose of d-verapamil was associated with 
prolongations of PR interval which were not significantly 
different from that associated with 240 mg of racemic 
verapamil, none of the subjects had any degree of A-V block. 
However, significant falls in blood pressure, particularly 
on standing, occurred with 1000 mg at approximately the time 
of maximum drug concentrations. From the effects on blood 
pressure and A-V conduction it appears that d-verapamil had 
a relatively greater effect on lowering blood pressure than 
on increasing A-V conduction. Thus, considering d-verapamil
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as an adjuvant in the treatment of cancer, the hypotensive 
action may be potentially more important than the negative 
dromotropic effect. A further consideration for the relative 
importance of these effects is that there are reports that 
the effect of verapamil on A-V conduction is decreased with 
age (Abernethy et al., 198 6).
The reported side effects, especially with the 500 and
1000 mg doses, included flushing, hypotension and epigastric 
pain. The epigastric pain may be due to a local gastric 
irritant effect because of the bulk of the tablets used (200 
mg x 5). There were no clinical signs indicating an 
impairment of myocardial contractility (negative inotropic 
effect).
In the present study, we used the concept of 
pharmacokinetic modelling to extrapolate beyond the existing 
data (Colburn et al., 1987) to predict steady state plasma 
concentrations from single dose data. The predicted
concentrations were adjusted to take account of the presumed
accumulation of verapamil at steady state on the assumption 
that d-verapamil displayed the same changes in disposition 
as racemic verapamil during continued administration (Shand 
et al, 1981; Freedman et al., 1981). On the basis of these 
predictions, a regimen of 500 mg d-verapamil four times 
daily would result in a peak plasma level of 3000 ng/ml 
(about 6 pM).
It appears, therefore, that relatively high 
concentrations, comparable to those indicated by the in 
vitro studies, can be achieved after the administration of
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the d-isomer of verapamil with little serious cardiac 
toxicity.
It is not yet clear if the effective range of verapamil 
concentrations obtained in vitro is directly applicable to 
man since many in vivo factors might intervene to affect the 
availability of verapamil at the required site of action. 
These include:
1. Verapamil in plasma is bound to plasma albumin 
(60%) and to alphal-acid glycoprotein (McGowan et al., 1983) 
which is increased in malignancy (Snyder & Ashwell, 1971; 
Weiss et al., 1979; Chio et al., 1979; for review see Wood,
1986). Potentially, therefore, the free concentration of 
verapamil, which can more readily penetrate into the 
tissues, will be reduced.
2. Drug concentrations in plasma do not necessarily 
reflect the concentrations in tissues and this may be 
particularly true of neoplastic tissues.
3. Norverapamil, which is generated as a result of the 
metabolism of verapamil in the liver, reaches concentrations 
which have been shown in vitro to have additive adjuvant 
effects. Thus, when verapamil and norverapamil are used in 
relatively low concentrations, each of 2 jjM, the cytotoxic 
effect is maximal (Merry et al., 1989). If this translates 
to in vivo effects then d-verapamil can be administered in a 
flexible range of doses to generate norverapamil in 
reasonable concentrations to achieve the desired combined 
concentrations. Thus a total concentration of 2 jaM (1000 
ng/ml) for the drug and metabolite might be achieved at
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relatively low’ doses of d-verapamil with a further reduction 
in cardiovascular side effects. Norverapamil appears to have 
only approximately 20% of the coronary vasodilatory activity 
of the parent compound (Neugebauer et al., 1978) and is 
itself unlikely to have major haemodynamic effects for the 
range of concentrations required.
4. Since verapamil may inhibit hepatic enzymes 
activity (c.f. its own clearance) and since there is 
evidence that it inhibits the metabolism of other drugs, 
such as antipyrine (Bauer et al., 1986), an interaction 
between verapamil and a concurrently administered 
chemotherapeutic agent may result in higher plasma levels 
and probably enhanced cytotoxic effects. Not only might this 
result in more chemotherapeutic toxicity but if the 
chemotherapeutic agent was also cardiotoxic (e.g. 
adriamycin) there would be further reasons for concern about 
the combined use.
It is concluded that d-verapamil can be used instead of 
racemic verapamil to achieve a range of concentrations 
thought to be appropriate for adjuvant cancer treatment but 
without serious cardiovascular side effects. However, the 
optimal dosing regimen and the interactions with cytotoxic 
drugs and the impact of the disease state require further 
clinical study in cancer patients.
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CHAPTER SEVEN
THE PHARMACOKINETICS AND PHARMACODYNAMICS OF NICARDIPINE IN 
PATIENTS WITH RENAL IMPAIRMENT
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INTRODUCTION
Since calcium antagonist drugs are extensively 
metabolised by the liver with a plasma clearance which 
depends primarily on liver blood flow and on hepatocellular 
function, many studies have concentrated upon investigations 
of the effect of liver disease on drug disposition and dose 
requirements. Such studies have shown that there were 
significant reductions in the plasma clearance of verapamil 
(Somogyi et al., 1981), nifedipine (Kleinbloesem et al.,
1986), nisoldipine (Van Harten et al., 1987; Joeres et al.,
1987) and nimodipine (Gengo et al., 1987) in patients with 
hepatic impairment. Little attention, therefore, has been 
addressed to the effects of renal impairment but since 
cardiovascular disease and renal impairment frequently 
coincide, it is of comparable importance to investigate the 
impact of renal disease on the clinical pharmacology of 
calcium antagonist drugs.
The present study investigates the pharmacokinetics and 
pharmacodynamics of nicardipine in patients with varying 
degrees of renal impairment.
SUBJECTS AND METHODS
The study design was single blind (patient-blind) and 
randomised. Three separate groups of patients whose clinical 
characteristics are listed in table 7.1. were recruited for 
•the study.
Group 1: patients with mild to moderate essential 
hypertension with normal renal functions;
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group 2 : patients with mild to moderate essential
hypertension with varying degrees of renal 
impairment;
group 3: patients with end-stage renal failure on
regular haemodialysis three times per week 
(study days occurred between the dialysis 
treatments).
All patients gave written, informed consent and 
reported to the Clinical Pharmacology Research Unit having 
fasted over night. The 3 groups were randomly assigned to 
receive a single intravenous dose and a single oral dose 
(acute) of nicardipine on two separate study days with a 
wash out period of 7 days between. Groups 1 and 2 
additionally undertook a third study day following a 1 week 
of treatment with nicardipine 45 mg twice daily. Intravenous 
nicardipine was administered as a short intravenous infusion 
(70 ug/kg body weight) over 10 minutes. Blood samples were 
collected before the dose and at 2, 5 and 10 minutes during 
infusion and 2, 5, 10, 20, 40, 60 minutes and 2, 3, 4, 5,
6, 8 hours after infusion.
Oral nicardipine was administered as a slow release 
formulation (45 mg, biphasic formulation). The morning dose 
was given at 8:30 with 150 mis of water. Blood samples were 
collected before the dose and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 
8 and 12 hours after the dose.
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TABLE 7.1.
CLINICAL CHARACTERISTIC OF PATIENTS
CRCL Age Weight Previous
Group ml/min (years) (Kg) Medication
Normal renal function
1.1 72 53 57
1.3 97 61 90 *Bendrofluazide
1.4 89 47 55
1.5 88 64 85 *Allopurinol
1.6 103 58 80
1.7 95 41 63
Mean 91+11 54+9 72+15
Renal Impairment group
2.1 40 47 75
2.2 55 57 78 Spironolactone
2.3 43 65 55 Diltiazem, Bendrofluazide
2.4 49 50 65 Nifedipine
2.5 49 62 105 *Bendrofluazide, KCL, aspirin
2.6 22 65 69 *Frusemide
2.7 13 62 77. *Frusemide
Mean 39+16 5 8+7 75+.16
Dialysis group
3.1 50 65 Ferrous sulphate
3.2 33 47 Ferrous sulphate
3.3 49 77
3.4 20 66
3.5 58 67 ^Dipyridamole
3.6 23 47 Ferrous sulphate
3.7 61 75
3.8 30 73 Floxacillin
Mean 41+16 65+12
CRCL : Creatinine clearance.
* Drugs which are continued throughout the study
Dialysis group (group 3) were continued on vitamin B, ascorbic 
acid, folic acid, Alu-Cap (Aluminium hydroxide) 
throughout the study.
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Blood pressure and heart rate: were recorded in 
duplicate by a semiautomatic shygmomanometer (Sentron, Bard 
Medical) at times corresponding to the times of blood 
sampling for drugs.
Apparent Liver blood flow: was measured 1 hour after 
dosing from the plasma clearance of an intravenously 
administered dose of indocyanine green (ICG) (0.5 mg/kg).
Renal function: glomerular filtration rate (GFR) and 
effective renal plasma flow (ERPF) were measured 1.5 hours 
after dosing from the clearance of ^Cr-EDTA anc} 125j_ 
Hippuran respectively.
Analytical Methods
Nicardipine plasma levels were determined by an HPLC 
method (Wu et al., 1984)
Indocyanine green plasma levels were determined by an 
HPLC method as described by Rappaport et al., (1982) .
Pharmacokinetic analysis
The individual concentration time profiles were first 
plotted on semi-log graph. The concentrations after 
intravenous infusion were best fitted to a two compartment 
model of the form described by Gibaldi & Perrier (1975) as 
described in the methods chapter.
The plasma drug clearance and volume of distribution 
were directly estimated from the model. Elimination half 
life was calculated by dividing 0.693/p.
After oral administration, the concentration time 
profile was biphasic in shape and it was inappropriate to 
fit the data to a model. The pharmacokinetic parameters such
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as ^max or tmax anc* bioavailability were estimated by 
standard technique as described in the method section.
Statistical Analysis
Logarithmic (to the base e) transformation was required 
to normalise the distribution of plasma clearance of 
nicardipine and for liver blood flow data. For comparison 
between groups, one way analysis of variance (ANOVA) was 
used. The relationship between the pharmacokinetic 
parameters and indices of renal function for this whole group 
was undertaken by linear regression analysis. Time and 
treatment effect on blood pressure and heart rate was 
evaluated by repeated measures analysis of variance using 
BMDP package. Data throughout are presented as mean + SD.
RESULTS
Intravenous infusion
Mean plasma concentration time profiles of nicardipine 
for the 3 groups are shown in figure 7.1.. The fitted 
pharmacokinetic parameters are presented in table 7.2. and 
the derived pharmacokinetic parameters in table 7.3.
The plasma clearance of nicardipine was significantly 
lower in patients with renal impairment (group 2) compared 
to those with normal renal function (group 1): (10.41 vs
6.53 ml/min/kg; P =0.03), whereas plasma clearance in 
patients with end stage renal failure (group 3) (12.54
ml/min/kg) was not different from the value in the normal 
group (figure 7.2.) . These changes were associated with a
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slight and insignificant increase in elimination half life 
in group 2 & 3 compared to group 1. The volume of 
distribution of the central (Vc) and the peripheral 
compartment, although apparently higher in group 3, was not 
significantly different from group 1 or group 2 (figure 
7 .3 .).
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Figure 7.1. Mean plasma nicardipine levels following an 
intravenous infusion of nicardipine HCL 
(70 ug/kg for 10 minutes). The plasma 
concentrations decline in bi-exponential 
manner.
181
TABLE 7.2.
THE PHARMACOKINETIC PARAMETERS OF NICARDIPINE 
FOLLOWING INTRAVENOUS INFUSION 7 0 UG/KG OVER 10 MINUTES
GROUP 1
A Alpha B Beta
Group (ug/1) (1/h) (ug/1) (l/li) R2 value
1.1 0.014 14.9 0.0138 0.400 0.904
1.3 0.0032 50.0 0.0189 0.356 0.801
1.4 0.0056 11.2 0.0131 0.450 0.942
1.5 0.0062 13.3 0.0160 0.500 0. 986
1.6 0.0054 16.0 0.0226 0 . 600 0.850
1.7 0.0058 7.0 0.0180 1.680 0.877
Mean 0.0067 18.73 0.0171 0. 664
Sd 0.0037 15.64 0.0035 0.505
GROUP 2 
2.1 0.0105 16.4 0.0230 0.250 0.902
2.2 0.0122 3.6 0.0106 0.290 0.970
2.3 0.0125 40.0 0.0770 0.360 0.912
2.4 0.0121 15.8 0.0240 0.500 0. 976
2.5 0.0046 21.5 0.0112 0.877 0.956
2.6 0.0140 22.8 0.0312 0.409 0.960
2.7 0.0154 9.7 0.0416 0.135 0.988
Mean 0.0116 18.5 0.0312 0.403
Sd 0.0035 11.6 0.0230 0.240
GROUP 3
3.2 0.0066 6.6 0.0300 0.079 0.823
3.3 0.0074 23.9 0.0090 1.120 0.893
3.4 0.0179 30.0 0.0083 0.395 0.986
3.5 0.0084 16.0 0.0140 1.170 0.992
3.6 0.0065 16.5 0.0164 0.691 0.994
3.7 0.0046 8.9 0.0240 0.293 0. 946
3.8 0.0072 8.5 0.0036 0.434 0.942
Mean 0.0084 15.8 0.0150 0.590
Sd 0.0043 8.7 0.0093 0.410
: % variability explained by the model.
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TABLE 7.3.
THE DERIVED PHARMACOKINETIC PARAMETERS OF NICARDIPINE
FOLLOWING INTRAVENOUS INFUSION OF 70 UG/KG OVER 10 :MINUTES
GROUP 1
K21 C l V I T l / 2  A lp h a T l / 2  B e ta
G ro u p ( 1 /h ) ( m l /m in /k g ) ( 1 /k g ) (h ) (h )
1.1 0.77 10.49 0.081 0.046 1.73
1.3 2.34 8.37 0.065 0.014 1.95
1.4 1.37 16.21 0.260 0.062 1.54
1.5 1.63 8.82 0.130 0.052 1.39
1.6 2.68 7.42 0.120 0.043 1.16
1.7 6.35 11.13 0.036 0.010 0.41
Mean 2.52 10.41 0.115 0.037 1.36
Sd 1.99 3.15 0.079 0.020 0.54
GROUP 2
2.1 0.77 6.66 0.075 0.042 2.77
2.2 0.50 9.40 0.270 0.191 2.39
2.3 2.45 3.36 0.034 0.017 1.93
2.4 1.39 7 .15 0.075 0.044 ' 1.39
2.5 2.75 10.06 0.088 0.032 0.79
2.6 1.27 5.33 0.043 0.030 1.69
2.7 0.48 3.78 0.083 0.071 5.13
Mean 1.37 6.53 0.096 0.061 2.29
Sd 0.91 2.58 0.079 0.060 1.41
GROUP 3 
3.2 0.415 9.68 0.46 0.105 8 .770
3.3 2.350 13.18 0.07 0.029 0.617
3.4 0.574 9.64 0.03 0.023 1.750
3.5 2.780 11.09 0.09 0.043 0.590
3.6 2.190 15.46 0.17 0.042 1.000
3.7 1.560 7.68 0.27 0.077 2.370
3.8 0.636 21.11 0.22 0.082 1.600
Mean 1.500 12.54 0.18 0.057 2.380
Sd 0.960 4.56 0.15 0.030 2.880
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Figure 7.2
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^ indicates a significant difference from group 1 
P <0.05 (ANOVA)
The plasma clearance of nicardipine following 
acute intravenous infusion of 70 ug/kg over 
10 minutes.
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Single oral doses of nicardipine
Mean plasma concentration time profiles after the 
single oral doses of nicardipine are presented in figure
7.4. The pharmacokinetic parameters are presented in table
7.4. and figure 7.5.
The AUCq-co after the first dose was significantly 
higher in patients with renal impairment (group 2) compared 
to patients with normal renal function (groupl) (153 vs 249 
ng/ml*h; P < 0.05). The AUC in the dialysis group (group 3) 
was 184 ng/ml*h which is not significantly different from 
group 1. Correspondingly, Cl/F was decreased from 105 
ml/min/kg in patients with normal renal function to 50 
ml/min/kg; P < 0.05, in patient with renal impairment but it 
was 93 ml/min/kg in the dialysis group. Peak plasma level 
was slightly higher in patients with renal impairment (group 
2) compared to group 1 (30 vs 51 ng/ml) but this was not 
statistically significant. Peak plasma level was 33 ng/ml in 
the dialysis group.
Chronic oral doses of nicardipine
The derived pharmacokinetic parameters of nicardipine 
after chronic treatment are presented in table 7.5. and 
figure 7.5. During continued administration the AUCq_^2 h 
was significantly higher in patients with renal impairment 
(group 2) compared to patients with normal renal function 
(group 1) (194 vs 509 ng/ml*h; P = 0.006) and the
clearance/F was significantly lower in patients with renal 
impairment compared to normal renal function group (20.8 vs
70.2 ml/min/kg; P = 0.006). Peak plasma level (Cmax)
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achieved a level of 87 ng/ml in the renal impairment group 
which is significantly higher than 38.3 ng/ml in group 1; P 
= 0.01. During the translation from acute to chronic, 
clearance/F was reduced with chronic dosing from 105.4 to
70.2 ml/min/kg (33%) in group 1 which is not significant 
whereas in group 2 clearance/F was significantly decreased 
from 50 to 21 ml/min/kg (58%) (P = 0.005) and the Cmax 
increased from 51 to 87 ng/ml (70%) (P = 0.006) (figure
7.5.).
The bioavailability after single doses of nicardipine 
was about 15% and there were no significant differences 
between the three groups. During chronic dosing there was a 
significant difference between the bioavailability in group 
1 (18%) and group 2 (34%) (P < 0.02) and, in group 2, the 
bioavailability had significantly increased from 18% after 
acute dosing to 34% after chronic dosing (mean difference 
16%, P < 0.003).
Apparent liver blood flow
There were no significant differences in liver blood 
flow between the groups and there were no effects attributa­
ble to nicardipine (table 7.6.).
Renal functions
Patients with renal impairment had significantly lower 
ERPF and GFR compared to patients with normal renal function 
and there were no effects attributable to nicardipine.
(table 7.7. & 7.8.)
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Figure 7.4. Mean plasma nicardipine levels for (group 1) 
and (group 2). The plasma levels shows the 
diphasic pattern of absorption between 1 and 
3 hours.
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TABLE 7.4.
THE PHARMACOKINETIC PARAMETERS OF NICARDIPINE
FOLLOWING SINGLE ORAL DOSES (45 MG SR) I
Bioavailability
(%)
GROUP
Group
1
AUC
(ng/ml*h) (SSfti)
Cl/F
(ml/min/kg)
1.1 282.3 53.2 5.0 46.6 23.1
1.3 203.2 46.7 0.7 41.0 25.1
1.4 54.5 8.4 5.0 250.0 6.6
1.5 191.4 31.1 5.0 46.0 21.1
1.6 113.1 22.3 5.0 82.9 9.0
1.7 71.8 19.9 4.0 165.9 6.4
Mean 152.7 30.26 4.1 105.4 15.2
Sd 87.9 17.00 1.7 85.1 8.8
GROUP
2.1
2
301.7 75.5 2.2 33.1 22.5
2.2 140.0 26.6 1.5 86.7 14 .2
2.3 389.0 97.3 0.7 35.0 16.6
2.4 154.8 24.6 6.0 74.5 10.7
2.5 142.8 28.2 1.5 50.0 20.6
2.6 390.0 63.1 3.2 27.9 25.0
2.7 226.8 42.4 4.0 42.9 13.5
Mean 249.3 51.1 2.7 50.0 17 . 6
Sd 111.6 28.2 1.8 22.3 5.2
GROUP 3
3.1 69.2 21.4 5.0 166.7 NR
3.2 155.6 18.1 6.0 102.6 10.0
3.3 95.0 23.8 1.5 102.5 14.2
3.4 135.0 38.7 0.9 84.2 13.4
3.5 425.5 74.3 3.2 26.3 40.4
3.6 396.0 56.8 5.0 40.3 31.0
3.7 70.2 14 . 6 2.2 142.4 5.2
3.8 124.4 19.6 0.9 82.6 24.5
Mean 183.8 33.4 3.1 93.4 19.8
Sd 143.5 21.6 2.0 47.0 12.6
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TABLE 7.5.
THE PHARMACOKINETIC PARAMETERS OF NICARDIPINE
FOLLOWING CHRONIC ORAL DOSING (45 MG SR B.D)
Bioavailability
(%)
GROUP
Group
1
AUC
(ng/ml*h) f e i )
Cl/F
(ml/min/kg)
1.1 484.0 92.2 3.17 25.2 36.9
1.3 192.0 40.2 3.17 41.2 20.9
1.4 105.0 15.8 0.92 119.0 13.7
1.5 172.0 29.0 3.17 47.8 18.3
1.6 109.0 24.6 4.00 80.0 8.8
1.7 101.0 27.8 0.67 108.0 8.4
Mean 193.8 38.3 2.50 70.2 17.8
Sd 147.2 27.6 1.40 38.1 10.6
GROUP 2
2.1 643.0 118.0 0.67 14.3 36.9
2.2 254.0 62.4 1.50 35.4 25.8
2.3 533.0 97.0 1.50 23.9 18.9
2.4 601.0 89.0 0.92 18.1 39.2
2.5 302.0 48.9 3.17 22.1 40.1
2.6 772.0 121.0 2.17 12.7 50.1
2.7 457.0 70.5 4.00 19.5 26.4
Mean 509.0 87.0 1.99 20.8 33.9
Sd 186.0 27.6 1.21 7.6 10.7
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5. The area under the concentration time 
curve (AUC) and Cl/F following oral 
dosing with nicardipine.
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Figure 7.6. Peak plasma level (C^ax) following acute 
and chronic oral dosing of nicardipine.
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TABLE 7.6.
LIVER BLOOD FLOW FOLLOWING INTRAVENOUS
AND ORAL ADMINISTRATION OF NICARDIPINE HCL
Pat. No.
Liver
I.V.
blood flow (ml/min/kg) 
Acute Chronic
Group 1 
1:1 23.3 17.0 26.9
1:3 37.6 43.4 28.4
1:4 21.2 31.1 22.9
1:5 13.8 13.8 14.5
1:6 16.6 17.5 15.2
1:7 25.1 25.7 19.7
Mean 22.9 24.7 21.3
Sd 8.3 11.1 5.8
Group 2 
2:1 32.6 22.4 32.6
2:2 13.0 16.6 14.2
2:3 14.1 15.3 15.3
2:4 15.7 NR 19.2
2:5 NR 12.0 12.4
2:6 61.9 15.4 42.5
2:7 8.8 11.0 12.3
Mean 24.3 15.4 21.2
Sd 20.1 4.0 11.7
NR : no result.
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TABLE 7.7.
EFFECTIVE RENAL PLASMA FLOWS (ERPF) FOLLOWING 
INTRAVENOUS AND ORAL ADMINISTRATION OF NICARDIPINE HCL
ERPF (ml/min)
Pat. No. I.V. Acute Chronic
Group 1
1:1 640 399 350
1:3 448 485 417*
1:4 431 430 390
1:5 398 431 389
1:6 413* 507* 410*
1:7 680 606 481
Mean 502 466 406
Sd 124 90 43
Group 2
2:1 129 116 163
2:2 321 303 198
2:3 NR NR NR
2:4 270 335 382
2:5 236 245 206
2:6 87 78 67
2:7 NR 47 48
Mean 209 187 178
Sd 98 122 120
’ values have been normalised to
Surface Area.
NR = No Result
* = Value calculated on the basis of plasma data
extrapolated to infinity because urine collection 
was incomplete.
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TABLE 7.8.
GLOMERULAR FILTRATION RATE (GFR) FOLLOWING 
INTRAVENOUS AND ORAL ADMINISTRATION OF NICARDIPINE HCL
GFR (ml/min)
Pat. No. I.V. Acute Chronic
Group 1
1:1 88.2 90.6 69.7
1:3 83.4 86.9 86.9*
1:4 91.7 93.8 86.5
1:5 72.4 82.1 68.0
1:6 80.4* 8 8.2* 95.2*
1:7 107.0 115.0 116.0
Mean 87.0 92.7 87.0
Sd 12.0 11.6 17.7
Group 2 
2:1 33.1 35.0 37.8
2:2 72.5 58.9 38.9
2:3 NR NR NR
2:4 71.4 57.3 71.4
2:5 68.9 71.3 64.1
2:5 22.2 17.4 12.6
2:6 NR 8.9 7.9
Mean 53.6 41.3 38.8
Sd 24.0 24.9 25.9
.All GFR values have been normalised to 1.7 3 mz Body 
Surface Area.
NR = No Result
* = Value calculated on the basis of plasma data
extrapolated to infinity because urine collection 
was incomplete.
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Relationship between the pharmacokinetics of
nicardipine and renal function
There was a significant inverse correlation between the 
AUC of nicardipine during chronic treatment and GFR (r = 
-0.73, p = 0.005, n = 13) and ERPF (r = -0.68, p = 0.01, n = 
13) (figure 7.6.). When the magnitude of change in AUC 
during the translation from acute to chronic dosing was 
correlated with renal function this also showed significant 
correlations between AAUC and GFR (r = -0.59, p = 0.03, n 
= 13) or AAUC and ERPF (r = -0.55, p =0.05, n = 13)
(figure 7.7.),
Blood pressure and heart rate
The blood pressure and heart rate after acute and 
chronic dosing with nicardipine are shown in table 7.9. In 
relation to the baseline blood pressure, supine blood 
pressure was reduced after dosing to a lowest value at about 
2 hours. In hypertensive patients with normal renal function 
(groupl) blood pressure was reduced after chronic oral 
dosing from 162/98 ± 21/12 mmHg before the dose to 141/88 ± 
10/6 mmHg 2 hours after the dose (P < 0.03 for the reduction 
in systolic blood pressure). In patients with renal 
impairment (group2), supine blood pressure was 169/97 + 22/9 
mmHg before dosing and 147/84 + 25/11 mmHg 2 hours after 
dosing (statistical significance achieved for both systolic 
and diastolic blood pressure; P < 0.04) . Supine heart rate 
was not affected by chronic nicardipine although there was 
an upward trends at 3 hours after dosing.
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TABLE 7.9.
SUMMARY OF BLOOD PRESSURE AND HEART RATE 
AFTER TREATMENT WITH NICARDIPINE IN PATIENTS
WITH DIFFERENT :DEGREES OF RENAL IMPAIRMENT
Group Pre-dosing 2-hours post dose
BP HR BP HR
Group 1
Acute I.V. 164/100±19/12 72±4 147/90±12/8 69±6
Acute oral 170/100+27/11 71±9 *146/87± 6/9 7 0±9
Chronic oral 162/98 ±21/12 70±9 *141/88±10/6 68±8
Group 2
Acute I.V. 173/100+45/14 8 0±13 158/91±35/16 70±9
Acute oral 174/104+41/20 81±13 153/8 6±33/13 8 0±16
Chronic oral 169/97 ±22/9 81±7 *147/*84±25/ll 80±14
Group 3
Acute I.V. 147/82 ±17/11 75±6 144/80±17/13 69±6
Acute oral 152/83 ±21/14 7 6±4 147/7 9±13/11 7 4±7
* Significantly different from pre-dose value, P< 0.05; 
(ANOVA).
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DISCUSSION
The positive findings, by many investigators, of the 
relationship between liver disease and reduction in the 
plasma clearance of calcium antagonist drugs and the absence 
of a correlation between renal impairment and altered 
pharmacokinetics for example with verapamil (Mooy et al., 
1986), nifedipine (Kleinbloesem et al., 1985), diltiazem 
(Pozet et al., 1983) and nitrendipine (Bortel et al., 1989), 
has supported the expected theoretical concept that the 
liver is the major site for the metabolism of these drugs. 
This has largely ignored the potential importance of renal 
disease on hepatic metabolic capacity and the possible 
resultant impact on the metabolism of other dihydropyridine 
calcium antagonists. This has led to a general assumption 
that renal disease has no effect on the pharmacokinetics of 
calcium antagonists (Chellingsworth and Kendall, 1987) . The 
present study has shown that the plasma clearance of 
nicardipine was significantly reduced in patients with renal 
impairment but restored towards normal in patients with end 
stage renal failure undergoing haemodialysis. These results 
are in agreement with other previous studies which showed 
that the AUC after dosing with nicardipine (20 or 30 mg 
orally) was significantly higher in patients with renal 
impairment compared to normal subjects (Lee et al., 1986). 
Similar results have been recently reported for nitrendipine 
(Ankermann et al., 1989). In these studies the effect of 
haemodialysis on drug disposition was not studied. There are 
only a few studies of calcium antagonist pharmacokinetics in
patients with end stage renal failure on regular 
haemodialysis and for nifedipine there were no differences 
(Martre et al., 1985; Kleinbloesem et al.-, 1986).
The mechanisms underlying the reduction in clearance in 
renal disease are not well defined but presumably reflect 
functional rather than structural changes. The overall 
correlation between the pharmacokinetic parameters, such as 
AUC, and the level of renal function suggests that the 
reduction in plasma clearance of nicardipine is related 
either directly to the deterioration in renal function 
(which is unlikely) or indirectly to the effects of renal 
dysfunction on hepatic metabolism. After oral administration 
nicardipine is subject to extensive hepatic metabolism 
(Higuchi et al., 1977; Graham et al., 1985) which may be 
saturable at relatively low.concentrations (Seki and Takena- 
ka, 1977; Silke et al., 1984). Thus the clearance of nicar­
dipine ultimately depends on both liver blood flow and 
hepatocellular function. However, in this study there were 
no differences between the groups for apparent liver blood 
flow. Alternatively, the positive and significant correla­
tion between the level of renal function and the magnitude 
of change in AUC, during the translation from acute to 
chronic dosing, might suggest that the reserve of the capac­
ity limited hepatic enzyme system was reduced or inhibited 
in patients with renal impairment, so that hepatic metabo­
lism was more easily saturated. Another explanation for the 
reduction in clearance is accumulation of renally-eliminated 
metabolites (Pyridine II) which in turn saturate or inhibit
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or inhibit further metabolism. Although data on the 
metabolites were not available, it can be presumed that the 
generation of metabolites is less rapid and less marked 
after intravenous dosing and yet the plasma clearance after 
intravenous administration was still reduced in renal 
impairment.
Renal disease is frequently associated with alterations 
in protein binding resulting in increases in free drug 
concentrations which can more readily be distributed into 
tissues with a subsequent increase in the volume of 
distribution. The protein binding of two dihydropyridine 
derivatives nifedipine and nitrendipine (Kleinbloesem et 
al., 1985; Ankermann et al., 1989) was found to be reduced 
in patients with renal impairment resulting in a significant 
increase in volume of distribution. The protein binding in 
the present study was about 98% for the three groups and the 
volume of distribution was not different between groups 1 & 
2 .
It is perhaps surprising that patients with end stage 
renal failure on regular haemodialysis behave similarly to 
hypertensive patients with normal renal function. It seems 
that the haemodialysis treatment, which occurred on the days 
before the pharmacokinetic study days, was able to restore 
metabolic activity towards normal, possibly, by clearing the 
blood of an inhibitory substance which interfered with 
hepatic metabolism.
Increased plasma levels of nicardipine in renal 
impairment might potentially lead to enhanced effect.
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Exaggerated responses to nifedipine (reduction in diastolic 
blood pressure) have been reported in renal impairment but 
these apparently were unrelated to plasma drug levels 
(Kleinbloesem et al., 1985). No such enhanced effects on 
blood pressure or heart rate are confirmed in the present 
study.
This study emphasises the importance of studying the 
pharmacokinetics of drugs which are highly extracted by the 
liver in patients with renal impairment even if the kidney 
is not the major site of elimination.
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CHAPTER EIGHT 
EFFECTS OF NICARDIPINE ON THE METABOLIC RESPONSES 
TO FOOD AND EXERCISE
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INTRODUCTION
The failure of conventional antihypertensive drug 
regimens, based upon thiazide diuretics and beta blockers, 
to produce a significant impact on the incidence of coronary 
heart disease has raised the possibility that adverse 
metabolic effects, and particularly changes in lipids and 
lipoproteins, might be compromising the beneficial effects 
of blood pressure reduction. The conventional approach to 
the assessment of metabolic effects during long-term 
antihypertensive treatment is to monitor the relevant 
indices under basal, non-stimulated conditions before and
4
after a period of drug treatment. An alternative approach, 
as described in this chapter, is to obtain hormonal and 
metabolic measurements in response to specific provocative 
stimuli (food and exercise). By stimulating metabolic and 
hormonal responses it may be possible to reveal a drug- 
related effect which might otherwise have been less readily 
detected under basal conditions.
Nicardipine is a dihydropyridine calcium antagonist for 
the treatment of hypertension and angina. Conventional 
studies of its effect on plasma lipids have elicited 
"neutral11 results i.e. neither beneficial nor adverse 
effects (Trost & Weidmann, 1987) and similarly, studies in 
animals have shown no other significant adverse metabolic 
effects (Naito et al., 1984). This study has been undertaken 
to evaluate the effect of nicardipine on the metabolic and 
hormonal indices in response to standardised food and 
exercise challenge in patients with mild to moderate
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essential hypertension.
SUBJECTS AND METHODS
Outline of study
Twelve patients (age 31-65 years; weight 72.5 ± 13 kg) 
with mild to moderate essential hypertension (supine 
diastolic blood pressure 90-110 mmHg) were recruited for a 
placebo controlled, double blind, randomised, crossover 
study which was approved by the Research and Ethical 
Committee of the northern District of the Greater Glasgow 
Health Board. Only 7 patients completed the study and their 
clinical characteristics are presented in table 8.1. The 
patients were randomly allocated to receive nicardipine 30 
mg three times daily, or corresponding placebo tablets for a 
4 weeks treatment period, at the end of which they attended 
the Clinical Pharmacology Research Unit for the first of 2 
study days. Following a washout period of 7 days, patients 
then commenced a 4 weeks treatment period with the opposite 
treatment and duly attended for a second study day.
Study days
Having fasted overnight, patients attended the C.P.R.U. 
where the metabolic and hormonal responses to standard food 
and exercise challenges were evaluated on each study day 
whose design is shown in figure 8.1. Following the insertion 
of an indwelling intravenous cannula and a period of rest 
for 20 minutes, blood samples were collected for basal 
values of lipids, lipoproteins, glucose, insulin, thyroid
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TABLE 8.1.
CLINICAL CHARACTERISTIC OF PATIENTS
WHO COMPLETED THE STUDY
Patients Age Weight Starting HR.
No. Yrs Kg BP. mmHg bpm
1 63 78 164/101 76
2 58 72 171/100 87
3 64 72 173/99 80
4 60 64 169/104 74
5 55 86 190/109 81
6 59 53 172/104 80
7 61 85 150/93 72
Mean 60 72.4
3 12. 6
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stimulating hormones (TSH), renin, aldosterone and 
catecholamines. Blood pressure and heart rate were recorded 
in duplicate both supine and after 2 minutes in the erect 
position using a semi automatic sphygmomanometer (Sentron, 
Bard Medical). The morning dose of drug (or placebo) was 
then administered.
Responses to a standard meal
One hour after drug dosing, patients ate a standard 
meal containing 64 gm of carbohydrate, 25 gm of fat and 10 
gm of protein with a total energy content of 2.3 m.j. (of 
which 40% was fat). The meal was prepared by the hospital 
dietetics department. Blood samples were collected before 
the meal and at 15, 30, 60, 120, 180, and 240 minutes 
thereafter for total cholesterol and cholesterol fractions, 
triglyceride, insulin and glucose.
Response to standard exercise
The maximal exercise capacity was predetermined 
according to the method described by Astrand and Astrand, 
1958 using bicycle ergometery immediately after the patients 
had completed the standard meal study. Radial pulse was 
counted at the last 15 seconds of the 5th and 6th minutes, 
when the heart rate was stabilised, with subjects cycling 
against a resistance of 50-75 Watts for 6 minutes. The 
maximum oxygen uptake was calculated using a nomogram 
(figure 8 .2 .) and the maximum exercise capacity was 
calculated in "Watts" from a standard table (table 8.2.) .
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(Modified from Astrand and Ryhming, 1954).
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TABLE 8.2.
PREDICTION OF MAXIMAL WORK LOAD (WATTS) FROM 
OXYGEN UPTAKE ON A BICYCLE ERGOMETER.
Oxygen uptake Maximal Work Load 
liters/min Watts
50
100
150
200
250
300
350
400
A second dose of the assigned drug was then administered at 
6 hours after the first (morning) dose and the standardised 
exercise test was then performed one hour after this second 
dose. The patients were exercised for two periods of 10 
minutes at 25% and 50% of the individually predetermined 
maximal exercise capacity. Blood samples were collected 
before starting the exercise, at the end of the first load, 
at the end of the second load and after a rest for 10 
minutes for the following: lipids, insulin, glucose, gluca­
gon, growth hormone, cortisol, catecholamines, free fatty 
acid, renin, aldosterone and lactate. In addition, blood 
samples for the measurement of nicardipine levels were 
collected before the exercise and 10 minutes after the 
exercise had finished.
0.9
1.5 
2.1 
2.8
3.5 
4.2 
5.0 
5.7
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Plasma concentrations analyses
1) Serum lipids and lipoproteins were analysed by 
conventional enzymatic methods (Farish et al.,
1986)
2) Free fatty acid was analysed by commercially 
available enzymatic kit (Wako Chemicals GmgH).
3) Glucose was measured by Beckman glucose analyser II 
(Glucose oxidase method).
4) Insulin, growth hormone, cortisol, renin, 
aldosterone, thyroxine and TSH were analysed by 
standard radio-immunoassays.
5) Immuno-reactive glucagon was analysed by courtesy of 
Professor K. Buchanan, Belfast.
6) Catecholamines were analysed by radio-enzymatic 
method (Peuler and Johnson, 1977) .
7) Plasma lactate was analysed by enzymatic UV-method 
(Boehringer Manheim GmBH).
Calculation of AUC and maximal change
The area under the concentration time curve (AUC) was 
chosen to represent the response after the standard meal or 
exercise. It is calculated for baseline adjusted data by 
trapezoidal rule; for meal- from the start of meal to four 
hours after meal; for exercise- from the beginning of 
exercise to 30 minutes after exercise.
Maximal change was the peak achieved after the meal or 
exercise which was calculated directly from the graph.
For most variables maximal changes took place shortly 
after the meal or during the first or second load of
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exercise but for some variables the maximum differences 
occurred later throughout the 4 hour study period. 
Accordingly, the data were analysed and presented both as 
maximal change after food or exercise and as baseline 
corrected profiles and AUC's.
Statistical analysis
Data throughout are presented for 7 patients as mean ±
sd.
Time and treatment effects were evaluated by repeated 
measures analysis of variance using the statistical package 
"Rummage".
Paired Student's t-test was used to test differences in 
the base- line values or the maximal change after meal or 
exercise.
RESULTS
Responses to standard meal
The mean results for lipids and lipoproteins are 
presented in table 8.3. and 8.4. In response to the standard 
meal total cholesterol, cholesterol fractions, glucose and 
insulin increased to a peak at 15 to 30 minutes, and then 
declined towards the pre meal values. There were no 
significant differences between nicardipine and placebo, 
either in the peak response or in AUC of response, when 
allowance is made for the baseline differences.
Although the post meal profiles of both total 
cholesterol and HDL cholesterol were higher after 
nicardipine (figure 8.3. and 8.4.) by analysis of covariance 
(using the baseline values as covariate) there were no
213
significant differences between the two treatments. Blood 
glucose and serum insulin increased after the meal, both 
after placebo and after nicardipine, with peak values 
between 30 and 60 minutes and thereafter a decline towards 
pre meal value. Statistical analysis showed no differences 
between the two treatments (figure 8.5.).
Response to standardised exercise
The mean results for biochemical values before and 
during exercise are listed in table 8.5. and the response 
expressed as AUC's adjusted for baseline are listed in table
8 .6 . During the exercise test the levels of total 
cholesterol and of the cholesterol fractions increased and 
were slightly higher after nicardipine (figure 8 .6 . and
8.7.). For HDL cholesterol the maximal change was higher 
after nicardipine compared to placebo (0.04 ± 0.1 vs 0.1 ±
0.06 mmol/1) but statistical analysis showed no difference. 
There were no significant differences in the AUC between 
nicardipine and placebo.
Glucose, glucagon, and insulin were reduced during 
exercise (figure 8 .8 . and 8.9.) but statistical analysis 
could not detect differences between the two treatments. 
Serum cortisol was reduced during exercise but started to 
increase above pre exercise level when the patients rested 
after the exercise had finished. Plasma lactate was slightly 
and insignificantly increased during exercise. There were no 
significant differences between nicardipine and placebo for 
growth hormone, aldosterone, renin, adrenaline and 
noradrenaline.
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TABLE 8,4.
THE AREA UNDER THE CURVE (AUCq .o Q^ HIN ) (BASELINE 
CORRECTED) AFTER STANDARD MEAL FOR SERUM LIPIDS, INSULIN 
AND GLUCOSE.
a u c 0 -2 4 0  m in  
P la c e b o  N i c a r d i p i n e
1. Lipids
(a) Total cholesterol -14.2 + 15 -30.2 ± 39
(mmol/ml)
(b) HDL-C (mmol/1) - 4 . 7 + 1 0  1 2 . 4 + 1 0
(c) LDL-C (mmol/1) -11.8 + 50 •24.2 + 64
(d) VLDL-C (mmol/1) 1.6 + 22 .0 + 36
(e) Triglyceride 
(mmol/1)
2. Glucose (mmol/1)
130.0 + 78 102.0 + 33
189.0 + 113 160.0 + 176
3. Insulin (MU/1) 7234.0 + 4360 8581.0 + 5710
* The unit for AUC is concentration unit * min.
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(O) . The data are presented as mean and error 
bars represents the standard error of the 
mean (SE).
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TABLE 8.6.
THE AREA UNDER THE CURVE (AUCq ._3q MIM) -(BASELINE 
CORRECTED) DURING EXERCISE FOR SERUM LIPIDS, LIPOPROTEINS 
AND HORMONES.
AUCq_3q 
P la c e b o  N i c a r d i p i n e
1. Lipids
(a) Total cholesterol 8.6 + 4.0 7.4 + 3.4
(mmol/ml)
(b) HDL-C (mmol/1) 1.0 + 1.8 1. 9 ± 1.3
(c) LDL-C (mmol/1) 6.8 + 2.8 6.8 ± 4.0
(d) VLDL-C (mmol/1) 1.1 + 3.0 -1.1 + 3.0
(e) Triglyceride 5.0 + 3.0 3.7 ± 7.0
(mmol/1)
2. Glucose (mmol/1) -16.0 i 20.0 -16.0 ± 27.0
3. Insulin (MU/1) -388.0 -h 385.0 -443.0 + 393.0
4. Glucagon (ng/ml) -293.0 + 925.0 -125.0 + 237.0
5. Cortisol (nmol/1) 143.0 + 708.0 22.8 + 1317.
6. Free fatty acid 2.7 + 6.0 4.7 ± 4.5
(mmol/1)
7. Lactate (mg/100 ml) 151.0 + 104.0 259 ± 209
* The unit for AUC is concentration unit * min.
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Figure 8 .6 . Total cholesterol (a) and high density
lipoprotein cholesterol (b) responses to 
exercise after placebo (•) or nicardipine (O) . 
The data are presented as mean and error bars 
represents the standard error of the mean 
(SE) .
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Response to exercise presented as the change 
(baseline adjusted) for total cholesterol (a) 
and high density lipoprotein cholesterol (b) 
after placebo (•) or nicardipine (O). The data 
are presented as mean and error bars represent 
the standard error of the mean (SE).
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Blood pressure and heart rate
Basal supine blood pressure was reduced after 
nicardipine compared to placebo (164/96 + 31/10 vs 149/85 ± 
16/10 mmHg) and statistical significance was observed for 
diastolic pressure. This was not associated with a change in 
heart rate (65 + 9 vs 6 4 + 8  bpm).
Basal levels (fasting:ore dosing)
There were small, variable and non-significant in­
creases in all lipid fractions after nicardipine compared to 
placebo (table 8.3.). There were no significant changes in 
the fasting levels of serum insulin or blood glucose, nor in 
plasma adrenaline and noradrenaline. There was a statisti­
cally significant increase in the fasting level of plasma 
aldosterone, from 87 + 56 pg/ml after placebo to 142 ± 60 
pg/ml after nicardipine (p < 0 .01) but plasma renin activity 
was not significantly increased by nicardipine (3.4 ± 2.5 
vs 2.7 ± 1.6 ng Al/ml/hr on placebo). There was a small but 
significant increase in thyroid stimulating hormone (TSH) 
after nicardipine (1.6 + 0.76 vs 1.16 + 0.7 nmol/1; p <
0.04) although thyroxine was not affected (102 ± 11 vs 101 ± 
13 nmol/1) (table 8.7.).
Adverse effects
Three patients were withdrawn from the study because of 
volunteered side effects: 2 during nicardipine treatment 
(One patient had fatigue, flushing, nausea and headache and 
the second had nausea) and 1 during placebo treatment 
(headache). Two further patients were found to. have been
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TABLE 8.7.
BASAL (FASTING) LEVELS OF RENIN, ALDOSTERONE, 
CATECHOLAMINE AND THYROID INDICES
Parameters Placebo Nicardipine
Aldosterone (pg/ml) 87 ± 56 142 + 60 *
Renin (ng Al/ml/h) 3.3 ± 2.5 2. 7 +. 1. 4
Adrenaline (nM) 0.3 ± 0.2 0 . 3 ± 0 . 4
Noradrenaline (nM) 1.2 + 0.7 1.2 + 0 .8
TSH (ulU/ml) 1.2 + 0.7 1.6 + 0.7 *
T4 (ulU/ml) 102 + 11 101 + 13
* Significant difference P < 0.05 between placebo and 
nicardipine.
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inadequately compliant when tablet counts and plasma drug 
concentrations were measured and their results have been 
excluded. Thus, full metabolic and hormonal results were 
available for analysis on 7 patients. For the 7 patients who 
completed the study, mild and transient side effects were 
reported during the nicardipine phase: two patients had 
fatigue and one patient had headache after nicardipine.
DISCUSSION
Many metabolic functions, including the release of 
hormones, are partly dependent on the availability and 
intracellular influx of calcium ions and there is 
experimental evidence that hormone release can be blocked by 
calcium antagonists (Grodsky & Bennet, 1966; Devis et al., 
1975). To complement the studies which have measured lipid 
profiles under basal circumstances this study was designed 
to investigate the effect of antihypertensive treatment with 
nicardipine on the metabolic and hormonal responses to two 
different physiological stimuli, feeding and exercise.
There was no significant effect attributable to 
nicardipine either under basal conditions or in response to 
food or exercise. Since complex metabolic and hormonal 
inter-relationships are involved in plasma lipid and 
lipoprotein regulation (Ganong, 1985) the interpretation of 
changes in serum lipid is complex. For example, lipoprotein 
lipase and hormone-sensitive lipase are two of the enzymes 
involved in lipid metabolism and there is evidence that they 
are differently affected b.y feeding and stress (Ganong,
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1985) . The activity of hormone-sensitive lipase is increased 
in the fasting state and decreased by feeding, and by 
insulin (Ganong, 1985). In addition, hormone sensitive 
lipase can be activated by increases in cyclic AMP in 
response to catecholamines, glucagon and TSH, and by a 
slower process by other hormones, such as growth hormone and 
cortisol (Ganong, 1985) . In contrast, feeding increases the 
activity of lipoprotein lipase whereas fasting and stress 
decrease it. Similarly, changes in plasma volume, or in 
catecholamine levels, might indirectly influence metabolism 
but there was no evidence,of any such changes in this study.
In addition, it has been proposed that abnormalities of 
glucose and insulin metabolism have a role in both the 
aetiology and the clinical course of hypertension and some 
antihypertensive drugs are associated with deterioration in 
glucose tolerance (Reaven et al., 1987). In this clinical 
study, normal insulin release and glucose-stimulated insulin 
release were not affected by nicardipine. This lack of 
significant interference with insulin release, which is in 
agreement with earlier results with nicardipine (Dow et al., 
1985) , is consistent with a concentration-dependent effect 
since there is evident from in vitro studies to show that 
the concentration needed to interfere with insulin release 
is much greater then the concentration known to reduce 
vascular tone (Al-mahmoud et al., 1986; Marre et al., 1986).
In the present study short-term treatment with 
nicardipine for 1 month was accompanied by significant 
increase in the level of aldosterone, while the change in
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plasma renin activity was not significant. This finding is 
in agreement with other short-term and chronic studies with 
calcium antagonist drugs ( Weber et al., 1987; Staessen et 
al., 1989) .
The small increase in thyroid stimulating hormone (TSH) 
is surprising although previous studies (Isles et al., 1986) 
also have shown a small and insignificant increase in TSH 
with nicardipine. The mechanism behind the increase in TSH 
is not clear. However, there is some evidence that the acute 
intravenous infusion of calcium to normal subjects reduces 
prolactin and TSH release (Feely et al., 1986) and it is 
possible that the blockade of calcium influx will increase 
the release of TSH.
The impact of adverse drug-related metabolic effects is 
obviously a long-term problem and it might be argued that a 
4-week treatment period is insufficient. However, since 
calcium ions are involved in acute processes such as hormone 
release, and not synthesis, it is likely that 4 weeks would 
be enough to show an effect. There is evidence in both 
patients and volunteers that treatment periods of only 2 
weeks are sufficient to demonstrate effects on lipoprotein 
metabolism with the beta blockers atenolol, propranolol and 
pindolol (Durrington et al., 1985).
In conclusion this study of relatively short-term 
treatment with nicardipine has shown no evidence of any 
adverse-related metabolic or hormonal effect. The 
"provocative" approach used in this study, which is seen as 
complementary to long-term evaluations under basal
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conditions, has confirmed the "lipid-neutral" status of the 
drug.
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GENERAL DISCUSSION
GENERAL DISCUSSION
The principal aim of this thesis was to investigate 
aspects of the clinical pharmacology of calcium antagonist 
drugs, particularly in relation to issues arising in 
clinical practice such as occur in elderly patients with 
hypertension and angina and with special attention to renal 
function and metabolic effects.
Since the proportion of individuals aged 65 years and 
older is increasing in Western society there is an obvious 
and increasing need to direct attention to the 
pharmacokinetic and pharmacodynamic characteristics of drugs 
which are commonly used in elderly patients.
There is now increasing evidence that the 
pharmacokinetics of many calcium antagonist drugs are 
altered in elderly patients so that the plasma clearance may 
be reduced and elimination half life increased. Such changes 
have been reported with nifedipine (Robertson et al-., 1988), 
amlodipine (Elliott et al., 1988), nitrendipine (Kendall et • 
al., 1987; Crome et al., 1987; Van Harten et al., 1989) and 
with verapamil (Abernethy et al., 1986). Our findings with 
verapamil (chapter 5) confirmed that age-related changes in 
pharmacokinetics led to small but significant increases in 
peak plasma levels probably as a reflection of a reduction
in drug clearance. However, it was also noted that the
variability in the pharmacokinetic parameters increased
markedly with age. Overall, it was concluded that dosage
adjustment based solely on patient's age is inappropriate. 
Furthermore, to consider dosage adjustment solely on the
basis of pharmacokinetic differences requires that a clear 
relationship exists between concentration and effect. There 
is now evidence of a direct, although not simple, 
relationship between the plasma levels of verapamil and its 
antihypertensive effects (chapter 3). The "effect modelling" 
method of characterising responsiveness by integrating the 
kinetic and dynamic information (i.e. fall in blood pressure 
(mmHg) per unit change in drug concentration) additionally 
can be used to identify factors, such as age, which might 
influence the response.
Buhler and colleagues (1982) were the first to suggest 
that the antihypertensive effect of calcium antagonist drugs 
was greater in the elderly. This was attributed to increased 
tissue responsiveness, whether direct or indirect, and did 
not take account of any age related alteration in 
pharmacokinetics. If the elderly were truly more responsive 
to calcium antagonists then not only would there be 
advantageous increases in therapeutic responses but more 
critically, perhaps, there might be an increased risk of 
adverse effects, particularly on myocardial contractility 
or A-V conduction. The design of the study of single and 
multiple doses of verapamil in patients with angina 
pectoris, (chapter 4) on the basis of reports of age-related 
alterations to the pharmacology of verapamil and also the 
possibility of increased risk of adverse cardiac effects, 
therefore employed a relatively low range of doses. No such 
increase in adverse effects was observed and there was no 
significant effect on left ventricular ejection fraction,
either at rest or during exercise, and there was no 
significant effect on cardiac conduction (PR.interval). The 
conclusion of this study was that the elderly did not show 
exaggerated responses to verapamil in terms of adverse 
effects on cardiac function. The lack of effect on PR 
interval in this study which is in broad agreement with a 
previous report by Abernethy et al (1986) suggests that the 
sensitivity to verapamil-induced prolongation in 
electrographic PR interval is less in the elderly than the 
young.
The knowledge of the antihypertensive effects of 
calcium antagonists is increasing rapidly but of equal 
importance is information about their effects on end-organ 
blood flow, particularly on the kidneys, since hypertension 
and renal disease frequently coincide. The effects of 
calcium antagonists on renal function were extensively 
reviewed recently (Chellingsworth and Kendall, 1987; 
Schlueter and Batlle, 1989) and in this thesis has been 
evaluated with verapamil (chapter 3 and 4) and with 
nicardipine (chapter 7). The results of these studies showed 
that acute and chronic dosing with these drugs had no 
deleterious effect on glomerular filtration rate or renal 
plasma flow. This result, which is confirmatory to other 
studies (Lee et al., 1986; Littler et al., 1986; Baba et 
al., 1987; Cox et al., 1988), has emphasised the clinical 
usefulness of calcium antagonists in the treatment of 
hypertension without reducing (and in some reports, 
improving) renal function. Whether or not calcium antagonist
drugs actually improve renal function remains controversial. 
To optimise dosage requirements, it is important to identify 
whether or not renal disease has any effect on the 
pharmacokinetics of calcium antagonist drugs. Our results 
(chapter 7) demonstrated that renal impairment reduced the 
plasma clearance of nicardipine resulting in increases in 
plasma levels. Although, we were not able to demonstrate an 
enhanced effect on blood pressure in this group of patients 
with impaired renal function, other workers have shown that 
the antihypertensive effects of the calcium antagonist, 
nifedipine, may be increased in patients with renal impair­
ment (Kleinbloesem et al, 1985). Therefore, despite the 
prior assumption that no dosage adjustment would be required 
in hypertensive patients with renal impairment since nicar­
dipine was not renally eliminated, this study showed that 
there was altered drug metabolism, leading to higher plasma 
drug concentrations and potentially to increased drug re­
sponse.
Since elevated blood pressure is a risk factor for the 
development of coronary heart disease (CHD) and since there 
are also positive correlations between CHD and plasma levels 
of cholesterol and low density lipoprotein (LDL) cholesterol 
(and a negative correlation with high density (HDL) 
cholesterol) (Castelli et al., 1977; Miller et al., 1977; 
Gordon et al., 1977; Hulley et al., 1980; Yarri et al.,
1981; Castelli et al., 1986) there has been recent concern 
that antihypertensive drugs should not worsen the plasma 
lipid profiles. Recent reviews of the metabolic and hormonal
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effects of different antihypertensive drugs (Ames, 1986a; 
Ames, 1986b; Trost and Weidmann, 1987) have depended upon 
"longitudinal" studies i.e. with measurements made under 
basal conditions before and after treatment, for variable 
time periods, with the antihypertensive drugs. Many such 
studies have failed to incorporate adequate placebo data.
The metabolic and hormonal effects of nicardipine have been 
evaluated, using a "provocative" approach, and confirmed 
that it has a "neutral" effect on plasma lipids, 
lipoproteins and hormones (chapter 8). The relevance of 
drug-induced lipid changes remains to be established but 
more accurate assessment of the different drug effects would 
be possible if a standardised "test" could be applied.
Most of the effects of calcium antagonist drugs 
described in this thesis can be explained on the basis of 
calcium entry blockade. However, it is not surprising with 
this heterogeneous group of drugs that they have other 
effects which cannot fit simply into the concept of their 
calcium entry blockade activity. Such an example is the 
inhibition of the metabolism of drugs which are metabolised 
by the liver (Pochet et al., 1986; Batch et al., 1986; Hunt 
et al., 1989). Another potentially more clinically 
applicable use is in the treatment of cancer. Although, many 
calcium antagonist drugs (verapamil, diltiazem and several 
dihydropyridines) (Tsuruo et al., 1983b see Endicott and 
Ling, 1989 for review) have been tested in vitro and have 
shown activity as modulators in resistant malignant cells, 
verapamil has been shown to be the most potent agent but in
240
relatively high concentrations (6 uM; 2700 ng/ml). Such 
concentrations may be more readily achieved in vivo in man, 
without cardiovascular toxicity, using the d-isomer 
verapamil. From the nature of drug resistance there is no 
one general modulator which can be used in all type of 
resistant cells (Tsuruo et al., 1983a) thus the field of 
cancer research is in need of the introduction of more 
modulators to provide the oncologists with a flexible range 
of choice.
In conclusion, calcium antagonist drugs are likely to 
make an increasingly important contribution.to the effective 
treatment of cardiovascular (and other) disorders. They have 
no significant adverse impact on end-organ blood flow; they 
have a neutral effect on serum lipid and hormone profiles; 
they have no serious age-related toxicity; and, potentially, 
their use may be extended to the field of cancer research as 
adjuvant agents to overcome drug resistance.
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APPENDIX 1
Derivation of the kinetic model 
1. Intravenous Bolus Administration: l.v. DOSE
K12
X2XI
K21
P aram eters  ot the modelK 10
A, Alpha, 0 , B eta
dXl/dt - - (K12+ K10).XI + K21.X2 
dX2/dt = K12.X1-K21.X2
From equation 1
S.L(Xl) - XI (0) = - (K12 + KlO).L(Xl) + K12.L(X2)
From equation 2
S.L(X2) - X2(0) = K12. L (XI) - K21.L(X2)
Since this is the first dose
then: X I (0) = D, X 2 (0) = 0
Thus equation 4 can be simplified to
K12.L (XI)
L(X2) =
(S + K21) 
Substituting in equation 3
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. K12.K21.L(XI)
S.L(Xl) - D = - (K12 = K10) . L (XI) +  :-
(S + K21)
%
S + (K12 + KIO + K21).S + (K10.K21),L(X1)
D =
(S + K21)
D. (S +K21)
i.e. L (XI) = -— — — — — ----
2.
S + S .(K12 + KIO + K21) + K21.K10
D. (S + K21)
i.e. L(XI) = ---------------
(s + a  ) (s + jg )
Where a = K21.K10
a + (3 = KIO + K12 + K21
L(XI) is now in a standard form so that from the table of
inverse Laplace Transforms (table Al, function 9.),
D
Xi = ---------  (a - K21).e"at - (/?- K21) . e” & t)
( a - (3 )
and
C(t) = A.e" + B.e" I   6
D.(Ot - K21) D. (K21 - |8 )
Where A = ----   . and B = --------------
v i t a  - / 3  ) v ita . '  -  0  )
VI = Volume of the central compartment.
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TABLE Al
LAPLACE TRANSFORMATION
Functions Laplace Transforms
F(t) f(s)
1 1 1/s
2 A A/s
3 t 1/s2
4 tm m l/sm+1
5 A e'at A/(s + a)
6 Ate"at A/(s + a)1
7 A /, -at. ? (1 -  e ) A/s(s + a)
8 A -(b/a)t 
a A/(as + b)
9 (B - Aa)e"at -  (B -Ab)e'bt (b j  a) (As + B)/(s + a)(s + b)
10 A / -at -bt* T T ^ (e -  e > A/(s + a)(s + b)
11 e 'at[A + (B -  Aa)t] (As + B)/(s + a)2
- p ^ g P ’(A&i -  Ba + C)e"at
12 ) + Q(Ab!-B b  + C)e"bt ( (As* + Bs + C)/
+ R(Ac2- Bc+ C)e‘ ci] ( (s + a)(s + b)(s + c>
(P =b-c,  Q = c -a ,  R = a-b)
13 A [ ^ + i( i^ B 5 e' a t - b I^ b 5 e' bt]  A/s(s + a)(s + b)
14 T t “ ? ( 1 “ e’ at) A /s2(s + a)
B Aa • B -at Ab — B —bt / * < u « »15 + l^ T b 5 e . (As + B)/s(s + a)(s + b)
B a2 - Aa + B -at b2 - Ab + B -bt /«,* A
16 ab“ a (b -a )  e + bib- a) e (s +As + B)/s(s + a)(s + b)
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2 .  S in g le  o r a l  a d m in is t r a t i o n xg
dXg/dt = -Ka.Xg 
D
L(Xg) = ------
Ka
K12
K21
K1M
KIO
P a ra m e ters  of the model  
A. A lpha. B. B e ta .  Ka, 
K1M.VC/VM, KMO
X2X I
KMO
and Xg = D.e
(S + Ka) ,
The equation from the central and peripheral compartments 
are:
dXl/dt = - (K21 + KIO) .XI + K21.X2 + Ka.Xg  ---- — ---  7
dX2/dt = K12.X1 - K21.X2    8
From equation 8;
K12 . L(XI)
L(X2) = ------------   — -------------   9
(S + K21)
Substituting into equation 7;
K12.K21.L(XI) Ka.D
S.L(Xl) = - (K12 + KIO) . L (XI) + ---   +-------
(S + K21) (S + Ka)
(S + a j (S + 0 ) .L(XI) Ka.D
i.e.
(S + K21) (S + Ka)
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Where a & ^ are as previously defined.
Then;
Ka.D.(S + K21)
L (XI) = - --------------------- - --
(S .+ a  ) (S + 0 ) (S + Ka)
From table Al, function 12;
Ka.D.(. - K210) Ka.D.(. -K21)
Xi = ---------------- .e- + --------------- ,e“ +
(a - 0) (Ka - a) (PC - (3) (0 -Ka)
Ka.D.(Ka - K21)
------------;--- .e-Kat
(a - Ka) (Ka -0)
Assuming the fraction of the administered dose which is absorbed 
is F, then
Ka.D.F.(a - K210) Ka.D.F.(0 - K21)
XI = ------------------- .e“ at +  ------------------.e"'^t +
VI. (tt - |8) (Ka - an VI. (a - 0) (0 -Ka)
Ka.D.F.(Ka - K21)
VI.(a - Ka)(Ka -0)
Which may be written
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Cl = P.e"at + Q.e” fit _ (P+Q) #e"Kat -----------------  11
For the metabolite 
dXm/dt = Kl/m.Xl - Kmo.Xm 
(S + Kmo).L(Xm) = Kim.L(XI)
P.VI.Kim Q.VI.Kim (P + Q).VI.Kim
(S + a) ■ (S + j3) (S + Ka)
Thus
P.VI.Kim Q.VI.Kim (P + Q).VI.Kim
L (Xm) = ---  +     + — •— ■-----------
(S +a) (S + Kmo) (S + /?) (S + Kmo) (S + Ka)
and P.VI.Kim Q.V.Kim
Xra = --------- ..(e"at - e"Kmot) + ---------- . <e_ - e“Kmot)
(Kmo - a) (Kmo - /$)
(P + Q).V.Klm 
________________#(e-Kat _ e-Kmot
(Kmo - Ka)
and
P V.Klm)
Cm = --------- . (— ----) . (e“ - e“Kmo )^ +
(Kmo - CL) Vm
Q (V.Klm)
-------;---.(------ .). <e" - e-Kmot, _
(Kmo - j8 ) Vm 
(P + Q) (V.Klm)
--------- -.(------- ) . (e~Kat - e"Kmot)
(Kmo - Ka) Vm
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This can be simplified to
Cm = R.e“ at + S.e"^t + U.e“Kat + T.e-Kmot.
3. Effect model
K12
K21
K10
XI X2
Xe
Kcq
dXe/dt = Kle.Xl -Keq.Xe
S.L(Xe) - Xe(0) = Kle.L(Xl) - Keq.L(Xe)
Kle Kle.D
L (Xe) = ------- . L (XI) = -----------
i.e.
Xe
thus
Ce
(S + Keq)
Kle.D
(Ke - Keq)
Kle.D
Ve (Ke - Keq)
(S + Keq)(S + Ke)
. (e-Ke'Jt - e~Ket)
(e-Keqt _ e-Ket)
Since Kle.VI = Keq.Ve So that 
D.Keq
Ce = ------------  (e-1^  - e~Ket)
VI (Ke - Keq)
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Ce is the concentration in the effect compartment 
and the effect E may be related to any of the these 
models :
E = m.Ce +i Linear model
E = m.InCe + i
Emax.Ce
E =- --------  Langmuir equation
Ce50 + Ce 
Emax.Ce
E = ---------  Hill equation
* t  .
Ce50 + Ce
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